Effectiveness of Noninvasive Brain Stimulation Protocols on Drug Craving and Consumption/Relapse in Substance Use Disorders: A Systematic Review and Meta-analysis of 208 Clinical Trials and 36 Protocols

Ghazaleh Soleimani PhD[1,2], Afra Souki MSc[3], Sara Honari MD[4], Travis E Baker PhD[5], Andre R Brunoni MD-PhD[6], Mohsen Ebrahimi MSc[7], Eduardo A Garza-Villarreal MD-PhD[8], Tony P George MD[9,10], Professor Rita Z Goldstein PhD[11], Manish Kumar Jha MD[12], Tonisha Kearney-Ramos PhD[13], Rayus Kuplicki PhD[14], Professor Bernard Le Foll MD-PhD[15], Kelvin O Lim MD[1], Professor Martin P Paulus MD[14], Arash Rahmani MD[1], Gregory Sahlem MD[16], Victor M Tang MD[17], Hosna Tavakoli PhD[18], Alireza Valyan PhD[19], Professor Ti-Fei Yuan PhD[20], Mehran Zare-Bidoky MD[21], Professor Marom Bikson PhD[22], Colleen A Hanlon PhD[23,24], Professor Michael Nitsche MD[25,26,27], Hamed Ekhtiari MD-PhD[1, 14].

[1]Department of Psychiatry and Behavioral Sciences, University of Minnesota, MN, USA
[2]Department of Biomedical Engineering, University of Minnesota, MN, USA
[3]Department of Psychology, University of Tehran, Tehran, Iran
[4]Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
[5]Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, New Jersey 07102
[6]University of São Paulo Medical School, Psychiatry, São Paulo, Brazil
[7]Iranian National Center for Addiction Studies (INCAS), Tehran, Iran
[8]Institute of Neurobiology, Universidad Nacional de México campus Juriquilla, Queretaro, Mexico
[9]Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
[10]Addictions Division, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
[11]Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York City, New York
[12]Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
[13]Department of Psychiatry & Behavioral Sciences, Duke University Medical Center, Durham, NC 27710
[14]Laureate Institute for Brain Research (LIBR), OK, USA
[15]Department of Psychiatry, University of Toronto, Toronto, ON, Canada
[16]Brain Stimulation Lab, Department of Psychiatry & Behavioral Sciences, Stanford School of Medicine, Stanford, CA, USA
[17]Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada
[18]Institute for Cognitive Sciences Studies (ICSS), Tehran, Iran
[19] Allameh Tabataba'i University, Tehran, Iran
[20]Shanghai Key laboratory of Psychotic disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
[21]Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
[22]Department of Biomedical Engineering, The City College of New York, New York, NY, USA
[23]Department of Cancer Biology, Wake Forest University School of Medicine, NC, USA
[24]BrainsWay, Burlington, MA, USA
[25]Department of Psychology and Neurosciences, Leibniz Research Center for Working Environment and Human Factors, Dortmund, Germany
[26]University Clinic of Psychiatry and Psychotherapy, Protestant Hospital of Bethel Foundation, University Hospital OWL, Bielefeld University, Bielefeld, Germany
[27]German Center for Mental Health (DZPG), Bochum, Germany

Corresponding Author: Hamed Ekhtiari, MD, PhD
Department of Psychiatry and Behavioral Sciences, University of Minnesota, MN, USA
Director of Neuroscience-informed Interventions for Addiction Medicine (NIAM) Lab, Laureate Institute for Brain Research, Tulsa, OK, USA. Email: ekhti001@umn.edu, hekhtiari@laureateinstitute.org

Abstract

Background: Transcranial Magnetic, Electrical, and Focused-Ultrasound Stimulation (TMS/tES/tFUS) are major noninvasive brain stimulation (NIBS) techniques used to treat various psychiatric disorders, including substance use disorders (SUDs). Although NIBS with varying stimulation parameters shows promising effects on drug-related behaviors such as craving and consumption/relapse, the question of which protocol is most effective remains unresolved.

Method: To address this gap, we conducted a living systematic review and meta-analysis to quantify the effects of TMS/tES/tFUS on SUD. Controlled trials of TMS/tES/tFUS for all types of SUD were selected up to January 1, 2024.

Findings: The final systematic review included 208 trials (121 TMS, 86 tES, 1 tFUS), with 116 randomized sham-controlled trials (59 TMS, 57 tES) eligible for meta-analysis due to a low risk of bias. Data from 5,106 participants in active and 4,914 in sham groups were analyzed. TMS showed medium effects on craving ($g = 0.52$, 95% CI: 0.29-0.75, $p < 0.001$, $I^2 = 89.36$) and consumption ($g = 0.41$, CI: 0.26-0.56, $p < 0.001$, $I^2 = 61.56$). tES showed a medium effect on craving ($g = 0.40$, CI: 0.25-0.55, $p < 0.001$, $I^2 = 60.69$) and a small effect on consumption ($g = 0.27$, CI: 0.15-0.38, $p = 0.013$, $I^2 = 22.67$). Among the 36 different protocols examined, subgroup analyses identified the strongest effect for reducing both craving and consumption with high-frequency deep TMS using the H4 coil (single study) ($g = 3.92$ and 1.12, respectively, $p < 0.001$), with a maximum electric field over the frontopolar cortex. This effect was followed by high-frequency rTMS over the left DLPFC ($g = 0.66$ and 0.52, respectively, $p < 0.05$), as well as bilateral anodal-right cathodal-left ($g = 0.49$ and 0.42, respectively, $p < 0.0001$) and anodal-left cathodal-right ($g = 0.38$ and 0.31, respectively, $p < 0.05$) tES with direct current (tDCS) over the DLPFC, with maximum electric field on the frontopolar cortex.

Interpretation: Our results provide evidence that TMS and tES stimulation over frontopolar and DLPFC regions produce medium to large effect sizes in reducing drug craving and consumption/relapse in SUD. While requiring further replication in future studies, these findings highlight the promise of these interventions.

Keywords: transcranial electrical stimulation, transcranial magnetic stimulation, addiction psychiatry, systematic review, meta-analysis, substance use disorders, craving, relapse.

1. Introduction

Substance use disorders (SUDs) are major global health challenges, affecting millions of individuals worldwide and contributing significantly to morbidity and mortality. Alcohol use disorder affects approximately 5% of the global population (~400 million people),[1] and other SUDs impact about 0.7% of the population (~36 million worldwide).[2] These conditions impose a substantial burden on individuals, families, societies, and healthcare systems, highlighting the urgent need for effective global prevention and treatment strategies. Numerous compounds have undergone scrutiny as potential pharmacotherapies for SUDs. However, as of early 2025, only a limited number of medications have demonstrated robust efficacy (consistent, reproducible, and clinically durable) and gained approval from the United States Food and Drug Administration (FDA).[3] However, for some SUDs, such as methamphetamine use disorder (MUD) and cannabis use disorder (CUD), there are currently no FDA-approved pharmacological treatments, leaving clinicians with limited options beyond behavioral therapies.

The significant global burden of SUDs, combined with their neurotoxic and neuroadaptive effects on the brain, underscores a critical treatment gap due to the lack of effective pharmacotherapies. The high rates of relapse and ongoing health consequences in individuals with SUDs emphasize the pressing need for novel therapeutic approaches. Neuromodulation, particularly non-invasive brain stimulation (NIBS), has emerged as a promising alternative intervention, targeting the pathophysiological mechanisms underlying SUD.[4] In this regard, transcranial electrical (tES), magnetic (TMS), and focused ultrasound (tFUS) stimulation have shown promise as potential treatments for SUDs.[5,6] NIBS techniques employ varied stimulation protocols, including different frequencies, intensities, and target areas, to modulate brain activity and support therapeutic outcomes. Treatment outcomes in NIBS studies commonly include reduced drug craving, enhanced self-regulation, with key measures often assessing both short-term drug consumption and longer-term relapse prevention.

A major focus of recent NIBS research has been the application of anodal tES or high-frequency TMS to the dorsolateral prefrontal cortex (DLPFC), a region commonly targeted in depression protocols to enhance cortical excitability. This interest is driven by overlapping DLPFC-mediated executive function deficits observed in both depression and SUDs.[7] However, there are multiple trials targeting other sites, and the optimal site(s) and protocols for effective addiction treatment remain unclear.[8] To address this gap, we conducted a living systematic review and meta-analysis with three primary aims: (1) to characterize the heterogeneity of NIBS parameter spaces used in SUD research; (2) to quantify the overall effect size of NIBS on drug craving and consumption/relapse, and evaluate how stimulation parameters influence outcomes; and (3) to identify the most effective stimulation protocols. These findings aim to inform the development of more effective interventions and support policy and regulatory decisions in global addiction treatment efforts.

Regarding a recently published review of review papers on (non)invasive methods in the field of SUD, by the end of 2024, there are at least five systematic review papers (with or without meta-analysis) in this area.[9,10] One of the most recent and comprehensive ones was published in 2023

by Mehta et al., which covered studies up to the end of October 2023 and only reported the meta-analysis for alcohol and nicotine use disorders.[6] Here, (1) in the systematic review part, we reported results up to the end of 2023, which will be updated annually through the International network of tES and TMS for Addiction Medicine (INTAM) infrastructure,[5] (2) in the meta-analysis part, we conducted a comprehensive subgroup analysis covering all types of SUDs (rather than focusing on two samples as Mehta et al. did), and (3) we performed subgroup analyses of stimulation protocols specifically to identify the most effective protocol for each stimulation type, including deep and figure-of-eight coil TMS as well as tES studies.

2. Method

2.1. . Search Strategy in the Systematic Review Phase
A comprehensive literature search was conducted in PubMed for studies published up to January 1, 2024, involving tES, TMS, and tFUS as interventions for SUDs. Search terms are detailed in Table S1. The review follows the latest Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P).[11] The initial search identified 508 TMS, 663 tES, and 156 tFUS articles. Two independent investigators (AS, HT) screened and extracted data, with a 3rd reviewer (GS) resolving discrepancies by consulting with the senior author (HE) (see supplementary materials). Extracted data and key figures are available on the INTAM OSF page (https://osf.io/sv8ky) and will be updated annually, with comprehensive results published every five years.

2.2. . Study Inclusion for the Meta-Analysis Phase
For the meta-analysis, a refined subset of studies was selected from the systematic review dataset. Studies included if they: (1) were randomized controlled trials reporting craving and/or consumption/relapse as outcome measures, and (2) provided sufficient statistical data—such as means and standard deviations (SDs) for pre- and post-intervention, mean change scores, F-values, or relapse rates—to enable effect size estimation for active versus sham stimulation. Studies were excluded if they: (1) lacked a sham-controlled condition, or (2) did not report sufficient data for effect size calculation and failed to provide these data upon request from the first or last author.

2.3. . Assessment of the Risk of Bias of the Included Studies
Cochrane's risk-of-bias tool (RoB 2) was used to rate the methodological quality of the included studies.[12] The five main domains covered by this tool are (1) bias due to the randomization process and timing of identification or recruitment of participants, (2) deviation from intended intervention, (3) missing outcome data, (4) measurement of outcomes, and (5) selection of the reported result. Two authors (AS, SH) independently assessed each item for each study. If there were any unresolved disagreements, these were discussed with a third person (MZB), and the final decision was then made.

2.4. Hedges' g Calculations
Meta-analytic models were implemented using the "metafor" package in R. Effect sizes were calculated by comparing changes in drug craving/consumption/relapses between active stimulation and sham control groups. Hedges' g was used as the effect size metric, accompanied

by 95% confidence intervals (CIs). All analyses were conducted using random-effect models to account for between-study heterogeneity. Positive effect sizes indicated greater reductions in craving, consumption, or relapse following active stimulation compared to sham.

2.5. Publication Bias Assessment

To assess the potential impact of publication bias, which could either inflate or deflate effect sizes in meta-analyses,[13,14] two distinct evaluations were conducted. (1) The original funnel plot was compared with a modified version generated through the application of the trim and fill technique.[15] (2) Egger's regression test was implemented, which gauges the degree of funnel plot asymmetry by assessing the intercept resulting from a regression of standard normal deviation against precision.[16] A P-value for the intercept falling below 0.05 indicated the presence of substantial publication bias across the array of comparisons.

2.6. . Subgroup Analysis

Pooled effect sizes (small (≈0.2), medium (≈0.5), and large (≈0.8)) were calculated to clarify the effects of different parameters, including substance types, number of sessions, study design (parallel vs crossover), target laterality, stimulation target, stimulation intensity, and stimulation duration. To provide insights about different stimulation protocols, pooled effect sizes were also calculated based on stimulation type (excitatory vs inhibitory) and stimulation target.

3. Results

3.1. . Systematic Review Phase Results

121 TMS, 86 tES, and 1 tFUS studies met our inclusion criteria (see PRISMA flowchart in Figure 1). Notably, individual studies often included multiple experiments (e.g., targeting different brain regions), resulting in a greater number of experiments than the total number of studies.

Figure 1. PRISMA Flowcharts for tES, TMS, and tFUS Studies in Substance Use Disorders. This PRISMA flow diagram represents published trials of tES, TMS, and tFUS for individuals with substance use disorders from inception up to 1 January 2024. The last two sections of the PRISMA flow diagram indicate the total number of studies included in the systematic review and meta-analysis (studies that reported craving or consumption/relapse as outcome measures were included in the meta-analysis). Some studies reported both craving and consumption/relapse as outcomes, while others included multiple comparisons (e.g., varying stimulation intensities or control conditions). Consequently, a single publication could contribute multiple assessments/experiments to the analysis. In the systematic review part, "n" refers to the number of publications included, whereas in the meta-analysis part, "n" refers to the total number of assessments (e.g., craving or consumption/relapse assessments). <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation, tFUS: transcranial focused ultrasound stimulation. n=13 studies only defined the protocol, and n=3 studies used results from substance use disorders solely for electric field simulations without pre-post measures. Additionally, we were unable to retrieve the full text for one older study.

The included studies were conducted across 21 countries, with the highest contributions from the United States (n=49, 23.7%) and China (n=50, 24.2%). Studies were conducted on different substances, including nicotine (n=62, 28.2%), alcohol (n=60, 27.3%), amphetamines (n=40,

18.2%), cocaine (n=25, 11.4%), opioids (n=25, 11.4%), and cannabis (n=8, 3.6%). The time trend indicates that 60% of the studies were published in the last five years, with a publication peak in 2022 (Figure 2).

Figure 2. Global Distribution and Trends in tES/TMS Studies for Substance Use Disorders. The figure illustrates the global trends in tES/TMS research on substance use disorders. Colors range from light yellow to purple, with darker shades indicating a higher number of publications. Only papers with full text available in English were included, which may lead to a relative over-representation of English-speaking countries. In the lower panels, studies are color-coded by the type of intervention: tES in red and TMS in blue. (a) Global Map of Study Distribution: A heatmap displays the number of published tES/TMS studies in each country, with darker shades representing higher publication densities. (b) Annual Trends in Publications by Country: This panel presents the number of tES/TMS studies categorized by year of publication, grouped by addictive substance and country. (c) Study Distribution by Substance of Use and Country: This panel categorizes the number of tES/TMS studies in each country based on the type of addictive substance studied. Studies are color-coded by intervention type: tES in red and TMS in blue. Note that some studies included multiple types of addictive substances, resulting in a total count of 220 items, which exceeds the actual number of studies included. Abbreviations: tES: transcranial electrical stimulation; TMS: transcranial magnetic stimulation.

A total of 5,843 individuals received active stimulation (Figure 3), including 4,303 males, 1,200 females, and 340 participants with unspecified sex. Participants represented various substance use conditions: active users/non-treatment-seekers (44%), treatment-seekers/pre-treatment

(23%), detoxification (20%), and recovery (14%) phases. All individuals received one or more sessions of active TMS (n=3,740) or tES (n=2,103).

Figure 3: Participant Demographics in tES/TMS Trials for Substance Use Disorders (Total number of subjects in the active stimulation arm = 5843). This Sankey diagram illustrates the distribution of participants in the active arm, divided by gender, treatment status of their addiction, types of substances used, and types of intervention. The width of the boxes in each column indicates the relative prevalence of each category, while the width of the connecting ribbons represents the proportion of participants shared between categories. Note: 'Multiple' denotes studies that included participants with various substance use disorders or those that did not specify the dominant substance used by the patients. Abbreviations: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation.

Both tES and TMS studies targeted a range of brain regions, categorized into 10 main subregions (See supplementary materials Figure S.1). The majority of experiments focused on the dorsolateral prefrontal cortex (DLPFC, 81.5%; left DLPFC: 52.39%, right DLPFC: 29.11%). Other targets included frontopolar cortex (6.5%), insular cortex (4.4%), inferior frontal gyrus (IFG, 2.9%), frontal-parietal-temporal junction (FPT, 2.2%), anterior cingulate cortex (ACC, 0.7%), cerebellar cortex (0.7%), superior frontal gyrus (SFG, 0.4%), posterior cingulate cortex (PCC, 0.4%), and precuneus (0.4%). Figure 4 visualizes the distribution of TMS and tES experiments by stimulation type—excitatory (anodal tDCS, high-frequency TMS), inhibitory (cathodal tDCS, low-frequency TMS), and tACS—and by target region.

Figure 4: Stimulation targets for tES/TMS trials for substance use disorders. Stimulation targets based on the type of stimulation are shown for the cortical surface, <u>Excitatory</u>: HF TMS and anodal tDCS, tACS, <u>Inhibitory</u>: LF TMS, and cathodal tDCS. The depicted number of cortical locations is equal to 299 and exceeds 207 (the total number of tES/TMS studies in this systematic review) due to the application of multiple stimulation protocols in some studies. Notably, in one tDCS study, an HD electrode with anode and cathode placement over the left DLPFC was employed. In studies investigating bilateral and deep TMS stimulation protocols, as well as in one temporoparietal stimulation study, each reported target was considered as two targets: one in each hemisphere. The term "Frontopolar" collectively refers to the medial prefrontal cortex (mPFC), ventromedial prefrontal cortex (vmPFC), and superior medial frontal cortex (sMFC) regions across the studies. <u>Abbreviations</u>: tES: transcranial electrical stimulation, tDCS: transcranial direct current stimulation, tACS: transcranial alternating stimulation, TMS: transcranial magnetic stimulation, HF TMS: high-frequency TMS (≥ 5 Hz), LF TMS: low-frequency TMS (≤ 1 Hz), SFG: superior frontal gyrus, DLPFC: dorsolateral prefrontal cortex, IFG: inferior frontal gyrus, ACC: anterior cingulate cortex, PCC: posterior cingulate cortex.

Among the 121 TMS studies reviewed, most employed conventional (fixed/not-patterned frequency) repetitive TMS (rTMS, n=75) followed by intermittent theta burst stimulation (iTBS, n=16), continuous theta burst stimulation (cTBS, n=8), deep transcranial magnetic stimulation (dTMS, n=13), or combinations of different TMS types, such as cTBS and iTBS (n=9). Among the 86 tES studies, the vast majority used transcranial direct current stimulation (tDCS, n=83), with only three studies applying transcranial alternating current stimulation (tACS, n=3). Within the tDCS studies, only one study used 4x1 high-definition (HD) electrodes (n=1), while most employed large conventional electrode pads (n=78); electrode type was not reported for seven tDCS studies (supplementary materials Figure S.2). Additional methodological details are presented in supplementary Figures S2–S6, highlighting variability in electrode/coil positioning (most commonly: EEG 10–20 system; n = 112), primary outcome measures (craving: n = 159; consumption/relapse/abstinence: n = 111), and control conditions (most commonly sham-controlled; n = 110). The most frequently used stimulation parameters were 2 mA intensity for tES (n = 65) and 10 Hz frequency for TMS (n = 57). Notably, significant improvements were most

often reported following high-frequency TMS over the left DLPFC (n = 153) and anodal tDCS over the right DLPFC (n = 61).

3.2. Risk of Bias of the Included Studies

None of the included studies had a high risk of bias. Forty-eight percent (n=56) of the studies had some concerns. The main reason for the studies' risk of biases being rated as some concerns was related to the "selection of the reported result domain" (n=53), followed by the "randomization process" (n=3). The thorough rating for each study can be found in Supplementary Figure S.7.

3.3. Meta-Analysis Phase Results

From a total of 208 studies, 1 was related to tFUS. Out of 207 tES/TMS studies in our systematic review, our meta-analysis included 50 TMS studies for craving (69 total assessments) and 29 TMS studies for consumption/relapse (64 total assessments). In tES studies, 45 studies for craving (55 total assessments) and 31 studies (total 55 assessments) for consumption/relapses were included. All other reported outcome measures are categorized in supplementary materials Table S.4. For TMS, we included 1,661 participants in the active group, and 1,610 participants in the sham group for craving, and 711 active and 695 sham participants for consumption. In total, our meta-analysis evaluated data from 5,106 participants in the active groups and 4,914 participants in the sham groups. Our results showed a significant medium effect of TMS on craving (Hedges' g = 0.52, CI = [0.29, 0.75], $p < 0.001$, I^2 = 89.36) and a medium effect on consumption/relapse (Hedges' g = 0.41, CI = [0.26, 0.56], $p < 0.001$, I^2 = 61.56). tES demonstrated a similar medium effect on craving (Hedges' g = 0.40, CI = [0.25, 0.55], $p < 0.001$, I^2 = 60.69) and a small effect on consumption/relapse (Hedges' g = 0.27, CI = [0.15, 0.38], p = 0.013, I^2 = 22.67). Associated forest and funnel plots are available in the supplementary materials, Figures S8, and the specific questionnaires used in the different studies to quantify craving and consumption/relapse are detailed in Figure S.10.

3.4. Subgroup Analysis

In our subgroup analysis, we examined the effects of different stimulation protocols on craving and consumption/relapse outcomes. The analysis identified high-frequency deep TMS with the H4 coil as having the strongest effect on both craving (Hedges' g = 3.92) and consumption (Hedges' g = 1.12), with a highly significant p-value of <0.0001 (single study). The H4 coil is designed to target the anterior cingulate cortex (ACC) and the bilateral insula, which are key regions involved in the salience network (this coil induces the maximum electric field strength over the frontopolar area). This effect was followed by high-frequency repetitive TMS (rTMS) targeting the dorsolateral prefrontal cortex (DLPFC), which also showed significant ($p < 0.05$) reductions in craving (Hedges' g = 0.65, in a total 21 studies) and consumption (Hedges' g = 0.52, in a total 14 studies). Among the tES protocols, anodal tDCS over the left DLPFC with return electrode over the right DLPFC showed significant ($p < 0.05$) effects in reducing both craving (Hedges' g = 0.38, 14 studies) and consumption (Hedges' g = 0.3, 10 studies). Similarly, cathodal tDCS over the left DLPFC with the return electrode over the right DLPFC showed strong evidence ($p < 0.0001$) for reducing craving (Hedges' g = 0.49, 23 studies) and consumption (Hedges' g = 0.42, 15 studies). To show the primary target region in each protocol, we created computational head models to visualize the electric field distribution over the cortex. Based on the results, the

frontopolar area in the H4 coil trials, DLPFC stimulation in tES trials, with the stimulating electrode positioned over the left or right DLPFC and the return electrode placed on the contralateral DLPFC, and the left DLPFC in rTMS trials (which demonstrated the largest Hedges' g values) received the maximum electric field strength (Figure 5). Further subgroup analyses to show the effects of different parameters such as substance type, session type, randomization, hemisphere targeted, stimulation target, stimulation polarity or frequency, symmetry of stimulation or type of the coil, intensity, and duration of treatment can be found in supplementary materials Figure S.9. (e.g., for substance type, significant effects of tES on craving were found for opioids (Hedges' $g \approx 1.26$, $p = 0.000$), multiple substances (Hedges' $g \approx 0.85$, $p = 0.022$), nicotine (Hedges' $g \approx 0.45$, $p = 0.011$), and amphetamines (Hedges' $g \approx 0.44$, $p = 0.000$). For tES consumption, a significant effect was observed for multiple substances (Hedges' $g \approx 0.98$, $p = 0.000$). TMS significantly reduced craving for opioids (Hedges' $g \approx 1.15$, $p = 0.006$) and amphetamines (Hedges' $g \approx 0.93$, $p = 0.000$), and significantly reduced consumption for cocaine (Hedges' $g \approx 1.25$, $p = 0.022$) and nicotine (Hedges' $g \approx 0.47$, $p = 0.000$). All other subgroup effects were not statistically significant).

Figure 5: Exploring Overall Effects of 36 Protocols in tES/TMS Studies on Craving and Consumption. This figure illustrates the impact of tES/TMS on craving and consumption/relapse by examining different types of stimulation protocols. The total number of experiments is color-coded, with tES studies in red and TMS studies in blue. Additionally, the total number of participants in the active and sham arms is indicated in parentheses. Each horizontal line within the plots represents a distinct stimulation protocol, with dots for effect sizes and horizontal lines for confidence intervals. Computational head models show the protocols with the largest significant Hedges' g values in rTMS, dTMS, and tES trials, highlighted in green. In the tES section, the first position indicates anode placement, and the second indicates cathode placement. <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation, dTMS: deep transcranial magnetic stimulation. The figure includes three   color

codes: red, blue, and green. tES protocols are coded in red, while TMS protocols are coded in blue. The heatmap represents the number of studies, with darker tones indicating a higher number of assessments that utilized the corresponding protocol. On the right panel, rTMS, dTMS, and tES protocols are sorted based on the number of assessments that are used in each protocol. Protocols with significant Hedge's g values in both craving and consumption outcomes are highlighted in green, and their computational head models are presented.

4. Discussion

This systematic review and meta-analysis evaluated the parameter space of NIBS techniques — TMS, tES, and tFUS — for SUDs and quantified their effects on drug craving and consumption/relapse. A total of 208 studies published through early 2024 (TMS=121, tES=86, tFUS=1) were included, revealing substantial heterogeneity in experimental design, stimulation protocols, target regions, and outcome measures. The meta-analysis incorporated 50 TMS studies (69 assessments), 45 tES studies (55 assessments) examining craving, and 29 TMS studies (64 assessments) and 31 tES studies (55 assessments) examining consumption/relapse, constituting the largest analysis to date in this field.

The results showed that TMS had significant medium effects on both craving and consumption/relapse reduction ($g = 0.52$ and $g = 0.41$, respectively), while tES had a medium effect on craving ($g = 0.40$) and a small effect on consumption/relapse ($g = 0.27$). Subgroup analyses revealed notable variability in participant characteristics, study designs, stimulation parameters, and treatment efficacy. Among 34 evaluated protocols, the most effective approaches included: (1) tES targeting the DLPFC with a bilateral montage (stimulating electrode over the left or right DLPFC and return electrode on the contralateral side with maximal electric field over the frontopolar cortex), (2) high-frequency deep TMS using an H4 coil targeting the ACC and bilateral insula (regions within the salience network, with maximal electric field over the frontopolar cortex), and (3) high-frequency rTMS over the left DLPFC. Additional subgroup findings indicated that tES was most effective in opioid, nicotine, and polysubstance use disorders, while TMS showed significant effects in nicotine, cocaine, amphetamine, and opioid use disorders. Both single- and multi-session tES trials significantly reduced craving, whereas only multi-session TMS trials were effective in reducing consumption. Other stimulation parameters did not show consistent effects across craving and consumption/relapse outcomes.

The largest prior meta-analysis by Song et al. (2019) included 1,095 participants with conditions including alcohol, nicotine, illicit drug, and food-related disorders.[17] While their results indicated that active stimulation (tDCS and TMS) outperformed sham, the final meta-analysis results differed in some aspects from our findings. The divergence of findings could be related to differences in the included trials. Nevertheless, similar to our findings, their TMS results showed a medium effect on craving (g=0.52, CI=[0.29, 0.75], p<0.001, I²=89.36) and consumption (g=0.45, CI=[0.25, 0.65], p<0.001, I²=67.7). tES showed a medium effect on craving (g=0.40, CI=[0.25, 0.55], p<0.001) and a small effect on consumption (g=0.19, CI=[0.06, 0.32], p=0.015) (12). These results contrast with Mostafavi et al. (2020), which reported no significant effects of tDCS/rTMS in 617 participants with alcohol use disorders,[18] but align with many other meta-analyses in the field.[6,17,19-22]

Comparing multi-session and single-session protocols, we found that increasing the number of TMS sessions was linked to larger reductions in craving and consumption, consistent with the meta-analysis by Song et al. (2019),[17] who reported a larger impact from multi-session protocols. Within the same meta-analysis, a focused analysis of rTMS over the DLPFC also found a significant positive correlation between the total number of stimulation pulses and craving reduction effect size in studies employing excitatory stimulation over the left DLPFC (P = 0.01).[17] However, our results for tES were more heterogeneous: while both single (n=24) and multi-session (n=31) tES protocols significantly reduced craving, only single-session (n=7), not multi-session (n=25), protocols showed a significant effect on consumption. This may be potentially due to the early assessment conducted shortly after the single stimulation, the high dropout rate in follow-ups for multi-session trials, which is a common challenge in SUD studies, or the low number of single-session studies of consumption. In this vein, it is important to note that while sufficient multi-session TMS trials (n=50 for craving and n=43 for consumption) were available, the number of trials for single-session TMS was limited (n=19 for craving and n=2 for consumption), potentially similarly affecting the robustness of these findings. Additionally, the effectiveness of rTMS in reducing craving was protocol-dependent, with variability observed across studies. The differences in outcomes may also reflect the heterogeneity in protocols, including variations in stimulation intensity, duration, frequency, and electrode/coil positioning. For example, while some protocols demonstrated strong positive effects, others yielded unclear or even negative outcomes. This variability underscores the need to interpret aggregated results cautiously, as averaging across diverse protocols may obscure the positive effects of specific approaches. Interestingly, no significant effects were observed for alcohol use disorder in the studies included in the meta-analysis, which may be due to insufficiently tailored protocols or the limited number of high-quality trials focusing on this substance.

Despite the promising results, only one protocol has received FDA clearance to date. Our meta-analysis identified this FDA-cleared protocol—dTMS with the H4 coil—as having the largest effect size compared to the other included 34 protocols (including rTMS, dTMS with different coils, and tES). However, more studies are needed with this coil with craving and consumption as outcome measures.[23] The next most efficacious protocol, high-frequency rTMS over the left DLPFC, showed a medium but significant effect on both outcomes, supported by 21 published papers. This protocol has received CE approval in Europe for psychoactive substance use disorder (PSUD) based on the results of only two SUD trials in cocaine addiction.[24-26] This efficacy is in line with the meta-analysis by Zhang et al. (2019),[27] who reported that excitatory rTMS of the left DLPFC was effective in reducing substance craving and consumption (Hedge's g = -0.62), with a significant positive association between the total number of stimulation pulses and effect size (P = 0.01). Tseng et al. (2022)[28] also found that 10-Hz rTMS over the left DLPFC was associated with the largest decrease in smoking frequency (standardized mean difference = -1.22). Additionally, Petit et al. (2022)[29] reported that the participants who received tES/TMS were 2.39 times more likely to achieve sustained abstinence compared to those receiving sham stimulation, with an even greater likelihood observed for rTMS over the left DLPFC (risk ratio = 4.34) and for deep rTMS targeting the lateral prefrontal cortex and insula bilaterally (risk ratio = 4.64). However, TMS applied to the right DLPFC showed mixed effects. For tES, placing the anode over either the left or right hemisphere significantly affected craving reduction. However, laterality had no

significant impact on reducing consumption or relapse. The most effective tES protocols involved bilateral DLPFC stimulation with the anode placed over either the left or right DLPFC, which induced the maximum electric fields over the frontopolar area.[30]

5. Limitations

This meta-analysis has several limitations that should be considered when interpreting the findings. Our literature search was restricted to English-language databases, potentially missing relevant studies published in other languages. There was substantial clinical heterogeneity (e.g., participant characteristics, substances used) and methodological variability (e.g., study design and outcome assessments) among the included studies. Despite these differences, the data from these studies were aggregated and analyzed as if they represented a single, uniform sample and intervention, which may have influenced the findings. Additionally, our meta-analysis included a variety of tools for measuring craving and consumption, with 17 different questionnaires for craving, 12 for objective, and 4 for subjective measures of consumption (Figure S.10). This diversity in measurement tools may introduce inconsistencies and limit the comparability of results across studies. Differences in study designs, such as variations in session duration, frequency, and intervention intensity, may also have influenced the overall effect sizes, contributing to the observed heterogeneity. These factors emphasize the need for identifying the optimal features (for enhancing select outcomes) that could then be used to develop more standardized protocols in future research to enable more precise comparisons.

6. Conclusion

This systematic review and meta-analysis, the largest to date, provided a comprehensive overview of the parameter space and therapeutic effects of NIBS technologies for SUDs. Analyzing 207 TMS and tES studies across 21 countries, along with one tFUS study, the findings underscore both the promise and complexity of NIBS interventions in this field. These findings suggest that: (1) both TMS and tES show significant therapeutic effects for SUDs, with varying levels of effectiveness, (2) both conventional and deep TMS, as well as bilateral DLPFC-targeted tES, demonstrate clinical utility, with the strongest evidence observed for deep TMS (dTMS)—though this is currently based on a single published study and requires replication, (3) the frontopolar cortex—receiving the highest electric field from the FDA-approved H4 dTMS coil and bilateral DLPFC tES montages—emerges as a promising target, supported by converging neuroimaging and lesion-mapping evidence, [31,32] (4) while dTMS shows a larger effect size, the left DLPFC remains a validated and widely studied target. Together, these findings highlight the potential of targeting both frontopolar-limbic and DLPFC-executive control circuits as dual intervention pathways in SUD treatment.[33] The global contribution to these studies suggests strong scalability of NIBS technologies, although cost-effectiveness and accessibility remain important areas for future investigation.

Funding: Research reported in this publication was supported by the University of Minnesota MnDRIVE (Minnesota's Discovery, Research and Innovation Economy) initiative awarded to G.S. and University of Minnesota's Medical Discovery Team on Addiction (MDTA) support for International Network of tES/TMS Trials for Addiction Medicine (INTAM) (https://med.umn.edu/addiction/network/intam) awarded to H.E.
COI: M.A.N. is a member of the scientific advisory boards of Neuroelectrics and Precisis. **C.H.** is a member of BrainsWay's senior leadership (since November 2022) and has a financial interest in BrainsWay. She

has also served on an advisory board for Welcony-Magstim and as a consultant for BrainsWay and Roswell Park Cancer Center. **M.B.** is an inventor on patents held by The City University of New York related to brain stimulation and holds equity in Soterix Medical Inc. He has served as a consultant, expert witness, grantee, or scientific advisor for multiple entities, including SafeToddles, Zabara Family Foundation, Boston Scientific, GlaxoSmithKline, Biovisics, Axonics, Mecta, SigmaStim, Lumenis, Halo Neuroscience, Wave Neuroscience, Google-X, i-Lumen, Humm, Neurolief, Allergan (AbbVie), Apple, Ybrain, Ceragem, Ceragem Clinical, and Remz. **M.K.J.** has received contract research grants from Neurocrine Bioscience, Navitor/Supernus, and Janssen Research & Development; honoraria for editorial roles with *Psychiatry & Behavioral Health Learning Network* and *Psychiatric Clinics of North America* (Elsevier); consulting fees from Janssen Scientific Affairs and Boehringer Ingelheim; DSMB service fees for studies funded by Eliem, Skye, Inversago, Vicore Pharma, and IQVIA; and speaker honoraria from multiple CME organizations. **B.L.F.** has received funding and in-kind donations from Indivior and Canopy Growth Corporation through CAMH and the University of Toronto. He has served on advisory boards or as a consultant for Indivior, Shinogi, and ThirdBridge, and has received travel support from Bioprojet. He is supported by CAMH, Waypoint Centre for Mental Health Care, and holds academic awards and a Chair in Addiction Psychiatry at the University of Toronto. **V.M.T.** has received research support from the Brain & Behavior Research Foundation, Canadian Institutes of Health Research, Physician Services Incorporated Foundation, NIDA, CAMH Discovery Fund, and several other institutional and philanthropic sources. **The remaining authors have nothing to disclose.**

References

1.   *Global status report on alcohol and health and treatment of substance use disorders*. 2024.

2.   *World Drug Report* 2021. https://www.unodc.org/unodc/en/data-and-analysis/wdr-2021_booklet-1.html

3.   Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. *Am J Psychiatry*. Aug 2005;162(8):1432-40. doi:10.1176/appi.ajp.162.8.1432

4.   Volkow ND, Skolnick P. New Medications for Substance Use Disorders: Challenges and Opportunities. *Neuropsychopharmacology*. 2012/01/01 2012;37(1):290-292. doi:10.1038/npp.2011.84

5.   Ekhtiari H, Tavakoli H, Addolorato G, et al. Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. *Neurosci Biobehav Rev*. Sep 2019;104:118-140. doi:10.1016/j.neubiorev.2019.06.007

6.   Mehta DD, Praecht A, Ward HB, et al. A systematic review and meta-analysis of neuromodulation therapies for substance use disorders. *Neuropsychopharmacology*. Mar 2024;49(4):649-680. doi:10.1038/s41386-023-01776-0

7.   Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. *Nature Reviews Neuroscience*. 2011/11/01 2011;12(11):652-669. doi:10.1038/nrn3119

8.   Petersen N, Apostol MR, Jordan T, et al. Comparing neuromodulation targets to reduce cigarette craving and withdrawal: A randomized clinical trial. *Neuropsychopharmacology*. 2025:1-8.

9.   Oesterle TS, Bormann NL, Al-Soleiti M, et al. Invasive and Non-Invasive Neuromodulation for the Treatment of Substance Use Disorders: A Review of Reviews. *Brain Sciences*. 2025;15(7):723.

10.   Souki A, Soleimani G, Hanlon C, Ekhtiari H. Neuromodulation (Brain Stimulation) Technologies for Treatment of Substance Use Disorders. *The Sage Handbook of Addiction Psychology*. 2025;

11.   Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. Jan 1 2015;4(1):1. doi:10.1186/2046-4053-4-1

12.   Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj*. Aug 28 2019;366:l4898. doi:10.1136/bmj.l4898

13.   Begg CB, Berlin JA. Publication Bias: A Problem in Interpreting Medical Data. *Journal of the Royal Statistical Society Series A: Statistics in Society*. 1988;151(3):419-445. doi:10.2307/2982993

14.   Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. *Jama*. Feb 8 2006;295(6):676-80. doi:10.1001/jama.295.6.676

15. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. Jun 2000;56(2):455-63. doi:10.1111/j.0006-341x.2000.00455.x

16. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629. doi:10.1136/bmj.315.7109.629

17. Song S, Zilverstand A, Gui W, Li HJ, Zhou X. Effects of single-session versus multi-session non-invasive brain stimulation on craving and consumption in individuals with drug addiction, eating disorders or obesity: A meta-analysis. *Brain Stimul*. May-Jun 2019;12(3):606-618. doi:10.1016/j.brs.2018.12.975

18. Mostafavi SA, Khaleghi A, Mohammadi MR. Noninvasive brain stimulation in alcohol craving: A systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. Jul 13 2020;101:109938. doi:10.1016/j.pnpbp.2020.109938

19. Enokibara M, Trevizol A, Shiozawa P, Cordeiro Q. Establishing an effective TMS protocol for craving in substance addiction: Is it possible? *Am J Addict*. Jan 2016;25(1):28-30. doi:10.1111/ajad.12309

20. Kang N, Kim RK, Kim HJ. Effects of transcranial direct current stimulation on symptoms of nicotine dependence: A systematic review and meta-analysis. *Addict Behav*. Sep 2019;96:133-139. doi:10.1016/j.addbeh.2019.05.006

21. Ma T, Sun Y, Ku Y. Effects of Non-invasive Brain Stimulation on Stimulant Craving in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-Analysis. *Front Neurosci*. 2019;13:1095. doi:10.3389/fnins.2019.01095

22. Maiti R, Mishra BR, Hota D. Effect of High-Frequency Transcranial Magnetic Stimulation on Craving in Substance Use Disorder: A Meta-Analysis. *J Neuropsychiatry Clin Neurosci*. Spring 2017;29(2):160-171. doi:10.1176/appi.neuropsych.16040065

23. Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. *World Psychiatry*. Oct 2021;20(3):397-404. doi:10.1002/wps.20905

24. Madeo G, Terraneo A, Cardullo S, et al. Long-Term Outcome of Repetitive Transcranial Magnetic Stimulation in a Large Cohort of Patients With Cocaine-Use Disorder: An Observational Study. *Front Psychiatry*. 2020;11:158. doi:10.3389/fpsyt.2020.00158

25. MagVenture. MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms. https://www.prnewswire.com/news-releases/magventure-receives-ce-approvals-for-noninvasive-brain-treatment-of-addiction-ocd-and-depression-with-anxiety-symptoms-301278708.html

26. Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Gallimberti L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. *Eur Neuropsychopharmacol*. Jan 2016;26(1):37-44. doi:10.1016/j.euroneuro.2015.11.011

27. Zhang JJQ, Fong KNK, Ouyang RG, Siu AMH, Kranz GS. Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. *Addiction*. Dec 2019;114(12):2137-2149. doi:10.1111/add.14753

28. Tseng PT, Jeng JS, Zeng BS, et al. Efficacy of non-invasive brain stimulation interventions in reducing smoking frequency in patients with nicotine dependence: a systematic review and network meta-analysis of randomized controlled trials. *Addiction*. Jul 2022;117(7):1830-1842. doi:10.1111/add.15624

29.   Petit B, Dornier A, Meille V, Demina A, Trojak B. Non-invasive brain stimulation for smoking cessation: a systematic review and meta-analysis. *Addiction*. Nov 2022;117(11):2768-2779. doi:10.1111/add.15889

30.   Soleimani G, Kuplicki R, Camchong J, et al. Are we really targeting and stimulating DLPFC by placing transcranial electrical stimulation (tES) electrodes over F3/F4? *Hum Brain Mapp*. Dec 1 2023;44(17):6275-6287. doi:10.1002/hbm.26492

31.   Joutsa J, Moussawi K, Siddiqi SH, et al. Brain lesions disrupting addiction map to a common human brain circuit. *Nature Medicine*. 2022/06/01 2022;28(6):1249-1255. doi:10.1038/s41591-022-01834-y

32.   Soleimani G, Joutsa J, Moussawi K, et al. Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment. *Am J Psychiatry*. Feb 1 2024;181(2):100-114. doi:10.1176/appi.ajp.20221022

33.   Soleimani G, Kuplicki R, Lim K, Paulus M, Ekhtiari H. Dual Neuromodulation Targets for Treatment of Substance Use Disorders: Unraveling the Interacting Role of DLPFC and Frontopolar Cortex During Drug Cue Reactivity. SPRINGERNATURE CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND; 2023:418-419.

Effectiveness of Noninvasive Brain Stimulation Protocols on Drug Craving and Consumption/Relapse in Substance Use Disorders: A Systematic Review and Meta-analysis of 208 Clinical Trials and 36 Protocols

Supplementary materials

Contents

Search terms

Table S.1. key terms used to search in the PubMed database

The key terms for TMS: 1-"transcranial magnetic stimulation", 2-TMS, 3-rTMS, 4-"theta burst stimulation", 5-cTBS, 6-iTBS
The key terms for tES: 1-"transcranial direct current stimulation", 2-tDCS, 3-tES, 4-"transcranial electrical stimulation", 5- tCS, 6- "transcranial current stimulation", 7- "transcranial Alternating Current Stimulation", 8- tACS, 9- "transcranial random noise stimulation", 10- tRNS, 11- "electrical stimulation"
The key terms for tFUS: 1- "transcranial focused ultrasound", 2-"tFUS", 3-"TUS", 4-"transcranial Ultrasound", 5-"HIFU", 6-"LIFU"
The key terms related to addiction: 1-addiction, 2-"substance use", 3-"substance abuse", 4-"substance related disorder", 5-"drug abuse", 6-"behavioral addiction", 7-dependency, 8-craving, 9-alcohol, 10-nicotine, 11-tobacco, 12-smoking, 13- cigarette, 14-cannabis, 15-opioid, 16-marijuana, 17-crack, 18-cocaine, 19- morphine, 20-heroin, 21-methamphetamine, 22-caffeine

Data extraction process

After finalizing the inclusion process, literature search results were imported into three separate sheets for TMS, tES, and tFUS studies. Data extracted from the literature were filled into a spreadsheet by AS and HT. Consistency between the authors was honed through a calibration exercise in which all authors evaluated and discussed their ratings for 20 randomly chosen studies.[1] GS further refined the data extraction form to reduce inconsistency and ambiguity after the exercise. Data on study design features and basic methodological parameters were extracted first, and each article was reviewed independently by two investigators (AS and HT) in two separate spreadsheets, with inconsistencies resolved in discussions with GS and HE. Despite following a similar data extraction policy to the previously published INTAM systematic review,[2] a comprehensive screening of the literature by 2018 was conducted once again to ensure the absence of any inconsistencies. This step was taken to guarantee the accuracy and reliability of the extracted data. By re-screening the entire range of publications within the specified timeframe, potential discrepancies or errors in the data extraction process were identified and rectified. This approach aimed to maintain the integrity and consistency of the review, providing a robust foundation for the analysis and conclusions drawn from the included studies.

Inclusion/Exclusion criteria and data extraction

The initial search yielded a total of 508 articles on TMS, 663 articles on tES, and 156 articles on tFUS. Two independent investigators (AS, HT) reviewed the list of included studies and collected the coded data, and the 3rd investigator (GS) reviewed the collected databases and solved eventual conflicts. During the initial screening, based on titles and abstracts, 179 TMS records, 418 tES records, and 151 tFUS records were excluded. The reasons for exclusion encompassed articles that were book chapters, commentaries, author corrections, editorials, and studies focused on disorders other than substance use disorders (SUDs). One TMS study was identified as a duplicate under a different title. Subsequently, 327 TMS articles, 242 tES, and 5 tFUS articles progressed to the next stage, which involved full-text screening to identify eligible articles. A precise full-text review was conducted, resulting in the inclusion of 121 TMS, 86 tES, and 1 tFUS articles. Exclusion criteria at this stage included review articles, studies with only healthy subjects, case reports and case series, studies involving subjects other than humans, study protocols, electric field modeling, and studies published in languages other than English. Single or paired-pulse TMS studies were excluded, while studies including repetitive transcranial magnetic stimulation (rTMS) and deep transcranial magnetic stimulation (dTMS) (a type of rTMS) were included. Notably, no published study utilizing transcranial random noise stimulation (tRNS) in the field of tES was identified. The PRISMA flowchart illustrating the inclusion/exclusion procedure for TMS, tES, and tFUS studies are presented in Figure 1, respectively.

Publication details, including the country of publication (defined as the first affiliation of the first author, or the affiliation of the majority of the authors if the country of the first author was unclear), the publication year (based on PubMed's indexing), the main substance(s) of interest in the study, the main site of stimulation (were the stimulation electrode or coil is placed), the number of active stimulation sessions (participants received active tES or TMS), the number of subjects in the active arms, and the number of female subjects in the active arm were extracted. We categorized the current state of participants to four distinct time intervals at which the interventions were administered: (1) before the participant sought standard treatment (2) while the subject was treatment seeking but before undergoing standard treatment, (3) within the first month of standard treatment (mainly detoxification and stabilization) and (4) after the initial recovery period (more than one month). Additionally, the duration of the follow-up period, the control condition (active, sham, another therapy, another clinical population, or no-control conditions), the randomization method, the coil/electrode positioning system,

the stimulation dose (for TMS: site of pulses, stimulation type, frequency, intensity, and the number of pulses; for tES: anode/cathode size and location, stimulation intensity, and duration), and the primary/secondary outcome measures were extracted. Additionally, a binary rating system (Yes/No) was used to indicate whether a study observed any significant effects on a specific outcome measure in response to the stimulation. We also checked if computational head models were generated for electric field distribution pattern assessment.

Table S.2. Data Extraction for tES Studies.

Study	Substance	Active arm	Current status	Session	Follow up	Control	Randomization	Positioning	Target	Anode	Cathode	Duration	Intensity	Findings
Boggio et al.,(2008)[3]	Alcohol	11	Detoxification	1	NA	Active controlled and sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	35	35	20	2	Craving ↓
Fregni et al.,(2008)[4]	Nicotine	23	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	35	100	20	2	Cue-induced craving ↓
Boggio et al.,(2009)[5]	Nicotine	13	Active user non-treatment seeker	5	NA	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	35	100	20	2	Craving ↓ Cigarette consumption ↓
Boggio et al.,(2010)[6]	Cannabis	17	Detoxification	1	NA	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	35	35	15	2	Propensity for risk-taking ↑ Craving ↓ (Right anodal)
Nakamura-Palacios et al.,(2012)[7]	Alcohol	49	Detoxification	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS	35	35	10	1	Mean amplitude of P3 associated with alcohol-related sounds ↑ Cognitive function performance↑
da Silva et al.,(2013)[8]	Alcohol	6	Detoxification	5	< 1 month	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	35	35	20	2	Craving ↓ Depression symptoms ↓ Change in executive function ↑ Relapse ↓ Block the increase in neural activation triggered by alcohol related and neutral cues.
Pripfl et al.,(2013)[9]	Nicotine	36	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	5.3	35	15	0.45	Risk-taking in the 'cold' decision ↓ Risk-taking in the 'hot' decision ↑

	Substance	N	Population	Sessions	Follow-up	Control	Design	System	Montage					Outcome
Xu et al.,(2013) [10]	Nicotine	24	Pre-treatment treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS	35	35	20	2	Negative affects ↓
Conti et al.,(2014) [11]	Cocaine	7	Detoxification	5	3 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Left DLPFC activity ↑ (Neutral cues) Left DLPFC activity ↓ (Drug cues) Right DLPFC, FPC, OFC, ACC activity ↑ (Drug cues) Relapse ↓
Conti & Nakamura-Palacios,(2014) [12]	Cocaine	7	Detoxification	1	NA	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	ACC activity after visualization of drug cues ↓
Klauss et al.,(2014) [13]	Alcohol	16	Detoxification	10	6 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	13	2	Relapse ↓ Perception of quality of life ↑
Gorini et al.,(2014) [14]	Cocaine	18	Detoxification	1	NA	Active controlled and sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	32	32	20	1.5	Risk taking (from BART) ↓ Safe behaviors (from GDT) ↑ (right DLPFC) Risk taking (from GDT) ↑ (left DLPFC)
Fecteau et al.,(2014) [15]	Nicotine	12	Pre-treatment treatment seeker	5	NA	Sham controlled	Crossover	EEG System	right DLPFC-Anodal tDCS	35	35	30	2	Cigarette consumption ↓ Rejected offers of cigarettes ↑
Meng et al.,(2014) [16]	Nicotine	30	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Parallel	EEG System	right TPC-Cathodal tDCS/left TPC-Cathodal tDCS/right TPC-Cathodal tDCS	33.18	33.18	20	1	Bilateral cathodal stimulation resulted in a decreasing trend in attention to smoking-related cues; however, the effects were not significantly different from sham stimulation. Cigarette consumption ↓
Shahbabaie et al.,(2014) [17]	Amphetamines	30	Detoxification	1	NA	Sham controlled	Crossover	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Immediate craving ↓ Cue-induced craving ↑
Batista et al.,(2015) [18]	Cocaine	17	Detoxification	5	< 1 month	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Craving ↓

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Imaging	Montage					Outcomes
den Uyl et al.,(2015) [19]	Alcohol	29	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Parallel	NA	left DLPFC-Anodal tDCS/right IFG-Anodal tDCS	35	35	10	1	Mild craving ↓ (in the DLPFC group) Reaction time ↓
Pripfl & Lamm,(2015)	Nicotine	17	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	5.3	35	15	0.45	Negative affect in emotion appraisal ↓ (In anodal right group)
Smith et al.,(2015) [21]	Nicotine	14	Active user non-treatment seeker	5	< 1 month	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	5.08	5.08	20	2	MATRICS Consensus Cognitive Battery (MCCB) Composite score ↑ MCCB Working Memory and Attention-Vigilance ↑
den Uyl et al.,(2017) [22]	Alcohol	30	Detoxification	4	12 months	Active controlled and sham controlled and another therapy	Parallel	NA	left DLPFC-Anodal tDCS	35	100	20	2	Craving ↓ Approach bias ↓ Relapse ↓
den Uyl et al.,(2016) [23]	Alcohol	19	Active user non-treatment seeker	3	NA	Active controlled and sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	35	35	15	1	Cue-induced craving ↓
Falcone et al.,(2016) [24]	Nicotine	25	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS	25	25	20	1	Latency to smoke ↑ Cigarette consumption ↓
Nakamura-Palacios et al.,(2016)	Alcohol/Cocaine	21	Detoxification	5	NA	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20/26	2	Relapse ↓ Craving ↓ vmPFC activation ↑
Wang et al.,(2016) [26]	Opioids	10	Recovery	1	NA	Sham controlled	Parallel	NA	left TPC-Cathodal tDCS	35	35	20	1.5	Craving ↓
Wietschorke et al.,(2016) [27]	Alcohol	15	Detoxification	1	NA	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	1	Intention and desire to drink ↓ Startle amplitudes ↑ for alcohol-related cues (indicating more negative processing in alcohol-dependent patients)

Study	Substance	N	Population	Sessions	Duration	Control	Design	Measurement	Montage					Results
Kroczek et al.,(2016) [28]	Nicotine	13	Active user non-treatment seeker	1	NA	Sham controlled	Parallel	NA	left DLPFC-Anodal tDCS	35	35	15	2	Functional connectivity between the dlPFC and the OFC ↑
Shahbabaie, Ebrahimpoor, et al.,(2018) [29]	Amphetamines	15	Detoxification	1	NA	Sham controlled	Crossover	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Craving ↓ Significant modulation of DMN, ECN, and SN networks
Yang et al.,(2017) [30]	Nicotine	32	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS	35	100	30	1	Craving ↓
Klauss, Anders, Felippe, Nitsche, et al.,(2018) [31]	Alcohol	23	Recovery	10	3 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Craving ↓ Relapse ↓
Vitor de Souza Brangioni et al.,(2018) [32]	Nicotine	19	Active user non-treatment seeker	5	< 1 month	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	35	35	20	1	Cigarettes consumption ↓ Higher levels of motivation were associated with a larger tDCS response.
Mondino et al.,(2018) [33]	Nicotine	17	Pre-treatment treatment seeker	10	< 1 month	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	100	20	2	Craving ↓ Brain activity (right posterior cingulate) ↓
den Uyl et al.,(2018) [34]	Alcohol	20	Active user non-treatment seeker	4	12 months	Sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	35	100	20	2	Only active tDCS combined with real attentional bias modification (ABM) showed an overall avoidance bias toward alcohol-related cues. No main or interaction effects of tDCS and ABM on the bias scores, craving, or relapse(effects on relapse after active tDCS were in the expected direction).
Sharifi-Fardshad et al.,(2018) [35]	Opioids	20	Recovery	1	NA	Sham controlled	Parallel/Crossover	EEG System	right DLPFC-Anodal tDCS/left DLPFC-Anodal tDCS	35	35	20	2	Drug craving ↓

Study	Substance	N	Phase	Sessions	Follow-up	Control	Design	System	Montage					Results
Klauss, Anders, Felippe, Ferreira, et al.,(2018) [36]	Cocaine	19	Detoxification	10	2 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Craving scores ↓ (over five measurements, in both sham- and real tDCS groups) Relapse rates were high and quite similar between groups in the 30- and 60-days follow-up after discharge from the hospital.
Shahbabaie, Hatami, et al.,(2018) [37]	Amphetamines	75	Detoxification	1	NA	Active controlled and sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS/left DLPFC-Anodal tDCS/left DLPFC-Anodal tDCS/left DLPFC-Anodal tDCS	35	35	26	2	Attentional bias ↓ (left DLPFC/right shoulder and left DLPFC/right DLPFC montages)
Eskandari et al.,(2019) [38]	Opioids	20	Detoxification	1	NA	Active controlled and sham controlled	Parallel		left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	NA	NA	20		No significant difference between the two active groups Right DLPFC: BDNF ↑ anxiety ↓ craving ↓ Left DLPFC: depression ↓ anxiety ↓ stress ↓ craving ↓
Hajloo et al.,(2019) [39]	Nicotine	20	Active user non-treatment seeker	10	1 month	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	NA	NA	20	2	Number of cigarette smoking ↓ (both daily and social smoking groups) Craving ↓
Martinotti et al.,(2019) [40]	Alcohol/Cannabis/Cocaine/Opioids	18	Pre-treatment treatment seeker	5	NA	Sham controlled	Parallel	EEG System	left DLPFC-Cathodal tDCS	25	25	20	1.5	Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Barratt Impulsiveness Scale, and visual analog scale (VAS) in all subjects ↓ Significant time by group interaction for VAS in favor of the active group. Regression analysis showed that the pre-VAS score had a significant influence on the post-VAS score.
Taremian et al.,(2019) [41]	Opioids	20	Recovery	10	< 1 month	Sham controlled and another therapy	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Craving ↓ (in the active tDCS group compared to sham and methadone-only groups) Depression and anxiety symptoms ↓ (in the active tDCS group compared to the other two groups)
Claus et al.,(2019) [42]	Alcohol	20	Active user non-treatment seeker	4	1 month	Sham controlled and another therapy	Parallel	EEG System	right IFG-Anodal tDCS	11	11	20	2	Alcohol approach biases ↔ remained significant at baseline, but neither cognitive bias modification, tDCS, nor the interaction reduced bias at follow-up. Drinks per drinking day (DDD) ↓ (1-week/1-month follow-ups) DDD and percent heavy drinking days ↔ no significant effects of the intervention
Ghorbani Behnam et al.,(2019) [43]	Nicotine	70	Pre-treatment treatment seeker	20	6 months	Active controlled and sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	35	100	20	2	Abstinence rates ↔ 6-month point: Group D (25.7%), Group A (20%), Group B (7%), Sham groups C and D (3.1% and 3%) Nicotine dependency ↓ (Group D compared to Group A) Abstinence rates ↔ no significant differences between Group D and Group A (salivary cotinine)

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Device	Montage					Results
Alghamdi et al.,(2019) [44]	Nicotine	12	Pre-treatment treatment seeker	3	4 months	Sham controlled	Parallel	EEG System	right DLPFC-Cathodal tDCS	25	25	20	1.5	Significant effect of time but no effect of group for the number of smoked cigarettes. Number of cigarettes in both groups ↓ No significant changes in long-term follow-up.
Falcone et al.,(2019) [45]	Nicotine	71	Pre-treatment treatment seeker	3	< 1 month	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	25	25	20	1/2	Abstinence rates ↔ no significant differences across dose groups during the quit period (sham: 2.5, 1 mA: 2.5, 2 mA: 2.4 days) Smoking rate ↔ no significant changes among dose groups (sham: 12.6, 1 mA: -11.8, 2 mA: -11.7 CPD) Latency to smoke and cigarettes smoked ↔ no effects of dose group during the smoking lapse paradigm Side effects ↔ mild (<5 out of 10); active and sham treatments indistinguishable by participants
Witkiewitz et al.,(2019) [46]	Alcohol	47	Pre-treatment treatment seeker	8	2 months	Sham controlled and another therapy	Parallel	EEG System	right IFG-Anodal tDCS	15	15	30	2	Drinks per drinking day ↓ Number of groups attended ↔ significant dose effect Percent heavy drinking days and alcohol cue reactivity ↔ significant effects of time and dose for groups attended Primary and secondary outcomes ↔ no significant differences between active and sham tDCS
Verveer, van der Veen, et al.,(2020) [47]	Cocaine	29	Detoxification	10	3 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	13	2	Cocaine use days and craving ↔ no significant effects of active tDCS Relapse rates ↔ frequent in both active (48%) and sham (69.2%) tDCS groups, despite ↓ craving during the first two weeks Cognitive functions ↔ no observed effects Crack cocaine relapse rates ↓ (active tDCS group)
Verveer, Remmerswaal, van der Veen, et al.,(2020) [48]	Nicotine	34	Active user non-treatment seeker	6	3 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	13	2	No significant effect of active tDCS one day after stimulation protocols in terms of behavioral and neurophysiological. A three-month follow-up revealed significant improvement in reaction time and a decrease in P3 amplitude in response to smoking cues.
Holla et al.,(2020) [49]	Alcohol	11	Detoxification	5	3 months	Sham controlled	Parallel	EEG System	left DLPFC-Cathodal tDCS	35	35	20	2	Integrated global efficiency of brain networks↑ (predictor of relapse) Integrated global clustering↓ (positive correlation with impulsivity) Functional connectivity of a specific sub-network involving prefrontal regions↑
Kooteh et al.,(2020) [50]	Opioids	14	Recovery	8	NA	Active controlled and another therapy	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	45	2	Significant differences between groups in terms of craving and thoughts and fantasies about drug use. The decrease is higher in the tDCS + emotion regulation group.

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Localization	Montage					Outcomes
Aronson Fischell et al.,(2020)[51]	Nicotine	43	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Crossover	Beam F3	left DLPFC-Anodal tDCS/right FPC-Anodal tDCS	35	35	25	2	Default mode network (DMN) nodes during the working memory task ↓ Activation of ACC (greater activity in smokers) ↑ Nicotine withdrawal reduced task engagement and attention and reduced suppression of DMN nodes.
Ververe, Remmerswaal, Jongerling, et al.,(2020)[52]	Nicotine	35	Active user non-treatment seeker	6	3 months	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	13	2	Number of smoked cigarettes a day up to one week after the last tDCS session in both conditions ↓ Active treatment had no additional effect on cigarette consumption, craving, and affect.
Sadeghi Bimorgh et al.,(2020)[53]	Opioids	14	Detoxification	7	NA	Sham controlled and another therapy	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Depression, anxiety, and stress of participants ↓ significantly in the intervention group. The relapse rate showed no significant changes between the two groups.
Vanderhasselt et al.,(2020)[54]	Alcohol	45	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Reward-triggered approach bias ↓ Alcohol consumption ↓ No significant change in self-reported craving Association between, reward-triggered approach bias and alcohol consumption only in the sham group.
Mondino et al.,(2020)[55]	Nicotine	19	Pre-treatment treatment seeker	1	NA	Sham controlled and another therapy	Crossover	EEG System	left DLPFC-tACS/right DLPFC-tACS	9	9	30	2	Time spent looking at smoking-related pictures (tACS+ABM) ↓ Prevented the increase of self-reported desire to smoke. Proportion of impulsive choices ↓
Daughters et al.,(2020)[56]	Alcohol/Cocaine/Cannabis/Opioids	20	Pre-treatment treatment seeker	1	NA	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-tACS/right DLPFC-tACS	25	35	40	2	Inhibitory control ↑ A large and significant effect of alpha-Tacs. There were no significant effects of the condition on distress tolerance.
Alizadehgoradel et al.,(2020)[57]	Amphetamines	19	Detoxification	10	1 month	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	35	35	20	2	Task performance across all executive functions (EFs) (immediately after and 1 month) ↑ Craving (immediately after and 1 month) ↓ A significant correlation between cognitive control improvement and craving reduction.
Dormal et al.,(2020)[58]	Alcohol	20	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-Anodal tDCS	35	35	20	1.5	No significant behavioral differences between tDCS and sham stimulation groups. Attentional resource mobilization (indexed by the N2 component) ↑ Inhibition processes (indexed by the P3 component) remained unchanged.

Study	Substance	N	Status	Sessions	Follow-up	Control	Design	Device	Stimulation					Results
Brown et al.,(2020) [59]	Alcohol	36	Pre-treatment treatment seeker	8	NA	Sham controlled and another therapy	Parallel	EEG System	right IFG-Anodal tDCS	15	15	30	2	In response to alcohol cues: Craving ratings ↓ Late positive potential (LPP) ↓ The magnitude of alcohol image craving reductions was associated with the number of mindfulness-based relapse prevention (MBRP) group sessions attended. Active tDCS was not associated with craving ratings, but it was associated with greater LPP amplitudes across image types.
Mostafavi et al.,(2022) [60]	Opioids	20	Detoxification	10	NA	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	NA	NA	20	2	The amplitude of slow brain waves (delta, theta, and alpha) in prefrontal, frontal, occipital, and parietal areas ↓ Coherence of beta, delta, and theta frequency bands in the parietal, central, and temporal regions ↑ Sham group: The amplitude of the alpha wave ↓ The coherence of delta and theta waves ↓
Perri & Perrotta,(2021) [61]	Nicotine	10	Active user non-treatment seeker	5	NA	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	25	25	20	2	Cigarette craving (50%) ↓ The number of cigarettes smoked remained unchanged.
Gaudreault et al.,(2021) [62]	Cocaine	8	Recovery	15	1 month	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Self-reported craving ↓ Perceived quality of life ↑ Impulsivity ↓ Daytime sleepiness and readiness to change drug use showed significant Group × Time interactions, with improvements observed only in the real-tDCS group. One-month follow-up indicated transient effects of tDCS on sleepiness and craving.
Xu et al.,(2021) [63]	Amphetamines	24	Recovery	20	NA	Sham controlled and another therapy and control group	Parallel	EEG System	right DLPFC-Anodal tDCS	38.5	38.5	20	1.5	Craving ↓ by tDCS + computerized cognitive addiction therapy (CCAT) Craving in active tDCS + CCAT < sham tDCS + CCAT Two Back task (TWOB) improved by tDCS + CCAT. Discounting did not change with active or sham tDCS.
Eskandari et al.,(2021) [64]	Opioids	21	Detoxification	10	NA	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	NA	NA	20	2	Drug craving (active and sham) ↓ Impulsivity and its dimensions (right/left DLPFC) ↓ Levels of IL-6 and TNF-α (not statistically) ↓
Alizadehgoradel et al.,(2021) [65]	Amphetamines	16	Detoxification	12	1 month	Active controlled and sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	NA	NA	20	1.5	Performance in most executive functions (EFs) tasks (tDCS+) ↑ (post-test phase and follow-up phase in real tDCS + mindfulness-based substance abuse treatment (MBSAT)) Craving ↓ (after intervention in all treatment groups, but not the sham stimulation group) The increase in EFs and the reduction in craving post versus pre-tDCS＋MBSAT intervention were correlated.

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Targeting	Montage			Duration	Intensity	Outcomes
Dubuson et al.,(2021) 66	Alcohol	64	Pre-treatment treatment seeker	5	12 months	Active controlled and sham controlled and another therapy	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Abstinence rate at the 2-week follow-up ↑ (did not persist beyond two weeks after the intervention) Higher abstinence rates for the verum tDCS associated with alcohol cue inhibitory control training (ICT). Neither the reduction of craving nor the improvement in executive control resulted specifically from prefrontal tDCS and ICT.
McKim et al.,(2021) 67	Alcohol	17	Recovery	1	NA	Sham controlled and healthy control	Parallel/Crossover	EEG System	left DLPFC-tACS/right DLPFC-tACS	19.8025	42.4085	30	2	Perseverative errors ↓ (in SUD group following tACS; reduction dependent on addiction history duration) Perseverative errors ↑ (in the control group following 10 Hz-tACS) Behavioral flexibility ↔ altered circuit-level dynamics by tACS Chronic substance abuse ↔ associated with circuit dynamics ameliorated by tACS
Müller et al.,(2021) 68	Nicotine	24	Active user non-treatment seeker	5	NA	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	25	25	20	2	Cigarette consumption ↓ (significant decrease observed after stimulation in both intervention groups) CO levels ↓ (significant decrease observed after stimulation in both intervention groups) Craving ↓ (significant decrease observed after stimulation in both intervention groups) Executive functions ↔ no improvements in either group Active group ↔ higher perceived stress linked to lower cigarette consumption; lower self-control linked to higher CO reduction
Lin et al.,(2021) 69	Nicotine/Opioids	18	Active user non-treatment seeker	5	< 1 month	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS/left FPC-Anodal tDCS	NA	NA	20	2	The expired CO concentration ↓ Number of cigarettes smoked in both groups ↓ No significant group difference with regard to craving tendency.
Patel et al.,(2022) 70	Cannabis	15	Active user non-treatment seeker	1	NA	Sham controlled	Parallel	Beam F3	right DLPFC-Anodal tDCS	35	35	15	2	No significant effects of stimulation on risk-taking behavior were found. There was a significant ↑ delay in discounting of a $1000 delayed reward during stimulation for the sham group. No significant effects for probability discounting.
Jiang et al.,(2022) 71	Amphetamines	23	Recovery	5	NA	Sham controlled	Parallel	MRI guided	right DLPFC-Anodal tDCS	11.4	11.4	20	2	Behavioral impulsivity ↑ (decreased accuracy for the deviant stimulus)
Weidler et al.,(2022) 72	Alcohol/Nicotine	35	Active user non-treatment seeker	1	NA	Sham controlled and healthy control	Parallel	EEG System	right DLPFC-Anodal tDCS	35	100	20	1.5	Alcohol-dependent patients (AD) did not exhibit the typical increase in aggression over time observed in other groups. Response inhibition ↑ in AD and tobacco users (TU) (following active, but not sham, stimulation)

Study	Substance	N	Population	N	Follow-up	Control	Design	Localization	Montage					Results
Fayaz Feyzi et al.,(2022) [73]	Amphetamines	15	Active user non-treatment seeker	16	1 month	Sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	35	35	20	2	Craving ↓ (in the active tDCS group compared to sham and psychotherapy-only groups) Auditory and visual memory ↑ (Wechsler), true and false answers ↑ (WCST) in the active tDCS Relapse rates ↔ no significant differences between groups A significant correlation in craving reduction and cognitive functioning (active tDCS group)
Gibson et al.,(2022) [74]	Alcohol	47	Pre-treatment treatment seeker	8	2 months	Sham controlled	Parallel	EEG System	right IFG-Anodal tDCS	15	15	30	2	Treatment adherence by the tDCS condition did not predict mindfulness; however, their interaction significantly predicted post-treatment craving. In the sham group, higher treatment adherence was associated with lower post-treatment craving, while no such relationship was observed in the active tDCS group.
Meng et al.,(2022) [75]	Opioids/Nicotine	11	Recovery	1	NA	Sham controlled	Parallel	EEG System	left TPC-Cathodal tDCS/right TPC-Cathodal tDCS	33.16625	33.16625	20	1	Daily cigarette consumption ↓ (observed in heavy smokers and those with heroin use history, lasting at least 48 hours) Detectable changes of the dynamic pupil light reflex after bilateral tDCS stimulation.
Ekhtiari et al.,(2022) [76]	Amphetamines	30	Detoxification	1	NA	Sham controlled	Parallel	Beam F3	right DLPFC-Anodal tDCS	35	35	20	2	Self-reported craving ↓ ↓ Brain reactivity to cues following sham but not active tDCS. There were significant time-by-group interactions in five main clusters in the middle and inferior frontal gyri, anterior insula, inferior parietal lobule, and precuneus. There was a significant effect of stimulation type in the relationship between electrical current at the individual level and changes in task-modulated activation. Brain regions with the highest electric current in the prefrontal cortex showed a significant time-by-group interaction in task-modulated connectivity in the frontoparietal network. In this trial, there was no significant effect of the one session of active-F4/Fp1 tDCS on drug craving self-report compared to sham stimulation. However, activation and connectivity differences induced by active compared to sham stimulation suggested some potential mechanisms of tDCS to modulate neural response to drug cues.
Khajehpour et al.,(2022) [77]	Amphetamines	22	Detoxification	1	NA	Sham controlled	Parallel	EEG System	right DLPFC-Anodal tDCS	3.14	3.14	20	2	P3 amplitude ↓ (following tDCS session compared to the sham group) P3 amplitude changes ↔ significantly correlated with communication efficiency (brain connectivity network (BCN) topology metrics) LPP amplitude ↔ no significant change due to tDCS application

Study	Substance	N	Phase/Status	Sessions	Follow-up	Control	Design	Measurement	Stimulation Protocol					Outcomes
Soleimani et al.,(2022) [78]	Amphetamines	15	Detoxification	1	NA	Sham controlled	Crossover	EEG System	right DLPFC-Anodal tDCS	35	35	20	2	Craving ↓ PFC node in executive control (ECN) ↑ PPI connectivity with precuneus and visual cortex PFC node in default mode (DMN) ↓ PPI connectivity with contralateral parietal cortex Connectivity ↑ within/between ECN-ventral attention (VAN) Connectivity ↓ between ECN-DMN Functional activity ↑ in ECN/VAN PFC nodes Functional activity ↓ in DMN PFC node EF direction ↔ outward in DMN; inward in ECN/VAN Bilateral tDCS ↔ cortical excitability ↑ in ECN/VAN; opposite effects in DMN.
Schwippel et al.,(2022) [79]	Alcohol	27	Detoxification	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-Cathodal tDCS	35	35	30	1	Implicit bias ↔ alcohol avoidance and nondrinking identity observed in abstinent alcohol use disorder patients Cathodal tDCS ↔ no modulation of alcohol-related implicit associations or control task performance
Kumar et al.,(2022) [80]	Opioids	14	Detoxification	10	NA	Sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS	3.14	3.14	20	2	Drug Questionnaire (DDQ) ↓ Obsessive-Compulsive Drug Use Scale (OCDUS) ↓ (except for 2 subcomponents) Clinical Opiate Withdrawal Scale (COWS) ↓ Glutamate-glutamine and GABA ↔ no significant changes at DLPFC in either active or sham groups Comparable changes observed in DDQ, OCDUS (except 2 subcomponents), COWS, and neurochemicals between active and sham groups.
Rezvanian et al.,(2022) [81]	Amphetamines	15	Pre-treatment treatment seeker	1	NA	Active controlled	Crossover	EEG System	right DLPFC-Anodal tDCS/left DLPFC-Anodal tDCS/right cerebellar-Anodal tDCS/left cerebellar-Anodal tDCS	NA	NA	20	2	Craving ↔ no significant changes observed after a single session of tDCS Cognitive inhibition ↑ (notably in protocol 2: right DLPFC cathodal and left DLPFC anodal stimulation)
Camchong et al.,(2023) [82]	Alcohol	31	Detoxification	10	4 months	Sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	25	25	13	2	Causal discovery analysis (CDA)-determined connectivity ↑ (LDLPFC to incentive salience and negative emotionality addiction networks in the active tDCS group only) Relapse rates ↓ (lower probability of relapse in active tDCS group compared to sham) Relapse rates ↔ unexpected sex-dependent effects observed in active tDCS group
Chen et al.,(2023) [83]	Amphetamines	10	Recovery	10	NA	Sham controlled and control group	Parallel	EEG System	right DLPFC-Anodal tDCS	35	35	13	2	Behavioral performance ↑ and cost of invalid cues ↓ (in drug users following tDCS delivery compared to controls) P300 amplitude ↑ (specifically for neutral cues after tDCS, resembling patterns seen in non-drug users)

Study	Substance	Active arm	Current status	Session	Follow up	Control	Randomization	Positioning	Target					Findings
Qin et al.,(2023) [84]	Nicotine	42	Active user non-treatment seeker	2/5	< 1 month	Active controlled and sham controlled and another therapy	Parallel/Crossover	EEG System	right DLPFC-Anodal tDCS	35	35	25/20	2	Cigarette consumption ↓ (enhancement effect of tDCS on psychoeducation (PE)) Craving ↓ and cigarette consumption ↓ (cumulative effect of repeated PE during intervention) Cigarette intake ↔ maintained at a low level for one week with PE combined with tDCS compared to PE alone.
He et al.,(2023) [85]	Amphetamines	58	Recovery	10	NA	Active controlled and sham controlled and healthy control	Parallel	EEG System	left DLPFC-Anodal tDCS/left DLPFC-Cathodal tDCS	NA	NA	20	2	Aggressiveness ↑ (in Methamphetamine (MA) addicts compared to healthy controls) Aggressiveness ↓ (following anodal tDCS intervention on the left DLPFC, especially under high-intensity provocation) Time × tDCS group ↔ statistically significant interaction
Lu et al.,(2023) [86]	Nicotine	33	Active user non-treatment seeker	1	NA	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-Anodal tDCS/right DLPFC-Anodal tDCS	35	35	20	2	Ipsilateral precuneus activity ↓ (following anodal stimulation over one DLPFC area during the go task state) Right DLPFC stimulation ↑ functional connectivity between bilateral DLPFCs and right anterior cingulate cortex (associated with cognition and executive function inhibition)
Soleimani et al.,(2023) [87]	Amphetamines	30	Detoxification	1	NA	Sham controlled	Parallel	Beam F3	right DLPFC-Anodal tDCS	35	35	20	2	At voxel, regional, and cluster levels ↔ no FDR-corrected significant correlations was observed between changes in functional activity and electric fields. Frontoparietal connectivity ↔ significant positive correlation with electric field at frontopolar stimulation site Network-based analysis ↔ revealed dependency of tDCS effects on individual regional current dose
Dayal et al.,(2024) [88]	Alcohol	22	Detoxification	10	3 months	Sham controlled and another therapy	Parallel	EEG System	left DLPFC-Anodal tDCS	25	25	20	2	Obsessive Compulsive Drinking Scale (OCDS) scores ↓ over time; however, treatment and treatment × time interaction ↔ no significant effects on OCDS scores Complete abstinence rates ↔ no significant differences between active and sham treatment groups

Abbreviations: tES: transcranial electrical stimulation, tDCS: transcranial direct current stimulation, tACS: transcranial alternating current stimulation, EEG: electroencephalography, MRI: magnetic resonance imaging, DLPFC: dorsolateral prefrontal cortex, FPC: frontopolar cortex, IFG: inferior frontal gyrus, TPC: temporoparietal cortex, NA: not available.

Table S.3. Data Extraction for TMS Studies.

Study	Substance	Active arm	Current status	Session	Follow up	Control	Randomization	Positioning	Target	Coil	Frequency	Intensity	Pulses	Findings
Eichhammer et al.,(2003) [89]	Nicotine	14	Pre-treatment treatment seeker	2	NA	Sham controlled	Crossover	5 cm rule	left DLPFC-HF TMS	NA	20	90	1000	Number of cigarettes ↓

Study	Substance	N	Treatment stage	Sessions	Follow-up	Control	Design	Localization	Target	Coil	Frequency	Intensity	Pulses	Outcome
Camprodon et al.,(2007) [90]	Cocaine	6	Detoxification	1	NA	Active controlled	Crossover	NA	right DLPFC-HF TMS/left DLPFC-HF TMS	NA	10	90	2000	Craving ↓
Amiaz et al.,(2009) [91]	Nicotine	26	Pre-treatment treatment seeker	10+6	6 months	Sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	1000	Cigarette consumption ↓ Nicotine dependence ↓ Cue-induce craving ↓
Mishra et al.,(2010) [92]	Alcohol	30	Detoxification	10	< 1 month	Sham controlled	Parallel	NA	right DLPFC-HF TMS	Figure of 8	10	110	1000	Craving ↓
Höppner et al.,(2011) [93]	Alcohol	10	Recovery	10	NA	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	NA	20	90	1000	There were no significant differences between the active and sham group in terms of alcohol craving or mood.
Rose et al.,(2011) [94]	Nicotine	15	Pre-treatment treatment seeker	1	NA	Active controlled	Crossover	EEG System	SFG-HF TMS/SFG-LF TMS	NA	10/1	90	4500/450	Craving after smoking cue ↑ (10 Hz SFG) Craving after neutral cue ↓ (Only in 10 Hz) Immediate craving ↓ (Only in 10 Hz) Intensity of interoceptive airway sensations ↓ (Only in 10 Hz)
Herremans et al.,(2012)	Alcohol	15	Recovery	1	< 1 month	Sham controlled	Parallel	5 cm rule	right DLPFC-HF TMS	Figure of 8	20	110	1560	One HF-rTMS session did not result in changes in craving (neither immediately after the stimulation session, nor in patients' natural environment during the weekend).
Wing et al.,(2012) [96]	Nicotine	6	Pre-treatment treatment seeker	20	NA	Sham controlled	Parallel	EEG System	right DLPFC-HF TMS/left DLPFC-HF TMS	Figure of 8	20	90	1500	Craving in the first week ↓
Herremans et al.,(2013) [97]	Alcohol	29	Recovery	1	NA	Sham controlled	Crossover	5 cm rule	right DLPFC-HF TMS	NA	20	110	1560	Commission error ↓ (both groups) Intra-individual reaction time variability in the active group ↓
Li, Malcolm, et al.,(2013) [98]	Amphetamines	10	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	6 cm rule	left DLPFC-LF TMS	Figure of 8	1	100	900	Cue-induced craving ↓

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Localization	Target	Coil	Frequency	Intensity	Pulses	Results
Li, Hartwell, et al.,(2013)[99]	Nicotine	14	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	6 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	3000	Cue-induced craving ↓ Greater nicotine dependence is associated with a larger decrease in craving.
Sheffer et al.,(2013)[100]	Nicotine	47	Active user non-treatment seeker	1	< 1 month	Active controlled and sham controlled	Crossover	6 cm rule	left DLPFC-HF TMS/left DLPFC-HF TMS	NA	20/10	110	900	Discounting of monetary gains ↓ Discounting of monetary losses ↑
Dieler et al.,(2014)[101]	Nicotine	38	Pre-treatment treatment seeker	4	12 months	Sham controlled and another therapy	Parallel	EEG System	right DLPFC-HF TMS	Figure of 8	50	80	600	Abstinence rate in 3 months ↑
Dinur-Klein et al.,(2014)[102]	Nicotine	32	Pre-treatment treatment seeker	13	6 months	Active controlled and sham controlled	Parallel	6 cm rule	left DLPFC-HF TMS/right DLPFC-HF TMS/right Insula-HF TMS/left Insula-HF TMS/left DLPFC-LF TMS/right DLPFC-LF TMS/right Insula-LF TMS/left Insula-LF TMS	H4 coil	10/1	120	990/600	Cigarette consumption (in HF group) ↓ Nicotine dependence (in HF group) ↓ Abstinence rate (in HF group) ↑
Prikryl et al.,(2014)[103]	Nicotine	18	Active user non-treatment seeker	21	< 1 month	Sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	110	2000	Cigarette consumption in the second week ↓
Pripfl et al.,(2014)[104]	Nicotine	11	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	MRI guided	left DLPFC-HF TMS	Figure of 8	10	90	1200	Cue-induced craving ↓ Delta power ↓
Ceccanti et al.,(2015)[105]	Alcohol	9	Detoxification	10	6 months	Sham controlled	Parallel	5 cm rule	right FP-HF TMS/left FP-HF TMS	H7 coil	20	120	1500	Blood cortisol↓ Prolactinoma ↓ Craving ↓ Alcohol intake ↓
Girardi et al.,(2015)[106]	Alcohol	10	Recovery	20	NA	Another therapy	Parallel	5.5 cm rule	right DLPFC-HF TMS/left DLPFC-HF TMS	H1 coil	20	120	2200	Craving ↓ Depression symptoms ↓
Herremans et al.,(2015)[107]	Alcohol	26	Detoxification	1	NA	Sham controlled	Crossover	5 cm rule	right DLPFC-HF TMS	Figure of 8	20	110	1560	Activity in the left inferior parietal lobule ↓

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Localization	Target	Coil	Freq	Intensity	Pulses	Outcomes
Jansen et al.,(2015) [108]	Alcohol	20	Detoxification	1	NA	Sham controlled	Parallel	MRI guided	right DLPFC-HF TMS	Figure of 8	10	110	3000	Connectivity within the left frontoparietal network ↑
Mishra et al.,(2015) [109]	Alcohol	20	Detoxification	10	1 month	Active controlled	Parallel	5 cm rule	right DLPFC-HF TMS/left DLPFC-HF TMS	Figure of 8	10	110	1000	Craving↓
Rapinesi et al.,(2015) [110]	Alcohol	11	Recovery	20	6 months	Another clinical population	Parallel	5.5 cm rule	right DLPFC-HF TMS/left DLPFC-HF TMS	H1 coil	20	120	1980	Hamilton Depression Rating Scale, Clinical Global Impressions severity scale and Global Assessment of Functioning scores remained significantly improved after the 6-month follow-up.
Trojak et al.,(2015) [111]	Nicotine	18	Pre-treatment treatment seeker	10	3 months	Sham controlled and another therapy	Parallel	MRI guided	right DLPFC-LF TMS	Figure of 8	1	120	360	Abstinence rate ↑ The compulsive factor of craving ↓
Bolloni et al.,(2016) [112]	Cocaine	10	Pre-treatment treatment seeker	12	6 months	Sham controlled	Parallel	NA	right DLPFC-HF TMS/left DLPFC-HF TMS	H1 coil	10	100	1000	Cocaine intake in the long period ↓
Del Felice et al.,(2016) [113]	Alcohol	8	Detoxification	4	1 month	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	10	100	1000	Inhibitory control and selective attention ↑ Depression symptoms ↓ Power of fast frequencies ↓
Hanlon et al.,(2016) [114]	Cocaine	18	Active user non-treatment seeker	2	NA	Healthy control	Parallel	EEG System	left FPC-HF TMS/left DLPFC-HF TMS	Figure of 8	NA	110	12	BOLD signal in putamen, caudate, thalamus, and anterior cingulate cortex ↑
Herremans et al.,(2016) [115]	Alcohol	19	Detoxification	1	< 1 month	Sham controlled	Crossover	5 cm rule	right DLPFC-HF TMS	Figure of 8	20	110	1560	Baseline dorsal anterior cingulate cortex (dACC) activation may act as a protective mechanism against relapse in alcohol-dependent. Accelerated HF-rTMS treatment influenced dACC activation in a rate-dependent manner (greater increases in dACC activity observed in patients with lower baseline activation).
Huang et al.,(2016) [116]	Nicotine	19	Active user non-treatment seeker	21	< 1 month	Sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	110	2000	Cigarette consumption in the first week ↓

Author	Substance	N	Population	Sessions	Follow-up	Control	Design	Localization	Target-Coil	Coil	Frequency	Intensity	Pulses	Outcome
Mishra et al.,(2016) [117]	Alcohol	25	Detoxification	10	NA	Sham controlled	Parallel	5 cm rule	right DLPFC-HF TMS	Figure of 8	10	110	1000	High-frequency rTMS improved cerebral hemodynamic parameters in alcohol dependence.
Qiao et al.,(2016) [118]	Alcohol	18	Detoxification	20	NA	Sham controlled	Parallel	NA	right DLPFC-HF TMS	Figure of 8	10	80	800	Memory function in recently detoxified alcohol-dependent patients ↑ These improvements correlated with increased levels of hippocampal brain metabolites, including N-acetyl aspartic acid (NAA) and choline (Cho), as detected by proton magnetic resonance spectroscopy.
Shen et al.,(2016) [119]	Opioids	10	Pre-treatment treatment seeker	5	NA	Sham controlled	Parallel	NA	left DLPFC-HF TMS	Figure of 8	10	100	2000	Cue-induced craving ↓
Terraneo et al.,(2016) [120]	Cocaine	16	Pre-treatment treatment seeker	5+3	2 months	Another therapy	Parallel	MRI guided	left DLPFC-HF TMS	Figure of 8	15	100	2400	Craving ↓ Relapse ↓
Addolorato et al.,(2017) [121]	Alcohol	5	Pre-treatment treatment seeker	12	NA	Sham controlled	Parallel	5.5 cm rule	right DLPFC-HF TMS/left DLPFC-HF TMS	H7 coil	10	100	1000	Dopamine transporter ↓ Alcohol intake ↓
Baker et al.,(2017) [122]	Nicotine	20	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	MRI guided	left DLPFC-HF TMS/left DLPFC-LF TMS	Figure of 8	10/1	110	500/500	Abstinent smokers exhibited an increased reward response to cigarette rewards over monetary rewards. rTMS reversed this pattern.
Hanlon et al.,(2017) [123]	Cocaine/Alcohol	49	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left FPC-LF TMS	Figure of 8	50	110	3600	BOLD signal in the caudate, accumbens, anterior cingulate, orbitofrontal and parietal cortex ↓
Li, Du, et al.,(2017) [124]	Nicotine	10	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	6 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	3000	Activity in the right insula and thalamus ↓ Connectivity from the site of rTMS to the left orbitomedial PFC ↓
Li, Sahlem, et al.,(2017) [125]	Nicotine	11	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	6 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	3000	Activity in the NAc and mOFC ↓ Self-Reported Craving ↓

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Localization	Protocol	Coil	Frequency	Intensity	Pulses	Outcomes
Liu et al.,(2017) [126]	Amphetamines	10	Recovery	5	NA	Active controlled	Parallel	EEG System	left DLPFC-HF TMS/right DLPFC-HF TMS/left DLPFC-LF TMS/right DLPFC-LF TMS	Round coil	1/10	100	600/2000	Cue-induced craving ↓
Sahlem et al.,(2018) [127]	Cannabis	18	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	Beam F3	left DLPFC-HF TMS	Figure of 8	10	110	4000	Treatment is well tolerated.
Su et al.,(2017) [128]	Amphetamines	15	Recovery	5	NA	Sham controlled and healthy control	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	80	1200	Cue-induced craving ↓ Verbal learning and memory and social cognition ↑ Depression ↓
Kamp et al.,(2018) [129]	Nicotine	NA	Active user non-treatment seeker	15	3 months	Sham controlled	Parallel	NA	left DLPFC-HF TMS	NA	10	NA	1000	No significant main effects or group differences in cigarette consumption over time, except for a significant influence of antidepressant use on smoking reduction. A trend suggested that rTMS treatment might be effective only for individuals classified as strong smokers.
Kearney-Ramos et al.,(2018)	Cocaine/Alcohol	49	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left FPC-LF TMS	Figure of 8	50	110	3600	Cue-related functional connectivity in frontal-striatal circuits↓
Kozak et al.,(2018) [131]	Nicotine	27	Pre-treatment treatment seeker	6	NA	Sham controlled	Crossover	NA	right DLPFC-HF TMS/left DLPFC-HF TMS	NA	20	90	750	Overnight smoking abstinence led to increased tobacco craving, withdrawal symptoms, and memory impairment in both smokers with schizophrenia and non-psychiatric controls, with these effects being reversed after smoking reinstatement. Short-term bilateral rTMS showed no significant effect on craving, withdrawal, or cognitive outcomes, emphasizing the necessity for longer-term studies to evaluate its potential benefits.
Q. Liang et al.,(2018) [132]	Amphetamines	15	Recovery	1	NA	Sham controlled and healthy control	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	2000	Post-error slowing effect in response times of methamphetamine addicts ↓ Reaction times during post-error trials ↓

Study	Substance	N	Status			Control	Design	Targeting	Site	Coil	Freq	Intensity	Pulses	Outcome
Martinez et al.,(2018)	Cocaine	6	Active user non-treatment seeker	13	NA	Active controlled and sham controlled	Parallel	NA	right FPC-HF TMS/left FPC-HF TMS/ACC-HF TMS/right FPC-LF TMS/left FPC-LF TMS/ACC-LF TMS	H7 coil	10/1	110	1200/900	Number of choices for cocaine ↓ (Only in 10 Hz)
Sheffer et al.,(2018) [134]	Nicotine	16	Pre-treatment treatment seeker	8	3 months	Sham controlled	Parallel	6 cm rule	left DLPFC-HF TMS	Figure of 8	20	110	900	Delay discounting rate ↓ Relative risk of relapse ↓ Abstinence rates ↑ Uptake of the self-help intervention ↑
Zhang et al.,(2018) [135]	Amphetamines	15	Recovery	1	< 1 month	Sham controlled and healthy control	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	90	2000	Emotional attention ↑
Y. Liang et al.,(2018) [136]	Amphetamines	24	Detoxification	10	NA	Sham controlled	Parallel	NA	left DLPFC-HF TMS	Round coil	10	100	2000	Craving ↓ Withdrawal ↓ Sleep quality ↑ Depression ↓ Anxiety ↓
McNeill et al.,(2018) [137]	Alcohol	20	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	right DLPFC-LF TMS	Figure of 8	50	80	600	Consumption ↑ Stop-signal reaction time ↑
Wu et al.,(2018) [138]	Alcohol	22	Recovery	15	NA	Healthy control	Single arm	MRI guided	right DLPFC-HF TMS	Figure of 8	20	110	1560	Alcohol-dependent patients showed reduced baseline grey matter volume (GMV) in various brain areas compared to healthy controls, with relapsers displaying greater GMV decreases in midline structures, insular, hippocampal, and amygdala regions. Accelerated high-frequency rTMS did not significantly affect GMV baseline, but baseline GMV emerged as a predictor of future relapse.
Hanlon et al.,(2019) [139]	Alcohol	24	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left FPC-LF TMS	Figure of 8	50	110	3600	Cue-evoked connectivity between the MPFC-Putamen ↓ Scalp-to-cortex distance was the strongest predictor, followed by fractional anisotropy tract integrity and gray matter volume.
Jansen et al.,(2019) [140]	Alcohol	39	Detoxification	1	NA	Sham controlled and healthy control	Parallel	MRI guided	right DLPFC-HF TMS	Figure of 8	10	110	3000	Self-reported experienced emotions in response to positive and negative images ↓ Experienced emotions ↓ (in healthy control) Right dlPFC activity during appraisal of affective images ↓

Study	Drug	N	Status	Sessions	Interval	Control	Design	Localization	Target/Protocol	Coil	Frequency	Intensity	Pulses	Results
Kearney-Ramos et al.,(2019) [141]	Cocaine	25	Active user non-treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left FPC-LF TMS	Figure of 8	50	110	3600	Individuals with a high striatal response to cocaine cues at baseline had significantly attenuated striatal activity after real but not sham.
Lin et al.,(2019) [142]	Opioids/Amphetamines	40	Recovery	30	NA	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	10	100	2000	Sleep quality ↑ Depression ↓ Anxiety ↓
Liu et al.,(2019) [143]	Amphetamines	52	Pre-treatment treatment seeker	20	2 months	Another therapy	Parallel	5 cm rule	left DLPFC-HF TMS	NA	10	100	2000	Craving ↓ Drug abuse history predicts the efficacy of chronic treatment, and the effects of TMS treatment were more pronounced in young, high-craving subjects.
Prashad et al.,(2019) [144]	Cannabis	10	Active user non-treatment seeker	1	NA	Active controlled and healthy control	Crossover	MRI guided	PCC-HF TMS/precuneus-HF TMS/PCC-LF TMS/precuneus-LF TMS	Double cone	10/1	80	2000	Amplitude in P3 ↓ latencies in the P3, N2, and P2 ↓
Sanna et al.,(2019) [145]	Cocaine	47	Pre-treatment treatment seeker	20	NA	Active controlled	Parallel	NA	right DLPFC-HF TMS/left DLPFC-HF TMS/right DLPFC-HF TMS/left DLPFC-HF TMS	H4 coil	50/15	80/100	600/2400	Consumption ↓ (in both groups) Craving ↓ (in both groups)
Schluter et al.,(2019) [146]	Alcohol	40	Recovery	10	NA	Sham controlled and another therapy	Parallel	EEG System	right DLPFC-HF TMS	Figure of 8	10	110	3000	HF-rTMS did not influence performance on the delay discounting, Go-NoGo, or stop signal tasks. No significant correlations were observed between changes in task performance and baseline impulsivity or the severity of alcohol use disorder.
Biernacki et al.,(2020) [147]	NA	11	Pre-treatment treatment seeker	1	NA	Sham controlled	Crossover	EEG System	left DLPFC-HF TMS	Figure of 8	10	110	1500	Applying robot-assisted TMS enhanced the amplitude of the reward positivity in the Active group. The active group performed relatively better at reward-based learning than the sham group

Study	Substance	n	Population	Sessions	Follow-up	Control	Design	Coil Localization	Target	Coil Type	MT	Freq (Hz)	Pulses	Results
Tianzhen Chen et al.,(2020) [148]	Amphetamines	55	Detoxification	10	NA	Active controlled and sham controlled and another therapy	Parallel	EEG System	left DLPFC-HF TMS/left FPC-LF TMS	Figure of 8	50/50	100/110	900/900	Craving ↓ (In all active groups) Changes in craving were positively correlated with the improvement of anxiety and withdrawal symptoms. Group C (iTBS and cTBS) also had a shorter response time than Group A (iTBS). Group C (iTBD and cTBS) was effective in improving depression symptoms and withdrawal symptoms compared with Group D (Sham). Group C (iTBD and cTBS) was significant in improve sleep quality compared with Group A (iTBS).
T. Chen et al.,(2020) [149]	Amphetamines	54	Detoxification	20	NA	Sham controlled and another therapy	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	900	Cognition and emotion differed between responders and non-responders in real rTMS group but not in the sham group. Better cognitive and emotional functions means that patients have higher possibility for better response to real rTMS treatment.
Gómez Pérez et al.,(2020) [150]	Cocaine	87	Pre-treatment treatment seeker	34	NA	No treatment	Single arm	MRI guided	left DLPFC-HF TMS	Figure of 8	15	100	2400	Sleep quality ↑ Craving ↓ Negative effect ↓
Li et al.,(2020) [151]	Nicotine	21	Pre-treatment treatment seeker	10	3 months	Sham controlled	Parallel	MRI guided	left DLPFC-HF TMS	NA	10	100	3000	Consumption ↓ (also in follow up) Craving ↓ (also in follow up) No main treatment effect was found between treatment groups in the mean Minnesota Nicotine Withdrawal Scale (MNWS).
Liu, Zhao, Liu, et al.,(2020)	Opioids	75	Pre-treatment treatment seeker	20	3 months	Active controlled	Parallel	EEG System	left DLPFC-HF TMS/left DLPFC-LF TMS	Figure of 8	10/1	100	2000/6000	Craving ↓ (in both groups) The results suggest that the effects of such treatment can persist for up to 60 days after cessation.
Liu, Zhao, Shen, et al.,(2020) [153]	Amphetamines	129	Pre-treatment treatment seeker	20	2 months	Active controlled	Parallel	NA	left DLPFC-HF TMS/left DLPFC-LF TMS	NA	10/1	100	2000/6000	Craving ↓ (in both groups) Only the 1 Hz group maintained a significant decrease in craving rates during the follow-up period (days 30–90).

Study	Substance	N	Population		Follow-up	Control	Design	Targeting	Protocol	Coil		Intensity	Pulses	Outcome
Newman-Norlund et al.,(2020) [154]	Nicotine	12	Active user non-treatment seeker	1	NA	Active controlled	Crossover	MRI guided	right IFG-HF TMS/right IFG-LF TMS	Figure of 8	50/50	80	900/600	iTBS improved inhibitory control, whereas cTBS impaired inhibitory control.
Perini et al.,(2020) [155]	Alcohol	23	Pre-treatment treatment seeker	15	3 months	Sham controlled	Parallel	NA	right Insula-HF TMS/left Insula-HF TMS	H8 coil	10	120	1500	Craving and consumption ↓ (in both groups) This study does not support the efficacy of rTMS targeting the insula in alcohol addiction.
Raikwar et al.,(2020) [156]	Alcohol	30	Recovery	10	< 1 month	Sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10	120	800	High-frequency rTMS over the left DLPFC did not have significant effect in reducing craving in patients with alcohol dependence syndrome.
Su, Liu, et al.,(2020) [157]	Amphetamines	25	Pre-treatment treatment seeker	20	< 1 month	Sham controlled	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	900	Craving ↓ Functional connectivity between left DLPFC and inferior parietal lobule ↑ Functional connectivity between the insula and inferior parietal lobule, medial temporal lobe, and precuneus ↓ The increase of functional connectivity between DLPFC and the inferior parietal lobule correlated with craving reduction
Su, Chen, Zhong, et al.,(2020) [158]	Amphetamines	25	Pre-treatment treatment seeker	20	NA	Sham controlled	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	900	γ-aminobutyric acid/n-acetyl-aspartate concentration ↓ (active group) glutamate and glutamine/n-acetyl-aspartate concentration ↓ (sham group) Changes in γ-aminobutyric acid concentration were significantly associated with problem-solving and error monitoring abilities.
Su, Chen, Jiang, et al.,(2020)	Amphetamines	70	Pre-treatment treatment seeker	20	12 months	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	50	100	900	Craving ↓ Cognition ↑ Sleep quality ↑

Study	Substance	N	Population	Sessions	Duration	Control	Design	Localization	Target	Coil	Train	Intensity	Pulses	Outcomes
Yuan et al.,(2020) [160]	Amphetamines	37	Recovery	10	< 1 month	Sham controlled and healthy control	Parallel	5 cm rule	left DLPFC-LF TMS	Figure of 8	1	100	600	Patients with methamphetamine use displayed higher impulsivity than healthy controls. Low-frequency rTMS improved impulsivity control, with these effects lasting at least three weeks and accompanied by reductions in cue-induced cravings, both linked to pretest impulsivity levels.
Zhao et al.,(2020) [161]	Amphetamines	83	Recovery	10	NA	Active controlled	Parallel	EEG System	left DLPFC-HF TMS/left DLPFC-LF TMS/right DLPFC-LF TMS	Figure of 8/Round coil	50	70	600	Craving ↓ (iTBS of the left DLPFC and cTBS of the right DLPFC)
Abdelrahman et al.,(2021) [162]	Nicotine	20	Pre-treatment treatment seeker	10	3 months	Sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	20	80	2000	Consumption ↓ (in both groups) Craving↓ (in both groups) Dependence ↓ (in both groups) But improvement persisted to 3 months in the active group but not in the sham group Anxiety ↓ (in active group) Depression ↓ (in active group)
Bozzay et al.,(2021) [163]	Alcohol	8	Active user non-treatment seeker	10	1 month	Sham controlled	Parallel	EEG System	right DLPFC-HF TMS		50	80	1800	Alcohol use disorder patients reported more adverse events. Depression ↓ (AUD who received active stimulation demonstrated a greater rate of improvement) The presence of AUD did not impact posttraumatic stress disorder symptom change.
Cardullo et al.,(2021) [164]	Cocaine	230	Pre-treatment treatment seeker	32	NA	Sham controlled and another clinical population	Parallel	MRI guided	left DLPFC-HF TMS	NA	15	100	2400	Cocaine use ↓ (in both groups) Craving ↓ (in both groups) Other negative affect symptoms ↓ (in both groups)
Chen et al.,(2021) [165]	Amphetamines	30	Detoxification	20	NA	Sham controlled	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	900	Error rate in discriminating the color of methamphetamine-related words ↓ Significant effect for the N1 amplitude (methamphetamine words > neutral words) and P3 latency (methamphetamine words > neutral words). The change of N1 amplitude was positively correlated with cravings in the active group. Beta band neural oscillation power ↓

Study	Substance	N	Population		Duration	Control	Design	Localization	Target	Coil	Sessions	Intensity	Pulses	Outcomes
Garza-Villarreal et al.,(2021) [166]	Cocaine	24	Active user non-treatment seeker	10	6 months	Sham controlled	Parallel	MRI guided	left DLPFC-HF TMS	Figure of 8	5	100	5000	Craving ↓ Impulsivity ↓ Functional connectivity between the left dorsolateral PFC and ventromedial PFC ↑ Functional connectivity between the ventromedial PFC and right angular gyrus ↑ Self-reported frequency and grams consumed for 6 months ↓ Clinical and functional connectivity effects were maintained for 3 months, but they dissipated by 6 months.
Gupta et al.,(2021) [167]	Alcohol	50	Pre-treatment treatment seeker	NA	9 months	Another therapy	Parallel	NA	right DLPFC-HF TMS/left DLPFC-LF TMS	NA	50	90	600	Relapse ↓
Li et al.,(2021) [168]	Opioids	50	Pre-treatment treatment seeker	40	NA	Another therapy	Parallel	NA	NA	NA	20	100	6000	Craving ↓ Depression ↓ Anxiety ↓ Sleep quality ↑
Lolli et al.,(2021) [169]	Cocaine	31	Pre-treatment treatment seeker	15	2 months	Sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	15	100	2400	Craving ↓ Cocaine use ↓ (in both groups) Impulsive behavior ↓ Depression ↓ (in both groups)
Tsai et al.,(2021) [170]	Opioids	11	Recovery	11	3 months	Sham controlled and another therapy	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	15	100	2400	Depression ↓ Barratt Impulsiveness Scale (BIS-11) attentional subscales ↓ Continuous Performance Test (CPT)'s commission T-scores ↓ (Improved impulse control and attention)
Wang et al.,(2021) [171]	Amphetamines	33	Recovery	20	NA	Sham controlled and healthy control	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	50	100	600	Executive function ↑ (iTBS in patients with methamphetamine use disorder) Craving ↓ (iTBS in patients with methamphetamine use disorder) Improved executive function, particularly working memory and inhibition, was identified as a potential predictor of therapeutic efficacy.
Zangen et al.,(2021) [172]	Nicotine	123	Pre-treatment treatment seeker	15+3	3 months	Sham controlled	Parallel	6 cm rule	right DLPFC-HF TMS/left DLPFC-HF TMS/right Insula-HF TMS/left Insula-HF TMS	H4 coil	10	120	1800	Abstinence ↑ Craving ↓ Consumption ↓

Author	Substance	N	Stage	Sessions	Follow-up	Control	Design	Localization	Target	Coil	Freq	Intensity	Pulses	Results
Ankit et al.,(2022) [173]	Opioids	20	Detoxification	14	NA	Sham controlled and another therapy	Parallel	EEG System	right FPC-LF TMS	Figure of 8	50	80	900	Craving ↓ (Both groups) Serum brain-derived neurotrophic factor (BDNF) ↓ (Both groups) No significant difference observed between the two groups. Significant correlation between serum BDNF levels over time and different clinical variables in the active group.
Belgers et al.,(2022) [174]	Alcohol	14	Detoxification	10	12 months	Sham controlled and another therapy	Parallel	EEG System	right DLPFC-HF TMS	Figure of 8	10	110	3000	Craving ↓ Alcohol use ↓ Differences in craving between groups were most prominent three months after treatment.
Bidzinski et al.,(2022) [175]	Cannabis	9	Pre-treatment treatment seeker	20	< 1 month	Sham controlled	Parallel	EEG System	right DLPFC-HF TMS/left DLPFC-HF TMS	Figure of 8	20	90	750	Cannabis use ↓ Positive and Negative Syndrome Scale (PANSS) positive subscale ↓ Attention ↑ Tobacco use ↓
Feng et al.,(2022) [176]	Alcohol	36	Pre-treatment treatment seeker	14	NA	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	10	110	1530	Response time in the oddball task ↓ The total score of MoCA ↑ The total score of BIS-II ↓
Harel et al.,(2022) [177]	Alcohol	23	Pre-treatment treatment seeker	15+5	3 months	Sham controlled	Parallel	4 cm rule	right FPC-HF TMS/left FPC-HF TMS/ACC-HF TMS	H7 coil	10	100	3000	Craving ↓ Alcohol consumption ↓ Functional connectivity of the dorsal anterior cingulate cortex with the caudate nucleus ↓ Connectivity of the medial prefrontal cortex to the subgenual anterior cingulate cortex ↓
Jin et al.,(2022) [178]	Opioids	17	Recovery	7	NA	Sham controlled and healthy control and another therapy	Parallel	6 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	2000	Spontaneous and heroin cue-induced craving ↓ The coupling between the left DLPFC and left parahippocampal gyrus ↑ The coupling between the right precentral gyrus and three key regions included in DMN ↓ the left DLPFC-PHG coupling negatively correlated with the spontaneous craving and the drug cue-induced craving.
Liu, Sun, et al.,(2022) [179]	Amphetamines	20	Pre-treatment treatment seeker	12	NA	Active controlled	Parallel	5 cm rule	left DLPFC-HF TMS/left DLPFC-HF TMS	Round coil	50/10	80/100	600/2000	Cue-induced craving ↓ (in both groups) Withdrawal symptoms ↓ (in both groups)

Study	Substance	N	Population	Sessions	Follow-up	Control	Design	Localization	Target	Coil		Intensity	Pulses	Outcomes
Marques et al.,(2022)	Nicotine	24	Active user non-treatment seeker	1	NA	Active controlled	Parallel	EEG System	left FPC-LF TMS	Figure of 8	1	110	1200	Cue-reactivity ↓ (left frontal pole group) Reactivity to affectively neutral pictures ↓ (left frontal pole group)
Martinotti et al.,(2022) [181]	Cocaine	36	Pre-treatment treatment seeker	20+24	3 months	Sham controlled	Parallel	Beam F3/MRI guided	left DLPFC-HF TMS	Figure of 8	15	100	2400	Cue-induced craving ↓ (in both groups) Consumption ↓ (in both groups) Depressive symptoms ↓ (active group)
McNeill et al.,(2022) [182]	Alcohol	60	Active user non-treatment seeker	1	NA	Active controlled	Parallel	EEG System	right DLPFC-LF TMS/left DLPFC-LF TMS/medial FPC-LF TMS	Figure of 8	50	80	600	Inhibitory control ↑ (in the right DLPFC group) Craving and consumption ↑ (in the left DLPFC group)
Mikellides et al.,(2022) [183]	Nicotine	59	Pre-treatment treatment seeker	20	< 1 month	Active controlled and sham controlled	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	600	Cigarette consumption, nicotine dependence, craving, and perceived stress ↓ (in all groups)
Moeller et al.,(2022) [184]	Nicotine	10	Pre-treatment treatment seeker	15	NA	Sham controlled	Parallel	6 cm rule	right Insula-HF TMS/left Insula-HF TMS/right DLPFC-HF TMS/left DLPFC-HF TMS	H4 coil	10	120	1800	Bilateral dTMS disrupted smoking behavior Active dTMS showing delayed initiation of smoking Insula blood flow ↓ Connectivity between the insula and default mode network ↑
Shevorykin et al.,(2022) [185]	Nicotine	23	Pre-treatment treatment seeker	8/12/16/24/32	6 months	Active controlled	Parallel	MRI guided	left DLPFC-HF TMS	Figure of 8	20	110	900	The duration and intensity of rTMS ↑ smoking cessation outcomes ↑ Delay discounting emerged as a promising therapeutic target Participant burden ↓ even with extended treatment protocols
Su et al.,(2022) [186]	Amphetamines	20	Pre-treatment treatment seeker	20	NA	Sham controlled and healthy control	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	900	rTMS intervention reversed the expression of three key metabolites (alpha-tocopherol, glyceric acid, and fumaric acid) and improvements in alpha-tocopherol levels were associated with enhanced cognitive function.
Zhang et al.,(2022) [187]	Alcohol	30	Active user non-treatment seeker	10	2 months	Sham controlled	Parallel	6 cm rule	left DLPFC-HF TMS	Figure of 8	20	110	2000	Days of heavy drinking ↓ Craving ↓ Serum neurofilament light chain levels ↓ Social function and mental health ↑
Li et al.,(2022) [188]	Nicotine	3	Pre-treatment treatment seeker	5	1 month	Sham controlled	Parallel	5.5 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	3000	Consumption ↓ Craving ↓

Liu, Xu, et al.,(2022) [189]	Amphetamines	29	Pre-treatment treatment seeker	20	NA	Healthy control	Single arm	5 cm rule	left DLPFC-HF TMS	Round coil	10	100	2000	Craving ↓ Stop-signal reaction time ↓
Hu et al.,(2022) [190]	Alcohol	125	Pre-treatment treatment seeker	10	6 months	Active controlled and sham controlled and another therapy	Parallel	EEG System	left DLPFC-HF TMS/right DLPFC-HF TMS	Figure of 8	10	110	1500	Relapse rate ↓ Depression ↓
Johnstone et al.,(2022) [191]	Cannabis	9	Pre-treatment treatment seeker	20	< 1 month	Sham controlled	Parallel	EEG System	right DLPFC-HF TMS/left DLPFC-HF TMS	Figure of 8	20	90	750	Consumption ↓ There is a moderating role of sustained attention, delayed discounting, and complex planning on the effects of rTMS on cannabis use.
Kang et al.,(2022) [192]	Opioids	22	Pre-treatment treatment seeker	30	NA	Sham controlled and healthy control	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	50	80	600	Two-choice oddball task performance ↑ Craving ↓
Lechner et al.,(2022) [193]	Nicotine	21	Active user non-treatment seeker	10	NA	Sham controlled and another therapy	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	10	100	2000	Letter-sequencing performance ↑ (rTMS group) Back-digit task performance ↑ (rTMS group) Performance on the smoking analog task ↓ (rTMS+WMT) Back-digit task performance ↓ (rTMS+WMT)
Sun et al.,(2022) [194]	Amphetamines	9	Pre-treatment treatment seeker	5	NA	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	50	80	600	Working memory performance ↑ (after one session) Working memory capacity ↑
Wang et al.,(2022) [195]	Amphetamines	30	Pre-treatment treatment seeker	12	NA	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	10	100	400	Craving ↓ Adverse selection and intensity of impulsive decision-making ↓
McCalley et al.,(2023) [196]	Alcohol	26	Pre-treatment treatment seeker	10	3 months	Sham controlled	Parallel	EEG System	left FPC-LF TMS	Figure of 8	50	110	3600	Individuals who received real TBS were significantly more likely to remain enrolled in the study and maintain sobriety three months after treatment initiation. Additionally, real TBS led to a notable reduction in brain reactivity to alcohol cues, particularly decreasing MPFC-striatum and MPFC-insula connectivity at 2- and 3-months post-treatment.

Study	Substance	N	Stage	Sessions	Follow-up	Control	Design	Localization	Target	Coil	Freq	Intensity	Pulses	Outcomes
Mikellides et al.,(2023)[197]	Nicotine	59	Pre-treatment treatment seeker	20	6 months	Active controlled and sham controlled	Parallel	Beam F3	left DLPFC-HF TMS	Figure of 8	50	100	600	Cigarette consumption, nicotine dependence, craving and perceived stress ↓ (in all groups)
Jin et al.,(2023)[198]	Opioids	30	Recovery	7	NA	Healthy control	Single arm	6 cm rule	left DLPFC-HF TMS	Figure of 8	10	100	2000	Craving ↓ Withdrawal ↓ The left IPL-left middle frontal gyrus coupling and the left IPL-right inferior occipital gyrus coupling ↓
Hoven et al.,(2023)[199]	Alcohol	40	Recovery	10	6 months	Sham controlled and another therapy	Parallel	EEG System	right DLPFC-HF TMS	Figure of 8	10	110	3000	HF-rTMS had no effect on the number of abstinent days over a six-month period. Additionally, HF-rTMS did not influence craving levels.
Dong et al.,(2023)[200]	Opioids/Amphetamines	38	Pre-treatment treatment seeker	20	NA	Active controlled and sham controlled	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	10/50	100	900	Memory, attention, social cognition ↑ (in iTBS) Serum EPI and GABA-Aα5 ↓ (iTBS)
Zhang et al.,(2023)[201]	Amphetamines	18	Recovery	20	NA	Sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Round coil	50	80	600	Working memory accuracy and discrimination ability ↑ Reaction time ↓ Resting-state delta power ↓
Gersner et al.,(2022)[202]	Nicotine	75	Pre-treatment treatment seeker	15+3	3 months	Sham controlled	Parallel	6 cm rule	right DLPFC-HF TMS/left DLPFC-HF TMS/right Insula-HF TMS/left Insula-HF TMS	H4 coil	10	120	1800	Three weeks of Deep TMS has a higher smoking addiction quit rate in participants who are younger, more educated, Caucasian, and with less extensive smoking history.
Shevorykin et al.,(2023)[203]	Nicotine	51	Pre-treatment treatment seeker	8/12/16/24/32	6 months	Active controlled and sham controlled	Parallel	EEG System	left DLPFC-HF TMS	Figure of 8	20	110	900	The overall research burden of rTMS treatment was relatively low, with participants reporting significantly lower experienced burden compared to anticipated burden. Additionally, neither the duration or intensity of rTMS nor race or income significantly influenced perceived research burden.
S. Upton et al.,(2023)[204]	Nicotine	37	Active user non-treatment seeker	1	NA	Active controlled	Crossover	MRI guided	right IFG-HF TMS/right IFG-LF TMS	Figure of 8	50	80	600	Inhibitory control task performance ↑ (in cTBS) Craving and smoking ↓ (both iTBS and cTBS) cTBS-induced improvement in IC task performance was associated with reduced craving. cTBS-induced reduction in craving was associated with reduced smoking.

Study	Substance	N	Population	Sessions	Duration	Control	Design	Targeting	Site-TMS	Coil	Freq	Intensity	Pulses	Outcome
Ibrahim et al.,(2023)[205]	Nicotine	24	Active user non-treatment seeker	20	2 months	Sham controlled and another therapy	Parallel	NA	right Insula-HF TMS/left Insula-HF TMS	H11 coil	10	120	1020	Abstinence rates ↑
Gong et al.,(2023)[206]	Opioids	38	Recovery	20	< 1 month	Active controlled and sham controlled and another therapy	Parallel	NA	left DLPFC-HF TMS	NA	50	100	900	Anxiety, depression, and craving ↓
Gerace et al.,(2023)[207]	Cocaine	58	Pre-treatment treatment seeker	15	2 months	Sham controlled and healthy control	Parallel	5 cm rule	left DLPFC-HF TMS	Figure of 8	15	100	2400	CUD patients exhibited reduced alpha diversity and notable alterations in gut and oral microbiota composition and function, including lower levels of butyric acid. After rTMS treatment, these microbiota changes were partially reversed, with butyric acid levels restored.
Spencer Upton et al.,(2023)[208]	Nicotine	31	Active user non-treatment seeker	1	NA	Active controlled	Crossover	MRI guided	right IFG-HF TMS/right IFG-LF TMS	Figure of 8	50	80	600	Craving ↓ (in cTBS) Consumption ↓ (in cTBS) Resting-state functional connectivity between the rIFG pars opercularis and subcallosal cingulate (fronto-striatal circuit), and between the rIFG pars opercularis and the right posterior parahippocampal gyrus ↑ (in cTBS)
Ding et al.,(2023)[209]	Opioids	32	Detoxification	30	NA	Healthy control	Single arm	5 cm rule	left DLPFC-HF TMS	Figure of 8	50	80	600	Resting-state EEG analysis identified four microstate classes (A-D), with significant increases in the duration, occurrence, and contribution of microstate class A following iTBS treatment. Machine learning achieved 81.5% classification accuracy, highlighting EEG microstates as reliable indicators of treatment effects in patients with heroin addiction.

Abbreviations: TMS: transcranial magnetic stimulation, HF TMS: high-frequency TMS (≥ 5 Hz), LF TMS: low-frequency TMS (≤ 1 Hz), rTMS: repetitive TMS, dTMS: deep TMS, iTBS: intermittent theta burst stimulation, cTBS: continuous theta burst stimulation, EEG: electroencephalography, MRI: magnetic resonance imaging, DLPFC: dorsolateral prefrontal cortex, ACC: anterior cingulate cortex, PCC: posterior cingulate cortex, FPC: frontopolar cortex, IFG: inferior frontal gyrus, SFG: superior frontal gyrus, NA: not available.

Stimulation targets

Figure S.1. Variations in Targets in tES/TMS Studies for Substance Use Disorders. This figure displays the number of studies tackling specific target areas. The studies are color-coded, with tES in red and TMS in blue. Note that some studies utilize multiple stimulation protocols, resulting in 275 total targets in this figure, exceeding the actual number of studies included. <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation, DLPFC: dorsolateral prefrontal cortex, FPC: frontopolar cortex, IFG: inferior frontal gyrus, TPC: temporoparietal cortex, ACC: anterior cingulate cortex, SFG: superior frontal gyrus, PCC: posterior cingulate cortex.

Electrode/coil positioning system

Of the 121 TMS studies reviewed, the majority focused on conventional repetitive transcranial magnetic stimulation (rTMS) (n=75). The remaining studies utilized intermittent theta burst stimulation (iTBS) (n=16), continuous theta burst stimulation (cTBS) (n=8), deep transcranial magnetic stimulation (dTMS) (n=13), or combinations of different TMS types, such as cTBS and iTBS (n=9). Among the 86 tES studies analyzed, the vast majority utilized transcranial direct current stimulation (tDCS) (n=83), while only three studies employed transcranial alternating current stimulation (tACS) (n=3). Among the tDCS studies, only one study utilized 4x1 high-definition (HD) electrodes (n=1), whereas the remaining tES studies employed large conventional electrode pads (n=78). For 7 tDCS studies, the type of electrodes used was not reported.

Figure S.2. Types of Stimulation, Coils/Electrodes, Targets, and Positioning Systems in tES/TMS Studies for Substance Use Disorders. This Sankey diagram depicts the distribution of 207 tES/TMS studies, categorized by the type of stimulation, coil/electrode, target area, and positioning system used. The number of studies is indicated in parentheses within the boxes. Note: 'Multiple' in the 'Type' layer refers to studies that employed a combination of two different types of stimulation (e.g., cTBS and iTBS). 'Multiple' in the 'Electrodes or Coil' layer refers to studies that utilized a combination of two different coil shapes (e.g., deep and figure 8). 'Multiple' in the 'Target' layer refers to studies that employed a combination of different target areas. <u>Abbreviations</u>: TMS: transcranial magnetic stimulation, tES: transcranial electrical stimulation, rTMS: repetitive TMS, dTMS: deep TMS, iTBS: intermittent theta burst stimulation, cTBS: continuous theta burst stimulation, tDCS: transcranial direct current stimulation, tACS: transcranial alternating current stimulation, EEG: electroencephalography, MRI: magnetic resonance imaging, DLPFC: dorsolateral prefrontal cortex, FPC: frontopolar cortex, IFG: inferior frontal gyrus, TPC: temporoparietal cortex, SFG: superior frontal gyrus.

In total, 207 TMS/tES studies were included in the analysis, employing various methods for positioning tES electrodes or TMS coils over the scalp. The most commonly utilized method was based on the EEG standard system (n=112). Additionally, other methods such as MRI-guided techniques (n=17) and Beam F3 methods (n=12) were used. Some studies utilized scalp measurements and applied different rules for electrode or coil placement using anatomical landmarks, including the 5 cm rule (n=26), 6 cm rule (n=13), 5.5 cm rule (n=4), and 4 cm rule (n=1). For 21 studies, the positioning system used was not reported.

Outcome measures

Each study included in our systematic review reported a diverse range of primary and secondary outcome measures. To organize and categorize these measures, we extracted data from the full text of the studies and identified seven main categories. We recorded both significant and non-significant results reported in the abstract for each outcome measure (see Figure S.6.). The most commonly reported outcome measure across the majority of studies was "craving" (n=159), with 84 significant reductions and 39 non-significant changes in response to TMS/tES reported in the abstracts. Other frequently reported outcome measures included "consumption/relapse/abstinence" (n=111), "cognitive functions" (n=95),

"physiological measures" (n=76), "negative valence" (n=59), "mental/general health" (n=33), and "positive valence" (n=8). Additionally, a few other outcome measures were reported, categorized as "other" (n=10). Across all studies, a total of 317 significant effects and 99 non-significant alterations in response to TMS/tES on the outcome measures were reported.

Figure S.3. Reported Outcome Measures and Their Significance in tES/TMS Studies for Substance Use Disorders Considering Type of Substances. This figure illustrates the various outcome measures from past tES and TMS studies, color-coded by the type of stimulation—tES in red and TMS in blue—and categorized by the type of substance use disorder. Colors range from light yellow to purple, with darker shades indicating a higher number of publications. Note that some studies have included more than one type of substance and outcome measures, resulting in the total items in this figure equaling 551 and exceeding the actual number of 207 studies included. The number of significant and non-significant outcome measures is depicted in line bar graphs, which are color-coded by significance: dark colors indicate significant, and light colors indicate non-significant results. <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation.

Outcome measures based on stimulation targets

To examine the impact of the stimulation target, type of stimulation (excitatory or inhibitory), and coil/electrode positioning system on the reported results (significant or non-significant alterations), our analysis revealed noteworthy findings. Specifically, for TMS studies, the most significant responses were observed in high-frequency stimulation of either the left or right DLPFC. Left DLPFC stimulation yielded 153 significant and 32 non-significant responses, while right DLPFC high-frequency stimulation resulted in 50 significant and 14 non-significant responses. Similar patterns were identified in tES studies, where excitatory DLPFC stimulation proved to be the most effective protocol. Notably, anodal tDCS targeting the right DLPFC exhibited 61 significant and 25 non-significant responses, while anodal tDCS targeting the left DLPFC produced 53 significant and 28 non-significant alterations.

Figure S.4-1. Reported Outcome Measures and Their Significance in tES/TMS Studies for Substance Use Disorders Considering Target Location and Stimulation Type. This figure illustrates the various outcome measures from 207 tES and TMS studies, color-coded by the type of stimulation—tES in red and TMS in blue—and categorized by the target location and type of stimulation (excitatory: anodal tES or HF TMS, inhibitory: cathodal tES or LF TMS). It is important to note that the total numbers reported for outcome measures do not add up to 207, as some studies reported multiple outcome measures. The number of significant and non-significant outcome measures is depicted in line bar graphs, color-coded by significance: dark colors indicate significant, and light colors indicate non-significant results. <u>Abbreviations</u>: tES: transcranial electrical stimulation, tDCS: transcranial direct current stimulation, tACS: transcranial alternating stimulation, TMS: transcranial magnetic stimulation, HF TMS: high-frequency TMS (≥ 5 Hz), LF TMS: low-frequency TMS (≤ 1 Hz), DLPFC: dorsolateral prefrontal cortex, FPC: frontopolar cortex, IFG: inferior frontal gyrus, TPC: temporoparietal cortex, ACC: anterior cingulate cortex, SFG: superior frontal gyrus, PCC: posterior cingulate cortex.

Considering that DLPFC stimulation emerged as the most frequently utilized target, yielding a substantial number of significant outcomes, we further explored the influence of electrode/coil positioning systems on the reported results. In TMS studies, several positioning methods demonstrated effectiveness in targeting the left DLPFC with high-frequency stimulation. The EEG standard system resulted in 39 significant and 9 non-significant responses, the 5 cm rule yielded 33 significant and 9 non-significant responses, MRI-guided techniques showed 20 significant and 1 non-significant responses, and the 6 cm rule resulted in 26 significant and 3 non-significant responses. In targeting the right DLPFC, the EEG standard system resulted in 15 significant and 7 non-significant responses. For tES studies, the EEG standard system proved to be the most effective positioning method for both right DLPFC (54 significant and 23 non-significant responses) and left DLPFC (44 significant and 24 non-significant responses) for anodal tDCS over DLPFC.

Figure S.4-2. Relationship Between Stimulation Type, Positioning Method, and Significant Outcomes in DLPFC-Targeted tES/TMS Studies. This figure illustrates the various outcome measures from 207 tES and TMS studies that targeted DLPFC, color-coded by the type of stimulation—tES in red and TMS in blue—and categorized by the type of stimulation (excitatory: anodal tES or HF TMS, inhibitory: cathodal tES or LF TMS) and electrode/coil positioning system. The number of significant and non-significant outcome measures is depicted in line bar graphs, color-coded by significance: dark colors indicate significant, and light colors indicate non-significant results. In the square panels, studies are color-coded by the type of intervention: tES in red and TMS in blue and darker shades indicating a higher number of studies. <u>Abbreviations:</u> tES: transcranial electrical stimulation, tDCS: transcranial direct current stimulation, tACS: transcranial alternating stimulation, TMS: transcranial magnetic stimulation, HF TMS: high-frequency TMS (≥ 5 Hz), LF TMS: low-frequency TMS (≤ 1 Hz), DLPFC: dorsolateral prefrontal cortex.

Study design and control condition

The study designs in our systematic review were categorized into two main types, parallel and crossover, and excluded all studies without a control condition. The most commonly utilized control condition across both TMS (n=62) and tES (n=48) studies was "sham control." However, other control methods were also employed, including active control, therapy other than TMS/tES, healthy control, other types of clinical populations, or combinations of different control conditions.

Figure S.5. Variations in Study Design and Control Conditions in tES/TMS Studies for Substance Use Disorders. This figure presents the number of tES/TMS studies in substance use disorders, categorized by the type of randomization and divided by the control condition. The studies are color-coded according to the type of intervention, with tES in red and TMS in blue. <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation.

Dosage, number of sessions, and follow-up

Considering the stimulation dose, our analysis revealed the utilization of various pulse frequencies in the included TMS studies. The most commonly used pulse frequency was 10 Hz (n=57). Additionally, other stimulation frequencies were employed, including 50 Hz (n=39), 20 Hz (n=21), 1 Hz (n=12), 15 Hz (n=8), and 5 Hz (n=1) which can be assigned to excitatory (high-frequency TMS (≥ 5 Hz)), or inhibitory (low-frequency TMS (≤ 1 Hz)) stimulation. Among the tES studies, the dominant stimulation dose was found to be 2 mA (n=65). The second most frequently used dose was 1 mA, with 11 trials reporting its utilization. Additionally, 1.5 mA (n=8) and 0.45 mA (n=2) were employed in previous studies. Out of the 86 tES studies, 3 used tACS. Among the remaining 83 tDCS studies, 75 used anodal electrodes (excitatory), while 7 used cathodal electrodes (inhibitory) over their main brain target. One study employed both anodal and cathodal electrodes over their target across two different study arms. One TMS and one tES study did not report the stimulation frequency/intensity.

Figure S.6-1. Variations in Stimulation Parameters in tES/TMS Studies for Substance Use Disorders. This figure displays the number of studies with different stimulation frequencies, which serve as an indicator of TMS dose, and

electrical current intensity, which indicates the dose in tES studies (for tACS studies, the peak-to-peak current amplitude is considered). The studies are color-coded, with tES in red and TMS in blue. <u>Abbreviations</u>: tES: transcranial electrical stimulation; TMS: transcranial magnetic stimulation.

In terms of the number of sessions included in the studies analyzed, we found that 30 TMS studies and 37 tES studies comprised single-session trials. For multi-session trials, 22 TMS and 15 tES studies applied 10 active stimulation sessions. 24 TMS and 2 tES studies applied 20 sessions of stimulation. 1 TMS trial applied 44 active stimulation sessions. Most of these studies had no follow-up, however, the most common duration for follow-up was less than one month (TMS: n=14, tES: n=10).

Figure S.6-2. Variation in the Number of Sessions and Follow-Ups in tES/TMS Studies for Substance Use Disorders. This figure illustrates the follow-up durations, categorized by the number of stimulation sessions, with TMS represented in blue and tES in red. The follow-up durations are organized into 9 main groups to summarize the results succinctly. <u>Abbreviations:</u> tES: transcranial electrical stimulation; TMS: transcranial magnetic stimulation.

Risk of bias

Figure S.7-1. Risk of Bias of tES studies using the Cochrane Risk of Bias (RoB) 2 tool. The figures summarize the judgments across key domains of bias, including (1) bias due to the randomization process and timing of identification or recruitment of participants, (2) deviation from intended intervention, (3) missing outcome data, (4) measurement of outcomes, (5) selection of the reported result. Each domain is categorized as "Low risk", "Some concerns", or "High risk" bias. The overall judgment for risk of bias is shown in the last column.

Figure S.7-2. Risk of Bias of TMS studies using the Cochrane Risk of Bias (RoB) 2 tool. The figures summarize the judgments across key domains of bias, including (1) bias due to the randomization process and timing of identification or recruitment of participants, (2) deviation from intended intervention, (3) missing outcome data, (4) measurement of outcomes, (5) selection of the reported result. Each domain is categorized as "Low risk", "Some concerns", or "High risk" bias. The overall judgement for risk of bias is shown in the last column.

Funnel plot:

Figure S.8-1. Funnel Plots for tES and TMS Studies on Craving and Consumption/Relapse This figure presents funnel plots illustrating the heterogeneity across studies on craving and consumption/relapse for both tES and TMS protocols. Panel A (upper left) shows the funnel plot for tES studies on craving, while Panel B (upper right) displays the funnel plot for tES studies on consumption/relapse. Panel C (lower left) illustrates the funnel plot for TMS studies on craving, and Panel D (lower right) shows the funnel plot for TMS studies on consumption/relapse. In each plot, dots represent individual studies, with the y-axis representing study precision (standard error) and the x-axis representing the study's estimated effect size (Hedges' g). Larger studies with greater precision are shown at the top, while smaller, less precise studies scatter more widely at the bottom. <u>Abbreviations:</u> tES: transcranial electrical stimulation; TMS: transcranial magnetic stimulation.

Forest plots

Figure S.8-2. Forest plot for tES effects on Craving. Hedges' g values for studies that reported craving in response to transcranial electrical stimulation (tES, with a total number of n=45 studies and 55 experiments). This forest plot provides a detailed analysis of the influence of tES on craving in various studies. Each horizontal line represents a specific study, with squares denoting effect sizes and horizontal lines indicating confidence intervals. Positive values indicate that active stimulation was effective in reducing craving. The diamond at the bottom illustrates the overall effect size across all studies, with the width representing the confidence interval. Units of analysis are added to studies with multiple experiments to highlight differences in study design. <u>Abbreviations</u>: tES: transcranial electrical stimulation, tDCS: transcranial direct current stimulation, tACS: transcranial alternating stimulation, DLPFC: dorsolateral prefrontal cortex, IFG: inferior frontal gyrus, CBM: cognitive bias modification, ABM: attentional bias modification, CCAT: computerized cognitive addiction therapy, Exp: experimental.

Author(s) and Year	Unit of Analysis	p-Value	Hedges' g [95% CI]
da Silva et. al., 2013	Relapse	0.073	-1.27 [-2.67, 0.12]
Fecteau et. al., 2014	Follow-up (9d)	0.048	0.84 [0.01, 1.68]
Fecteau et. al., 2014	Follow-up (5d)	0.061	0.79 [-0.04, 1.62]
Meng et. al., 2014	Single cathodal (SS)	0.619	0.24 [-0.69, 1.16]
Meng et. al., 2014	Double cathodal (DS)	0.159	0.68 [-0.27, 1.63]
Conti et. al., 2014	Relapse	0.067	1.30 [-0.09, 2.68]
Klauss et. al., 2014	Relapse	0.026	1.08 [0.13, 2.04]
Smith et. al., 2015	Immediate - Subj	0.775	0.10 [-0.59, 0.79]
Smith et. al., 2015	Follow-up (7d) - Subj	0.737	0.12 [-0.57, 0.81]
Smith et. al., 2015	Immediate - Obj	0.613	0.18 [-0.52, 0.87]
Smith et. al., 2015	Follow-up (7d) - Obj	0.589	0.19 [-0.50, 0.89]
den Uyl et. al., 2017	Relapse - +CBM (90d)	0.285	0.40 [-0.33, 1.14]
den Uyl et. al., 2017	Relapse - +CBM (365d)	0.090	0.72 [-0.11, 1.56]
Mondino et. al., 2018		0.718	0.15 [-0.66, 0.95]
Klauss et. al., 2018	Relapse	0.006	1.05 [0.29, 1.80]
den Uyl et. al., 2018	Relapse - +Control ABM	0.338	0.44 [-0.46, 1.35]
den Uyl et. al., 2018	Relapse - +Real ABM	0.461	0.33 [-0.56, 1.22]
Klauss et. al., 2018	Relapse	0.979	0.01 [-0.79, 0.81]
Klauss et. al., 2018	Relapse	0.462	0.31 [-0.51, 1.13]
Giovanni et. al., 2019		0.506	0.24 [-0.46, 0.94]
Claus et. al., 2019	-CBM (30d)	0.360	-0.29 [-0.91, 0.33]
Claus et. al., 2019	-CBM (7d)	0.198	-0.41 [-1.04, 0.22]
Claus et. al., 2019	+CBM (30d)	0.176	0.46 [-0.21, 1.12]
Claus et. al., 2019	+CBM (7d)	0.768	0.10 [-0.56, 0.76]
Alghamdi et. al., 2019	Follow-up (120d)	0.914	-0.05 [-0.98, 0.88]
Alghamdi et. al., 2019	Immediate	0.983	-0.01 [-0.94, 0.92]
Witkiewitz et. al., 2019	Follow-up (60d)	1.000	0.00 [-0.43, 0.43]
Witkiewitz et. al., 2019	Immediate	0.991	-0.00 [-0.43, 0.43]
Brown et. al., 2019		0.757	-0.08 [-0.55, 0.40]
Falcone et. al., 2019	1 mA	0.473	-0.17 [-0.64, 0.30]
Falcone et. al., 2019	2 mA	0.459	-0.18 [-0.64, 0.29]
Ghorbani Behnam et. al., 2019	Relapse - tDCS in 1 month	0.596	0.36 [-0.97, 1.70]
Ghorbani Behnam et. al., 2019	Relapse - tDCS in 3 month	0.029	1.29 [0.13, 2.45]
Vanderhasselt et. al., 2020		0.028	0.47 [0.05, 0.89]
Meng et. al., 2020	tDCS group (24h)	0.056	0.93 [-0.03, 1.89]
Meng et. al., 2020	tDCS-extreme group (24h)	0.010	1.92 [0.46, 3.38]
Meng et. al., 2020	tDCS group (48h)	0.034	1.05 [0.08, 2.02]
Meng et. al., 2020	tDCS-extreme group (48h)	0.001	3.00 [1.31, 4.69]
Verveer et. al., 2020	Relapse	0.127	0.48 [-0.14, 1.10]
Holla et. al., 2020	Relapse	0.516	0.58 [-1.17, 2.33]
Sadeghi Bimorgh et. al., 2020	Relapse	0.268	0.73 [-0.56, 2.02]
Alizadehgoradel et. al., 2020	Relapse	0.980	-0.03 [-2.17, 2.12]
Muller et. al., 2021	Follow-up (3d)	0.723	-0.11 [-0.70, 0.49]
Muller et. al., 2021	Immediate	0.980	0.01 [-0.59, 0.60]
Lin et. al., 2021	Follow-up (5d)	0.017	0.94 [0.17, 1.70]
Lin et. al., 2021	Immediate	0.038	0.80 [0.05, 1.56]
Dubuson et. al., 2021	Relapse - AICT (365d)	0.128	0.69 [-0.20, 1.59]
Dubuson et. al., 2021	Relapse - NICT (365d)	0.234	-0.56 [-1.48, 0.36]
Dubuson et. al., 2021	Relapse - AICT (30d)	0.100	0.48 [-0.09, 1.05]
Dubuson et. al., 2021	Relapse - NICT (30d)	0.661	0.13 [-0.44, 0.69]
FAYAZ FEYZI et. al., 2022	Relapse	0.154	0.79 [-0.30, 1.88]
Qin et. al., 2023	+Real PE (Exp1)	0.783	0.09 [-0.55, 0.73]
Qin et. al., 2023	+Control PE (Exp1)	0.952	0.02 [-0.62, 0.66]
Camchong et. al., 2023	Relapse	0.116	0.51 [-0.13, 1.14]
DAYAL et. al., 2023	Relapse	1.000	-0.00 [-0.64, 0.64]
RE Model for All Studies			0.27 [0.15, 0.38]

(Q = 79.9, df = 54, p = 0.013; I^2 = 22.67 % , τ^2 = 0.04)

Figure S.8-3. Forest plot for tES effects on Consumption/Relapse. Hedges' g values for studies that reported consumption/relapse in response to transcranial electrical stimulation (tES, with a total number of n=31 studies and 55 experiments). This forest plot provides a detailed analysis of the influence of tES on consumption/relapse in various studies. Each horizontal line represents a specific study, with squares denoting effect sizes and horizontal lines indicating confidence intervals. Positive values indicate that active stimulation was effective in reducing consumption/relapse. The diamond at the bottom illustrates the overall effect size across all studies, with the width representing the confidence interval. Units of analysis are added to studies with multiple experiments to highlight differences in study design. Abbreviations: tES: transcranial electrical stimulation, tDCS: transcranial direct current stimulation, CBM: cognitive bias modification, ABM: attentional bias modification, AICT: alcohol cue inhibitory control training, NICT: neutral inhibitory control training, PE: psycho-education, Exp: experiment, mA: milliampere.

Author(s) and Year	Unit of Analysis	p-Value	Hedges' g [95% CI]
Amiaz et. al., 2009	Neutral Cues	0.576	-0.22 [-0.97, 0.54]
Amiaz et. al., 2009	Smoking Cues	0.072	0.83 [-0.07, 1.73]
Mishra et. al., 2010		0.000	1.78 [1.06, 2.50]
Rose et. al., 2011	HF - Smoking Cues	0.152	-0.53 [-1.26, 0.20]
Rose et. al., 2011	LF - Smoking Cues	0.616	0.18 [-0.53, 0.90]
Rose et. al., 2011	HF - Neutral Cues	0.000	1.64 [0.81, 2.47]
Rose et. al., 2011	LF - Neutral Cues	0.529	-0.23 [-0.95, 0.49]
Herremans et. al., 2012		0.735	-0.12 [-0.83, 0.58]
Herremans et. al., 2013		0.874	-0.04 [-0.56, 0.47]
Li et. al., 2013	Neutral Cues	0.518	-0.29 [-1.17, 0.59]
Li et. al., 2013	Methamphetamine Cues	0.018	-1.15 [-2.09, -0.20]
Li et. al., 2013b		0.412	0.31 [-0.43, 1.06]
Dieler et. al., 2014		0.403	-0.19 [-0.65, 0.26]
Ceccanti et. al., 2015		0.936	-0.04 [-0.96, 0.89]
Herremans et al. 2015		0.908	0.03 [-0.51, 0.58]
Trojak et. al., 2015		0.738	-0.11 [-0.77, 0.54]
Del Felice et. al., 2016		0.940	-0.04 [-0.99, 0.92]
Shen et al. 2016		0.000	2.49 [1.32, 3.65]
Hanlon et al. 2017	Cocaine Users	0.721	0.10 [-0.45, 0.66]
Hanlon et al. 2017	Alcohol Users	0.784	-0.08 [-0.65, 0.49]
Sahlem et. al., 2017		0.440	-0.27 [-0.97, 0.42]
Su et. al., 2017		0.407	0.30 [-0.42, 1.02]
Liang et. al., 2018		0.000	4.49 [3.40, 5.57]
Jansen et. al., 2019		0.130	0.52 [-0.15, 1.20]
Chen et al, 2020a	iTBS	0.009	0.91 [0.23, 1.58]
Chen et al, 2020a	cTBS	0.000	1.25 [0.55, 1.96]
Chen et al, 2020a	iTBS + cTBS	0.000	1.48 [0.76, 2.19]
Chen et al, 2020b	Fast Responder	0.072	0.76 [-0.07, 1.59]
Chen et al, 2020b	General Responder	0.004	1.15 [0.36, 1.94]
Chen et al, 2020b	Non Responder	0.026	0.70 [0.09, 1.32]
Liu et. al., 2020	10 Hz	0.000	3.52 [2.77, 4.26]
Liu et. al., 2020	1 Hz	0.000	2.33 [1.69, 2.96]
Perini et. al., 2020		0.028	0.67 [0.07, 1.27]
Raikwar et. al., 2020		0.257	0.29 [-0.21, 0.80]
Su et al. 2020		0.003	0.81 [0.28, 1.34]
Su et. al., 2020b		0.006	0.81 [0.23, 1.38]
Su et. al., 2020c		0.000	1.20 [0.82, 1.58]
Yuan et. al., 2020		0.011	0.61 [0.14, 1.08]
Abdelrahman et. al., 2021		0.001	1.10 [0.43, 1.76]
Chen et. al., 2021		0.000	1.62 [0.97, 2.28]
Garza-Villareal et. al., 2021		0.039	0.64 [0.03, 1.25]
Lolli et. al., 2021		0.910	-0.03 [-0.55, 0.49]
Tsai et. al., 2021		0.493	-0.31 [-1.20, 0.58]
Zangen et. al., 2021		0.000	3.92 [3.51, 4.34]
Bidzinski et. al., 2022		0.398	0.42 [-0.55, 1.38]
Ankit et. al., 2022		0.483	0.22 [-0.40, 0.84]
Belgers et. al., 2022		0.083	0.65 [-0.08, 1.39]
Harel et. al., 2022		0.437	0.23 [-0.35, 0.81]
Jin et. al., 2022	Cue-induced	0.126	0.53 [-0.15, 1.20]
Jin et. al., 2022	Spontaneous	0.518	0.22 [-0.45, 0.88]
Marques et. al., 2022	Smoking Cues	0.215	0.53 [-0.31, 1.36]
Marques et. al., 2022	Neutral Cues	0.213	0.53 [-0.30, 1.36]
Martinotti et. al., 2022	Intensive Treatment	0.884	0.04 [-0.49, 0.57]
Martinotti et. al., 2022	Maintenance Treatment	0.980	0.01 [-0.76, 0.78]
McNeill et. al., 2022	Left DLPFC	0.002	-1.06 [-1.72, -0.39]
McNeill et. al., 2022	Right DLPFC	0.344	-0.30 [-0.92, 0.32]
McNeill et. al., 2022	Medial FPC	0.442	-0.24 [-0.87, 0.38]
Mikellides et. al., 2022		0.950	-0.02 [-0.52, 0.49]
Li et. al., 2022		0.661	0.34 [-1.17, 1.84]
Hu et. al., 2022	Right DLPFC-C0	0.888	-0.03 [-0.43, 0.37]
Hu et. al., 2022	Right DLPFC-C1	0.220	-0.28 [-0.72, 0.17]
Hu et. al., 2022	Left DLPFC-C0	0.600	-0.11 [-0.50, 0.29]
Hu et. al., 2022	Left DLPFC-C1	0.493	-0.16 [-0.60, 0.29]
Kang et. al., 2022		0.010	0.82 [0.19, 1.46]
Wang et. al., 2022		0.046	0.51 [0.01, 1.01]
McCalley et. al., 2023		0.056	0.61 [-0.02, 1.24]
Hoven et. al., 2023		1.000	0.00 [-0.47, 0.47]
Ibrahim et. al., 2023		0.815	-0.07 [-0.68, 0.54]
Gong et. al., 2023		0.002	0.73 [0.26, 1.19]

RE Model for All Studies — 0.52 [0.29, 0.75]

$(Q = 650.14, df = 68, p < 0.001; I^2 = 89.36\%, \tau^2 = 0.82)$

Figure S.8-4. Forest plot for TMS effects on Craving. Hedges' g values for studies that reported craving in response to transcranial magnetic stimulation (TMS, with a total number of n=50 studies and 69 experiments). This forest plot provides a detailed analysis of the influence of TMS on craving in various studies. Each horizontal line represents a

specific study, with squares denoting effect sizes and horizontal lines indicating confidence intervals. Positive values indicate that active stimulation was effective in reducing craving. The diamond at the bottom illustrates the overall effect size across all studies, with the width representing the confidence interval. Units of analysis are added to studies with multiple experiments to highlight differences in study design. <u>Abbreviations</u>: TMS: transcranial magnetic stimulation, cTBS: continuous theta burst stimulation, iTBS: intermittent theta burst stimulation, HF TMS: high-frequency TMS (≥ 5 Hz), LF TMS: low-frequency TMS (≤ 1 Hz), DLPFC: dorsolateral prefrontal cortex, FPC: frontopolar cortex, MA: methamphetamine, C0: cognitive behavioral therapy treatment without fixed schedule, C1: cognitive behavioral therapy treatment with fixed schedule.

Author(s) and Year	Unit of Analysis	p-Value	Hedges' g [95% CI]
Eichhammer et. al., 2003	First Trial	0.333	0.37 [-0.38, 1.12]
Eichhammer et. al., 2003	Second Trial	0.468	0.28 [-0.47, 1.02]
Amiaz et. al., 2009	Neutral Cue - Immediate - Obj - Acute	0.075	0.71 [-0.07, 1.48]
Amiaz et. al., 2009	Neutral Cue - Follow-up (180d) - Maintenance	0.816	-0.09 [-0.85, 0.67]
Amiaz et. al., 2009	Smoking Cue - Immediate - Obj - Acute	0.258	0.51 [-0.37, 1.38]
Amiaz et. al., 2009	Smoking Cue - Follow-up (180d) - Maintenance	0.115	0.72 [-0.17, 1.61]
Amiaz et. al., 2009	Neutral Cue - Immediate - Subj - Acute	0.846	0.07 [-0.68, 0.83]
Amiaz et. al., 2009	Smoking Cue - Immediate - Subj - Acute	0.099	0.75 [-0.14, 1.65]
Schefer et. al., 2013	Follow up (6h)	0.921	0.02 [-0.38, 0.42]
Schefer et. al., 2013	Follow-up (1d)	0.379	0.18 [-0.22, 0.59]
Dinur-Klein et. al., 2014	LF+Cue - Subj	0.854	-0.08 [-0.98, 0.81]
Dinur-Klein et. al., 2014	LF-Cue - Subj	0.421	0.37 [-0.53, 1.26]
Dinur-Klein et. al., 2014	HF+Cue - Subj	0.001	1.32 [0.54, 2.09]
Dinur-Klein et. al., 2014	HF-Cue - Subj	0.006	1.04 [0.30, 1.77]
Dinur-Klein et. al., 2014	LF-Cue - Obj	0.773	-0.14 [-1.09, 0.81]
Dinur-Klein et. al., 2014	LF+Cue - Obj	0.282	0.55 [-0.45, 1.54]
Dinur-Klein et. al., 2014	HF-Cue - Obj	0.244	0.44 [-0.30, 1.17]
Dinur-Klein et. al., 2014	HF+Cue - Obj	0.009	1.09 [0.27, 1.90]
Prikryl et. al., 2014	Immediate	0.145	0.50 [-0.17, 1.17]
Prikryl et. al., 2014	Follow-up (7d)	0.150	0.49 [-0.18, 1.17]
Dieler et. al., 2014	Relapse - Follow-up (90d)	0.053	0.52 [-0.01, 1.05]
Dieler et. al., 2014	Relapse - Follow-up (180d)	0.721	0.10 [-0.45, 0.64]
Ceccanti et. al., 2015	Immediate	0.076	0.87 [-0.09, 1.84]
Ceccanti et. al., 2015	Follow-up (90d)	0.031	1.09 [0.10, 2.08]
Trojak et. al., 2015	Relapse - Immediate	0.019	1.12 [0.19, 2.06]
Trojak et. al., 2015	Relapse - Follow-up (70d)	1.000	-0.00 [-0.98, 0.98]
Bolloni et. al., 2016	Follow-up (150d) - Subj	0.596	0.34 [-0.93, 1.62]
Bolloni et. al., 2016	Immediate - Obj	0.048	1.42 [0.01, 2.83]
Bolloni et. al., 2016	Follow-up (150d) - Obj	0.006	2.22 [0.63, 3.82]
Huang et. al., 2016	Immediate	0.000	1.52 [0.79, 2.25]
Huang et. al., 2016	Follow-up (21d)	0.000	1.66 [0.92, 2.41]
Bolloni et. al., 2016	Relapse	0.600	0.35 [-0.95, 1.64]
Addolorato et. al., 2017	DDD (TLFB)	0.207	0.79 [-0.44, 2.02]
Addolorato et. al., 2017	Total drinks (TLFB)	0.180	0.85 [-0.39, 2.09]
Li et. al., 2020	Immediate - Subj	0.247	0.38 [-0.26, 1.03]
Li et. al., 2020	Follow-up (30d) - Subj	0.246	0.38 [-0.26, 1.03]
Li et. al., 2020	Immediate - Obj	0.502	-0.22 [-0.86, 0.42]
Perini et. al., 2020	Immediate	0.531	-0.19 [-0.79, 0.41]
Perini et. al., 2020	Follow-up (84d)	0.173	-0.42 [-1.03, 0.18]
Su et. al., 2020	Relapse	0.311	0.65 [-0.61, 1.92]
Abdelrahman et. al., 2021	Immediate	0.000	1.62 [0.90, 2.33]
Abdelrahman et. al., 2021	Follow-up (90d)	0.000	1.52 [0.82, 2.23]
Garza-Villareai et al, 2021	Relapse	0.824	0.07 [-0.57, 0.72]
Lolli et. al., 2021	Relapse	0.113	0.57 [-0.14, 1.28]
Tsai et al 2021	Relapse - Immediate	0.121	-1.29 [-2.91, 0.34]
Tsai et al 2021	Relapse - Follow-up (60d)	0.964	-0.02 [-0.96, 0.91]
Zangen et. al., 2021	Relapse - Immediate	0.001	0.88 [0.34, 1.42]
Zangen et. al., 2021	Relapse - Follow-up (84d)	0.008	0.96 [0.25, 1.68]
Belgers et al. 2022		0.002	-1.13 [-1.85, -0.40]
Bidzinski et al. 2022	Subj	0.266	0.52 [-0.40, 1.43]
Bidzinski et al. 2022	Obj	0.370	0.42 [-0.49, 1.33]
Mikellides et al. 2022	Subj	0.623	-0.13 [-0.63, 0.38]
Mikellides et al. 2022	Obj	0.141	-0.38 [-0.89, 0.13]
Li et al. 2022		0.475	0.56 [-0.97, 2.08]
Moeller et. al., 2022		0.010	1.26 [0.30, 2.22]
Harel et al. 2022	Relapse - Acute phase	0.094	0.69 [-0.12, 1.49]
Harel et al. 2022	Relapse - Maintenance phase	0.019	0.84 [0.14, 1.53]
Martinotti et al. 2022	Relapse - Intensive phase	0.738	-0.10 [-0.69, 0.49]
Martinotti et al. 2022	Relapse - Maintenance phase	0.408	-0.24 [-0.82, 0.33]
Ibrahim et. al., 2023	Immediate	0.137	-0.47 [-1.09, 0.15]
Ibrahim et. al., 2023	Follow-up (150d)	0.302	-0.32 [-0.94, 0.29]
McCalley et. al., 2023	Relapse - Follow-up (30d)	0.867	-0.06 [-0.72, 0.61]
McCalley et. al., 2023	Relapse - Follow-up (90d)	0.186	0.55 [-0.27, 1.37]
Hoven et. al., 2023	Relapse	0.577	0.17 [-0.43, 0.77]
RE Model for All Studies			0.41 [0.26, 0.56]

$(Q = 160.9, df = 63, p < 0.001; I^2 = 61.56\%, \tau^2 = 0.22)$

Figure S.8-5. Forest plot for TMS effects on Consumption/Relapse. Hedges' g values for studies that reported consumption/relapse in response to transcranial magnetic stimulation (TMS, with a total number of n=29 studies and 64 experiments). This forest plot provides a detailed analysis of the influence of TMS on consumption/relapse in various studies. Each horizontal line represents a specific study, with squares denoting effect sizes and horizontal lines indicating confidence intervals. Positive values indicate that active stimulation was effective in reducing consumption. The diamond at the bottom illustrates the overall effect size across all studies, with the width

representing the confidence interval. Units of analysis are added to studies with multiple experiments to highlight differences in study design. Abbreviations: TMS: transcranial magnetic stimulation, HF TMS: high-frequency TMS (≥ 5 Hz), LF TMS: low-frequency TMS (≤ 1 Hz), d: day, Obj: objective, Subj: subjective, DDD: drinks per drinking day, TLFB: timeline follow back, d: day.

Subgroup analysis

Figure S.9-1. Exploring Overall Effects and Subgroup Analyses. This figure presents the results of a subgroup analysis on craving and consumption, featuring forest plots that detail the effect sizes by type of substance. These plots offer an in-depth look at the impact of tES/TMS on craving and consumption by examining the role of the type of

stimulation. Each horizontal line within the plots represents a distinct substance use disorder, with dots for effect sizes and horizontal lines for confidence intervals. Additionally, bar plots show the number of participants in the active (dark colors) and sham (light colors) arms. The total number of experiments is noted in parentheses adjacent to the related moderator. The final four rows illustrate the cumulative effects of stimulation on craving and consumption, with bars color-coded by the type of stimulation: tES studies in red and TMS studies in blue. Abbreviations: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation.

Figure S.9-2. Exploring Subgroup Analyses of tES Effects on Craving. This figure displays the results of a subgroup analysis focusing on craving, featuring forest plots that illustrate the effect sizes by different types of moderators. These plots provide a comprehensive analysis of the impact of tES on craving, considering key factors such as number of sessions, randomization, hemisphere, target, polarity, symmetry in DLPFC stimulation (in minutes), intensity (in mA), and stimulation duration. Each horizontal line within the plots signifies a specific moderator, with dots representing effect sizes and horizontal lines denoting confidence intervals. In addition, bar plots indicate the number of participants in the active (dark colors) and sham (light colors) arms, with the total number of experiments mentioned in parentheses next to each relevant moderator. Note that two studies did not report tES intensity. The hemisphere subgroup pertains to studies targeting the DLPFC. The left/right refers to tACS studies. Abbreviations:

tES: transcranial electrical stimulation, tACS: transcranial alternating stimulation, DLPFC: dorsolateral prefrontal cortex.

Figure S.9-3. Exploring Subgroup Analyses of tES Effects on Consumption. This figure displays the results of a subgroup analysis focusing on consumption, featuring forest plots that illustrate the effect sizes by different types of moderators. These plots provide a comprehensive analysis of the impact of tES on consumption, considering key factors such as the type of outcome measurement, outcome assessment timepoint, number of sessions, randomization, hemisphere, target, polarity, symmetry in DLPFC stimulation, intensity, and stimulation duration. Each horizontal line within the plots signifies a specific moderator, with dots representing effect sizes and horizontal lines denoting confidence intervals. In addition, bar plots indicate the number of participants in the active (dark colors) and sham (light colors) arms, with the total number of experiments mentioned in parentheses next to each

relevant moderator. The hemisphere subgroup pertains to studies targeting the DLPFC. <u>Abbreviations:</u> tES: transcranial electrical stimulation, DLPFC: dorsolateral prefrontal cortex.

Figure S.9-4. Exploring Subgroup Analyses of tES Effects on Relapse. This figure displays the results of a subgroup analysis focusing on relapse, featuring forest plots that illustrate the effect sizes by different types of moderators. These plots provide a comprehensive analysis of the impact of tES on relapse, considering key factors such as the type of outcome measurement, outcome assessment timepoint, number of sessions, randomization, hemisphere, target, polarity, symmetry in DLPFC stimulation, intensity, and stimulation duration. Each horizontal line within the plots signifies a specific moderator, with dots representing effect sizes and horizontal lines denoting confidence intervals. In addition, bar plots indicate the number of participants in the active (dark colors) and sham (light colors) arms, with the total number of experiments mentioned in parentheses next to each relevant moderator. The hemisphere subgroup pertains to studies targeting the DLPFC. <u>Abbreviations:</u> tES: transcranial electrical stimulation, DLPFC: dorsolateral prefrontal cortex.

Figure S.9-5. Exploring Subgroup Analyses of TMS Effects on Craving. This figure presents the results of a subgroup analysis focused on craving, featuring forest plots that demonstrate the effect sizes across various moderators. These plots offer a thorough analysis of TMS's impact on craving, considering key factors such as number of sessions, randomization, hemisphere in DLPFC stimulation, target, frequency, coil type, stimulation patterns, and type of TMS. 'Multi' in the 'Target' group refers to studies that employed a combination of different target areas. 'Multi' in the 'Polarity' group refers to studies that employed both HF and LF TMS simultaneously. Each horizontal line in the plots represents a specific moderator, with dots indicating effect sizes and horizontal lines showing confidence intervals. Additionally, bar plots display the number of participants in the active (dark colors) and sham (light colors) arms, with the total number of experiments indicated in parentheses alongside each moderator. Note that six studies did not report the type of TMS coil. The hemisphere subgroup pertains to standard TMS (classic or patterned) studies targeting the DLPFC. <u>Abbreviations</u>: TMS: transcranial magnetic stimulation, HF: high frequency, LF: low frequency, FPC: frontopolar cortex, DLPFC: dorsolateral prefrontal cortex.

Figure S.9-6. Exploring Subgroup Analyses of TMS Effects on Consumption. This figure presents the results of a subgroup analysis focused on consumption, featuring forest plots that demonstrate the effect sizes across various moderators. These plots offer a thorough analysis of the impact of TMS on consumption, taking into account key factors such as the type of outcome measurement, outcome assessment timepoint, number of sessions, randomization, hemisphere in DLPFC stimulation, target, frequency, coil type, stimulation patterns, and type of TMS. Each horizontal line in the plots represents a specific moderator, with dots indicating effect sizes and horizontal lines showing confidence intervals. Additionally, bar plots display the number of participants in the active (dark colors) and sham (light colors) arms, with the total number of experiments indicated in parentheses alongside each moderator. The hemisphere subgroup pertains to standard TMS (classic or patterned) studies targeting the DLPFC.

Figure S.9-7. Exploring Subgroup Analyses of TMS Effects on Relapse. This figure presents the results of a subgroup analysis focused on relapse, featuring forest plots that demonstrate the effect sizes across various moderators. These plots offer a thorough analysis of the impact of TMS on relapse, taking into account key factors such as type of outcome measurement, outcome assessment timepoint, number of sessions, randomization, hemisphere in DLPFC stimulation, target, frequency, coil type, stimulation patterns, and type of TMS. Each horizontal line in the plots represents a specific moderator, with dots indicating effect sizes and horizontal lines showing confidence intervals. Additionally, bar plots display the number of participants in the active (dark colors) and sham (light colors) arms, with the total number of experiments indicated in parentheses alongside each moderator. The hemisphere subgroup pertains to standard TMS (classic or patterned) studies targeting the DLPFC. Abbreviations: TMS:

transcranial magnetic stimulation, HF: high frequency, LF: low frequency, FPC: frontopolar cortex, DLPFC: dorsolateral prefrontal cortex.

Figure S.9-8. Exploring Subgroup Analyses of Substance on Relapse for tES/TMS. This figure presents the results of a subgroup analysis on relapse, featuring forest plots that detail the effect sizes by type of substance. These plots offer an in-depth look at the impact of tES/TMS on relapse by examining the role of the type of stimulation. Each horizontal line within the plots represents a distinct substance use disorder, with dots for effect sizes and horizontal lines for confidence intervals. Additionally, bar plots show the number of participants in the active (dark colors) and sham (light colors) arms. The total number of experiments is noted in parentheses adjacent to the related moderator. The final two rows illustrate the cumulative effects of stimulation on relapse, with bars color-coded by the type of stimulation: tES studies in red and TMS studies in blue. Abbreviations: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation.

Heterogeneity of craving and consumption measures in the meta-analysis

Figure S.10-1. Distribution of Craving Scales Used in tES and TMS Studies Included in the Meta-Analysis. This figure illustrates the various scales included in the meta-analysis, color-coded by the type of stimulation—tES in red and TMS in blue—and categorized by outcome measure (craving). <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation.

Figure S.10-2. Consumption/Relapse Outcome Measures Used in tES and TMS Studies Included in the Meta-Analysis. This figure illustrates the various scales used in the meta-analysis, color-coded by the type of stimulation—tES in red and TMS in blue—and categorized by outcome measure (consumption and relapse). <u>Abbreviations</u>: tES: transcranial electrical stimulation, TMS: transcranial magnetic stimulation, ng/mg: nanogram per milligram, mg/mL: milligrams per milliliter, CO: carbon monoxide, Cot/Cre: cotinine-creatinine ratio.

All available outcome measures

Table S.4. Outcome measures for tES/TMS studies for addiction medicine treatment.

Outcome Category	Subcategory	Assessment Instrument
Craving	General Craving	Self-report with Visual Analog Scale (VAS)
		Obsessive-Compulsive Drinking Scale (OCDS)
		Questionnaire of Smoking Urges (QSU)
		Tobacco Craving Questionnaire (TCQ)
		Alcohol Craving Questionnaire (ACQ)
		Marijuana Craving Questionnaire (MCQ)
		Alcohol Urge Questionnaire (AUQ)
		Craving subscale of the Cocaine Selective Symptoms Scale (CSSA)
		Urge to Smoke (UTS)
		Alcohol Approach and Avoidance Questionnaire (AAAQ)
		Pennsylvania Alcohol Craving Scale (PACS)
		Brief scale adapted from the Obsessive-Compulsive Cocaine Use Scale (OCCS)
		Obsessive Compulsive Drug Use Scale (OCDUS)
		Clinical evaluation of psychopathologic symptoms connected with craving
		Desire for Drug Questionnaire (DDQ)
		Desire for Alcohol Questionnaire (DAQ)
		Opiate Craving Scale (OCS)
		Drug Use Thoughts, Fantasies, and Temptations Questionnaire
		Sensitivity to Reinforcement of Addictive and other Primary Rewards questionnaire (STRAP-R)
		Craving Automated Scales for Cigarette Smoking (CAS-CS)
		Cocaine Craving Questionnaire (CCQ)
	Cue-induced Craving	Self-report with VAS
		Questionnaire of Smoking Urges (QSU)
		Shiffman-Jarvik withdrawal questionnaire (Craving subscale)
		Tobacco Craving Questionnaire (TCQ)

		Alcohol Urge Questionnaire (AUQ)
		Cocaine Craving Questionnaire-Brief (CCQB)
		Cue-induced Craving and Affective Picture Appraisal Task (CCAPAT)
	Implicit Craving (Biases)	Approach-Avoidance Task
		Alcohol Implicit Association Test (IAT)
		Visual Probe Task (VPT)
		Probe Detection Task (PDT)
		Dot Probe Task (DPT)
		Eye Tracking
Positive Valence	Hedonic Tone	Temporal Experience of Pleasure Scale (TEPS)
		Self-report with VAS for pleasure experience
		Snaith-Hamilton Pleasure Scale (SHAPS)
		Temporal Experience of Pleasure Scale (TEPS)
	Mindfulness	Toronto Mindfulness Scale (TMS)
		Assessment Scale for Mindfulness Interventions (ASMI)
	Willingness	Self-report with VAS (0-10 scale)
		Contemplation Ladder (Readiness to change drug use and affect)
	Motivation	Self-report with VAS (0-10 scale)
		Abstinence-Related Motivational Engagement (ARME)
		Motivation to Stop Smoking Questionnaire (Marino, 2000)
Negative Valence	Depression	Hamilton Depression Rating Scale (HDRS)
		Montgomery-Åsberg Depression Rating Scale (MADRS)
		Zung Self-Rating Depression Scale (SDS)
		Inventory of Depressive Symptomatology Self Report (IDS-SR)
		Calgary Depression Scale for Schizophrenia (CDSS)
		Depression subscale of the SCL-90
		Symptoms of Depression Questionnaire (SDQ)
		Patient Health Questionnaire (PHQ-9)
		Beck's Depression Inventory (BDI)
	Anxiety/Stress	State-Trait Anxiety Inventory (STAI)
		Hamilton Anxiety Rating Scale (HAMA)
		Self-Rating Anxiety Scale (SAS)
		Generalized Anxiety Disorder 7-item (GAD-7)
		Perceived Stress Scale-4 (PSS-4)
		Self-report with VAS
		Perceived Stress Scale (PSS)
		Beck Anxiety Inventory (BAI)

	Depression/Anxiety/Stress	Depression, Anxiety, and Stress Scale-21 (DASS-21)
	Mood	Profile of Mood States (POMS)
		Positive and Negative Affective Scales (PANAS)
		Self-reported General Mood using a 5-point Likert scale
		Self-report with VAS
		Self-Assessment Manikin (SAM)
	Withdrawal	Minnesota Nicotine Withdrawal Scale (MNWS)
		Amphetamine Withdrawal Questionnaire (AWQ)
		Cocaine Selective Severity Assessment (CSSA)
		Marijuana Withdrawal Checklist (MWC)
		Clinical Opiate Withdrawal Scale (COWS)
Mental/General Health Assessment	General Health/Functioning	Clinical Global Impressions (CGI) Scale
		Global Assessment of Functioning (GAF)
		Medical Outcomes Study Short Form 36 (SF-36)
		Quality of Life of the World Health Organization (WHOQOL-BREF)
		Patient Health Questionnaire-9 (PHQ-9)
		Pittsburgh Sleep Quality Index (PSQI)
		Insomnia Severity Index (ISI)
		Epworth Sleepiness Scale (ESS)
	Psychiatric Symptoms	Positive and Negative Syndrome Scale (PANSS)
		Symptom Checklist-90 (SCL90)
		Barratt Impulsiveness Scale version 11 (BIS-11)
		Modified Taylor Aggression Paradigm (mTAP)
		Young Mania Rating Scale
Drug Consumption /Relapse/Abstinence	Self-Report	Self-reported consumption
		Personal Drug Use Questionnaire
		Fagerström Test for Nicotine Dependence (FTND) Score
		Time Line Follow Back (TLFB)
		Alcohol Use Disorder Identification Test (AUDIT)
		Subjective Effects Battery (Number of choices of drug vs 5$)
		Severity of Alcohol Dependence Questionnaire Form-C (SADQ-C)
		Alcohol Dependence Scale (ADS)
		Obsessive-Compulsive Drug Use Scale (OCDUS)
		Nicotine Use Inventory (NUI)
		Severity of Dependence Scale (SDS)
		LifeData platform
	Objective Measure	Urine drug test
		Breathalyzer CO levels

		Hair Analysis
		Saliva Sample
		Ad libitum Smoking Phase
		Ad libitum Bogus Taste Test
		Ad libitum Taste Test
		Smoking Topography Device
		Phosphatidylethanol (PEth)
Cognitive Functions	General Cognitive Performance	Wisconsin Card Sorting Test (WCST)
		MATRICS Consensus Cognitive Battery (MCCB)
		Montreal Cognitive Assessment (MoCA)
		Mini Mental Status Examination (MMSE)
		Emotional Face Matching task
		Emotion Reappraisal Task
		Simple Reaction Time Task
		Dot Counting Test (DCT)
	Attention/Working Memory	Attentional Blink Paradigm
		Continuous Performance Tests (CPTs)
		Emotional Attention Task
		Spatial Delayed Response Task (SDR)
		Stroop Task
		Two-choice Oddball Task
		Visual Target Identification Task
		Eye tracking system
		Paced Auditory Serial Addition Task
		Working memory-Operation Span Task
		Free Recall Task
		N-Back Task
	Memory and Learning	Hopkins Verbal Learning Task (HVLT)
		Hidden Association Between Images Task (HABIT)
		Wechsler Memory Scale (WMS)
	Executive Function/Inhibition	Verbal Fluency Tasks
		Go-No Go Task
		Stop Signal Task (SST)
		Tower of London (ToL)
		Dimensional Change Card Sort
		Flanker Task
		Behavior Rating Inventory of Executive Function-Adults (BRIEF-A)
	Decision Making	Delay Discounting Task (DDT)
		Probability Discounting Tasks
		Columbia Card Task (CCT)
		Balloon Analog Risk Task (BART)
		Game of Dice Task (GDT)

		Risky Choices Gambling Task (RCGT)
		Cambridge Gambling Task
		Two-choice Gambling Task (TCGT)
		Iowa Gambling Task (IGT)
		Ultimatum GameTask
		Task-Based fMRI
Activity and Connectivity	Activity	Resting State fMRI
		ERP
		EMG
		fNIRS
		Resting State fMRI
	Connectivity	Task-Based fMRI
		DTI
		fMRI-based
	Brain Entropy (BEN)	Voxel-Based Morphometric (VBM)
	Gray Matter Volume (MRI)	EEG
	Neurophysiological Effects	ECG
		Pupil Size
		Single Photon Emission Computed Tomography (SPECT)
	Dopamine Transport (DAT)	Transcranial Doppler Sonography
	Cerebral Hemodynamic Indices	Proton Magnetic Resonance Spectroscopy (H-MRS))
	Metabolites	Gas Chromatography/Time-of-Flight Mass Spectrometry (GC/TOFMS)
		Blood Test (Cortisol and Prolactin)
		ELISA kits (IL-6 and TNF-a expression levels)
		Brain-Derived Neurotrophic Factor (BDNF)
		TMS-tDCS-PAS/EMG
	Motor Cortex Excitability	Retention rate of completing the study protocol as designed
Others	Adherence	The percentage of participants able to tolerate a full dose of intervention
	Tolerability	Correlation between EF and changes in network-level neural responses
	Electric Field	

References

1.   Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. Oct 2 2018;169(7):467-473. doi:10.7326/m18-0850

2.   Ekhtiari H, Tavakoli H, Addolorato G, et al. Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. *Neuroscience & Biobehavioral Reviews*. 2019/09/01/ 2019;104:118-140. doi:https://doi.org/10.1016/j.neubiorev.2019.06.007

3.   Boggio PS, Sultani N, Fecteau S, et al. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. *Drug Alcohol Depend*. Jan 1 2008;92(1-3):55-60. doi:10.1016/j.drugalcdep.2007.06.011

4.   Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS. Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized, sham-controlled study. *J Clin Psychiatry*. Jan 2008;69(1):32-40. doi:10.4088/jcp.v69n0105

5.   Boggio PS, Liguori P, Sultani N, Rezende L, Fecteau S, Fregni F. Cumulative priming effects of cortical stimulation on smoking cue-induced craving. *Neurosci Lett*. Sep 29 2009;463(1):82-6. doi:10.1016/j.neulet.2009.07.041

6.   Boggio PS, Zaghi S, Villani AB, Fecteau S, Pascual-Leone A, Fregni F. Modulation of risk-taking in marijuana users by transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC). *Drug Alcohol Depend*. Dec 1 2010;112(3):220-5. doi:10.1016/j.drugalcdep.2010.06.019

7.   Nakamura-Palacios EM, de Almeida Benevides MC, da Penha Zago-Gomes M, et al. Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current stimulation in alcoholics according to Lesch alcoholism typology. *Int J Neuropsychopharmacol*. Jun 2012;15(5):601-16. doi:10.1017/s1461145711001040

8.   da Silva MC, Conti CL, Klauss J, et al. Behavioral effects of transcranial direct current stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence. *J Physiol Paris*. Dec 2013;107(6):493-502. doi:10.1016/j.jphysparis.2013.07.003

9.   Pripfl J, Neumann R, Köhler U, Lamm C. Effects of transcranial direct current stimulation on risky decision making are mediated by 'hot' and 'cold' decisions, personality, and hemisphere. *Eur J Neurosci*. Dec 2013;38(12):3778-85. doi:10.1111/ejn.12375

10.   Xu J, Fregni F, Brody AL, Rahman AS. Transcranial direct current stimulation reduces negative affect but not cigarette craving in overnight abstinent smokers. *Front Psychiatry*. 2013;4:112. doi:10.3389/fpsyt.2013.00112

11.   Conti CL, Moscon JA, Fregni F, Nitsche MA, Nakamura-Palacios EM. Cognitive related electrophysiological changes induced by non-invasive cortical electrical stimulation in crack-cocaine addiction. *Int J Neuropsychopharmacol*. Sep 2014;17(9):1465-75. doi:10.1017/s1461145714000522

12.   Conti CL, Nakamura-Palacios EM. Bilateral transcranial direct current stimulation over dorsolateral prefrontal cortex changes the drug-cued reactivity in the anterior cingulate cortex of crack-cocaine addicts. *Brain Stimul*. Jan-Feb 2014;7(1):130-2. doi:10.1016/j.brs.2013.09.007

13.   Klauss J, Penido Pinheiro LC, Silva Merlo BL, et al. A randomized controlled trial of targeted prefrontal cortex modulation with tDCS in patients with alcohol dependence. *Int J Neuropsychopharmacol*. Nov 2014;17(11):1793-803. doi:10.1017/s1461145714000984

14.   Gorini A, Lucchiari C, Russell-Edu W, Pravettoni G. Modulation of risky choices in recently abstinent dependent cocaine users: a transcranial direct-current stimulation study. *Front Hum Neurosci*. 2014;8:661. doi:10.3389/fnhum.2014.00661

15.   Fecteau S, Agosta S, Hone-Blanchet A, et al. Modulation of smoking and decision-making behaviors with transcranial direct current stimulation in tobacco smokers: a preliminary study. *Drug Alcohol Depend*. Jul 1 2014;140:78-84. doi:10.1016/j.drugalcdep.2014.03.036

16.	Meng Z, Liu C, Yu C, Ma Y. Transcranial direct current stimulation of the frontal-parietal-temporal area attenuates smoking behavior. *J Psychiatr Res*. Jul 2014;54:19-25. doi:10.1016/j.jpsychires.2014.03.007

17.	Shahbabaie A, Golesorkhi M, Zamanian B, et al. State dependent effect of transcranial direct current stimulation (tDCS) on methamphetamine craving. *Int J Neuropsychopharmacol*. Oct 2014;17(10):1591-8. doi:10.1017/s1461145714000686

18.	Batista EK, Klauss J, Fregni F, Nitsche MA, Nakamura-Palacios EM. A Randomized Placebo-Controlled Trial of Targeted Prefrontal Cortex Modulation with Bilateral tDCS in Patients with Crack-Cocaine Dependence. *Int J Neuropsychopharmacol*. Jun 10 2015;18(12)doi:10.1093/ijnp/pyv066

19.	den Uyl TE, Gladwin TE, Wiers RW. Transcranial direct current stimulation, implicit alcohol associations and craving. *Biol Psychol*. Feb 2015;105:37-42. doi:10.1016/j.biopsycho.2014.12.004

20.	Pripfl J, Lamm C. Focused transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex modulates specific domains of self-regulation. *Neurosci Res*. Feb 2015;91:41-7. doi:10.1016/j.neures.2014.09.007

21.	Smith RC, Boules S, Mattiuz S, et al. Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study. *Schizophr Res*. Oct 2015;168(1-2):260-6. doi:10.1016/j.schres.2015.06.011

22.	den Uyl TE, Gladwin TE, Rinck M, Lindenmeyer J, Wiers RW. A clinical trial with combined transcranial direct current stimulation and alcohol approach bias retraining. *Addict Biol*. Nov 2017;22(6):1632-1640. doi:10.1111/adb.12463

23.	den Uyl TE, Gladwin TE, Wiers RW. Electrophysiological and Behavioral Effects of Combined Transcranial Direct Current Stimulation and Alcohol Approach Bias Retraining in Hazardous Drinkers. *Alcohol Clin Exp Res*. Oct 2016;40(10):2124-2133. doi:10.1111/acer.13171

24.	Falcone M, Bernardo L, Ashare RL, et al. Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking. *Brain Stimul*. Mar-Apr 2016;9(2):191-6. doi:10.1016/j.brs.2015.10.004

25.	Nakamura-Palacios EM, Lopes IB, Souza RA, et al. Ventral medial prefrontal cortex (vmPFC) as a target of the dorsolateral prefrontal modulation by transcranial direct current stimulation (tDCS) in drug addiction. *J Neural Transm (Vienna)*. Oct 2016;123(10):1179-94. doi:10.1007/s00702-016-1559-9

26.	Wang Y, Shen Y, Cao X, et al. Transcranial direct current stimulation of the frontal-parietal-temporal area attenuates cue-induced craving for heroin. *J Psychiatr Res*. Aug 2016;79:1-3. doi:10.1016/j.jpsychires.2016.04.001

27.	Wietschorke K, Lippold J, Jacob C, Polak T, Herrmann MJ. Transcranial direct current stimulation of the prefrontal cortex reduces cue-reactivity in alcohol-dependent patients. *J Neural Transm (Vienna)*. Oct 2016;123(10):1173-8. doi:10.1007/s00702-016-1541-6

28.	Kroczek AM, Häußinger FB, Rohe T, et al. Effects of transcranial direct current stimulation on craving, heart-rate variability and prefrontal hemodynamics during smoking cue exposure. *Drug Alcohol Depend*. Nov 1 2016;168:123-127. doi:10.1016/j.drugalcdep.2016.09.006

29.	Shahbabaie A, Ebrahimpoor M, Hariri A, et al. Transcranial DC stimulation modifies functional connectivity of large-scale brain networks in abstinent methamphetamine users. *Brain Behav*. Mar 2018;8(3):e00922. doi:10.1002/brb3.922

30.	Yang LZ, Shi B, Li H, et al. Electrical stimulation reduces smokers' craving by modulating the coupling between dorsal lateral prefrontal cortex and parahippocampal gyrus. *Soc Cogn Affect Neurosci*. Aug 1 2017;12(8):1296-1302. doi:10.1093/scan/nsx055

31.	Klauss J, Anders QS, Felippe LV, Nitsche MA, Nakamura-Palacios EM. Multiple Sessions of Transcranial Direct Current Stimulation (tDCS) Reduced Craving and Relapses for Alcohol Use: A Randomized Placebo-Controlled Trial in Alcohol Use Disorder. *Front Pharmacol*. 2018;9:716. doi:10.3389/fphar.2018.00716

32.	Vitor de Souza Brangioni MC, Pereira DA, Thibaut A, Fregni F, Brasil-Neto JP, Boechat-Barros R. Effects of Prefrontal Transcranial Direct Current Stimulation and Motivation to Quit in Tobacco

Smokers: A Randomized, Sham Controlled, Double-Blind Trial. *Front Pharmacol*. 2018;9:14. doi:10.3389/fphar.2018.00014

33.		Mondino M, Luck D, Grot S, et al. Effects of repeated transcranial direct current stimulation on smoking, craving and brain reactivity to smoking cues. *Sci Rep*. Jun 7 2018;8(1):8724. doi:10.1038/s41598-018-27057-1

34.		den Uyl TE, Gladwin TE, Lindenmeyer J, Wiers RW. A Clinical Trial with Combined Transcranial Direct Current Stimulation and Attentional Bias Modification in Alcohol-Dependent Patients. *Alcohol Clin Exp Res*. Oct 2018;42(10):1961-1969. doi:10.1111/acer.13841

35.		Sharifi-Fardshad M, Mehraban-Eshtehardi M, Shams-Esfandabad H, Shariatirad S, Molavi N, Hassani-Abharian P. Modulation of Drug Craving in Crystalline-Heroin Users by Transcranial Direct Current Stimulation of Dorsolateral Prefrontal Cortex. *Addiction & Health*. 2018;10(3):173-179. doi:http://dx.doi.org/10.22122/ahj.v10i3.613

36.		Klauss J, Anders QS, Felippe LV, et al. Lack of Effects of Extended Sessions of Transcranial Direct Current Stimulation (tDCS) Over Dorsolateral Prefrontal Cortex on Craving and Relapses in Crack-Cocaine Users. *Front Pharmacol*. 2018;9:1198. doi:10.3389/fphar.2018.01198

37.		Shahbabaie A, Hatami J, Farhoudian A, Ekhtiari H, Khatibi A, Nitsche MA. Optimizing Electrode Montages of Transcranial Direct Current Stimulation for Attentional Bias Modification in Early Abstinent Methamphetamine Users. *Front Pharmacol*. 2018;9:907. doi:10.3389/fphar.2018.00907

38.		Eskandari Z, Dadashi M, Mostafavi H, Armani Kia A, Pirzeh R. Comparing the Efficacy of Anodal, Cathodal, and Sham Transcranial Direct Current Stimulation on Brain-Derived Neurotrophic Factor and Psychological Symptoms in Opioid-Addicted Patients. *Basic Clin Neurosci*. Nov-Dec 2019;10(6):641-650. doi:10.32598/bcn.10.6.1710.1

39.		Hajloo N, Pouresmali A, Alizadeh Goradel J, Mowlaie M. The Effects of Transcranial Direct Current Stimulation of Dorsolateral Prefrontal Cortex on Reduction of Craving in Daily and Social Smokers. *Iran J Psychiatry*. Oct 2019;14(4):291-296.

40.		Martinotti G, Lupi M, Montemitro C, et al. Transcranial Direct Current Stimulation Reduces Craving in Substance Use Disorders: A Double-blind, Placebo-Controlled Study. *J ect*. Sep 2019;35(3):207-211. doi:10.1097/yct.0000000000000580

41.		Taremian F, Nazari S, Moradveisi L, Moloodi R. Transcranial Direct Current Stimulation on Opium Craving, Depression, and Anxiety: A Preliminary Study. *J ect*. Sep 2019;35(3):201-206. doi:10.1097/yct.0000000000000568

42.		Claus ED, Klimaj SD, Chavez R, Martinez AD, Clark VP. A Randomized Trial of Combined tDCS Over Right Inferior Frontal Cortex and Cognitive Bias Modification: Null Effects on Drinking and Alcohol Approach Bias. *Alcohol Clin Exp Res*. Jul 2019;43(7):1591-1599. doi:10.1111/acer.14111

43.		Ghorbani Behnam S, Mousavi SA, Emamian MH. The effects of transcranial direct current stimulation compared to standard bupropion for the treatment of tobacco dependence: A randomized sham-controlled trial. *Eur Psychiatry*. Aug 2019;60:41-48. doi:10.1016/j.eurpsy.2019.04.010

44.		Alghamdi F, Alhussien A, Alohali M, et al. Effect of transcranial direct current stimulation on the number of smoked cigarettes in tobacco smokers. *PLoS One*. 2019;14(2):e0212312. doi:10.1371/journal.pone.0212312

45.		Falcone M, Bernardo L, Wileyto EP, et al. Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trial. *Drug Alcohol Depend*. Jan 1 2019;194:244-251. doi:10.1016/j.drugalcdep.2018.10.016

46.		Witkiewitz K, Stein ER, Votaw VR, et al. Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial. *Alcohol Clin Exp Res*. Jun 2019;43(6):1296-1307. doi:10.1111/acer.14053

47.		Verveer I, van der Veen FM, Shahbabaie A, Remmerswaal D, Franken IHA. Multi-session electrical neuromodulation effects on craving, relapse and cognitive functions in cocaine use disorder: A randomized, sham-controlled tDCS study. *Drug Alcohol Depend*. Dec 1 2020;217:108429. doi:10.1016/j.drugalcdep.2020.108429

48.	Verveer I, Remmerswaal D, van der Veen FM, Franken IHA. Long-term tDCS effects on neurophysiological measures of cognitive control in tobacco smokers. *Biol Psychol*. Oct 2020;156:107962. doi:10.1016/j.biopsycho.2020.107962

49.	Holla B, Biswal J, Ramesh V, et al. Effect of prefrontal tDCS on resting brain fMRI graph measures in Alcohol Use Disorders: A randomized, double-blind, sham-controlled study. *Prog Neuropsychopharmacol Biol Psychiatry*. Aug 30 2020;102:109950. doi:10.1016/j.pnpbp.2020.109950

50.	Kooteh BR, Dolatshahi B, Nosratabadi M, Bakhshani NM, Mahdavi A, Hakami MC. Combination therapy and opioids: effectiveness of transcranial direct-current stimulation (tDCS) and emotion regulation training in reducing current drug craving. *Maedica*. 2020;15(1):53.

51.	Aronson Fischell S, Ross TJ, Deng ZD, Salmeron BJ, Stein EA. Transcranial Direct Current Stimulation Applied to the Dorsolateral and Ventromedial Prefrontal Cortices in Smokers Modifies Cognitive Circuits Implicated in the Nicotine Withdrawal Syndrome. *Biol Psychiatry Cogn Neurosci Neuroimaging*. Apr 2020;5(4):448-460. doi:10.1016/j.bpsc.2019.12.020

52.	Verveer I, Remmerswaal D, Jongerling J, van der Veen FM, Franken IHA. No effect of repetitive tDCS on daily smoking behaviour in light smokers: A placebo controlled EMA study. *PLoS One*. 2020;15(5):e0233414. doi:10.1371/journal.pone.0233414

53.	Sadeghi Bimorgh M, Omidi A, Ghoreishi FS, Rezaei Ardani A, Ghaderi A, Banafshe HR. The Effect of Transcranial Direct Current Stimulation on Relapse, Anxiety, and Depression in Patients With Opioid Dependence Under Methadone Maintenance Treatment: A Pilot Study. *Front Pharmacol*. 2020;11:401. doi:10.3389/fphar.2020.00401

54.	Vanderhasselt MA, Allaert J, De Raedt R, Baeken C, Krebs RM, Herremans S. Bifrontal tDCS applied to the dorsolateral prefrontal cortex in heavy drinkers: Influence on reward-triggered approach bias and alcohol consumption. *Brain Cogn*. Feb 2020;138:105512. doi:10.1016/j.bandc.2019.105512

55.	Mondino M, Lenglos C, Cinti A, Renauld E, Fecteau S. Eye tracking of smoking-related stimuli in tobacco use disorder: A proof-of-concept study combining attention bias modification with alpha-transcranial alternating current stimulation. *Drug Alcohol Depend*. Sep 1 2020;214:108152. doi:10.1016/j.drugalcdep.2020.108152

56.	Daughters SB, Yi JY, Phillips RD, Carelli RM, Fröhlich F. Alpha-tACS effect on inhibitory control and feasibility of administration in community outpatient substance use treatment. *Drug Alcohol Depend*. Aug 1 2020;213:108132. doi:10.1016/j.drugalcdep.2020.108132

57.	Alizadehgoradel J, Nejati V, Sadeghi Movahed F, et al. Repeated stimulation of the dorsolateral-prefrontal cortex improves executive dysfunctions and craving in drug addiction: A randomized, double-blind, parallel-group study. *Brain Stimul*. May-Jun 2020;13(3):582-593. doi:10.1016/j.brs.2019.12.028

58.	Dormal V, Lannoy S, Bollen Z, D'Hondt F, Maurage P. Can we boost attention and inhibition in binge drinking? Electrophysiological impact of neurocognitive stimulation. *Psychopharmacology (Berl)*. May 2020;237(5):1493-1505. doi:10.1007/s00213-020-05475-2

59.	Brown DR, Jackson TCJ, Claus ED, et al. Decreases in the Late Positive Potential to Alcohol Images Among Alcohol Treatment Seekers Following Mindfulness-Based Relapse Prevention. *Alcohol Alcohol*. Feb 7 2020;55(1):78-85. doi:10.1093/alcalc/agz096

60.	Mostafavi H, Dadashi M, Faridi A, Kazemzadeh F, Eskandari Z. Using Bilateral tDCS to Modulate EEG Amplitude and Coherence of Men With Opioid Use Disorder Under Methadone Therapy: A Sham-controlled Clinical Trial. *Clin EEG Neurosci*. May 2022;53(3):184-195. doi:10.1177/15500594211022100

61.	Perri RL, Perrotta D. Transcranial direct current stimulation of the prefrontal cortex reduces cigarette craving in not motivated to quit smokers: A randomized, sham-controlled study. *Addict Behav*. Sep 2021;120:106956. doi:10.1016/j.addbeh.2021.106956

62.	Gaudreault PO, Sharma A, Datta A, et al. A double-blind sham-controlled phase 1 clinical trial of tDCS of the dorsolateral prefrontal cortex in cocaine inpatients: Craving, sleepiness, and contemplation to change. *Eur J Neurosci*. May 2021;53(9):3212-3230. doi:10.1111/ejn.15172

63.	Xu X, Ding X, Chen L, et al. The transcranial direct current stimulation over prefrontal cortex combined with the cognitive training reduced the cue-induced craving in female individuals with

methamphetamine use disorder: A randomized controlled trial. *J Psychiatr Res*. Feb 2021;134:102-110. doi:10.1016/j.jpsychires.2020.12.056

64.   Eskandari Z, Mostafavi H, Hosseini M, Mousavi SE, Ramazani S, Dadashi M. A sham-controlled clinical trial to examine the effect of bilateral tDCS on craving, TNF-α and IL-6 expression levels, and impulsivity of males with opioid use disorder. *J Addict Dis*. Jul-Sep 2021;39(3):347-356. doi:10.1080/10550887.2021.1883208

65.   Alizadehgoradel J, Imani S, Nejati V, et al. Improved Executive Functions and Reduced Craving in Youths with Methamphetamine Addiction: Evidence from Combined Transcranial Direct Current Stimulation with Mindfulness Treatment. *Clin Psychopharmacol Neurosci*. Nov 30 2021;19(4):653-668. doi:10.9758/cpn.2021.19.4.653

66.   Dubuson M, Kornreich C, Vanderhasselt MA, et al. Transcranial direct current stimulation combined with alcohol cue inhibitory control training reduces the risk of early alcohol relapse: A randomized placebo-controlled clinical trial. *Brain Stimul*. Nov-Dec 2021;14(6):1531-1543. doi:10.1016/j.brs.2021.10.386

67.   McKim TH, Dove SJ, Robinson DL, Fröhlich F, Boettiger CA. Addiction history moderates the effect of prefrontal 10-Hz transcranial alternating current stimulation on habitual action selection. *J Neurophysiol*. Mar 1 2021;125(3):768-780. doi:10.1152/jn.00180.2020

68.   Müller T, Shevchenko Y, Gerhardt S, Kiefer F, Vollstädt-Klein S. The influence of perceived stress and self-control on efficacy of repeated transcranial direct current stimulation in non-treatment-seeking smokers. *Drug Alcohol Depend*. Sep 1 2021;226:108861. doi:10.1016/j.drugalcdep.2021.108861

69.   Lin SH, Chen PS, Chen KC, Chang WH, Wang TY, Yang YK. Transcranial direct current stimulation (tDCS) may reduce the expired CO concentration among opioid users who smoke cigarettes: a randomized sham-controlled study. *Psychiatry Res*. May 2021;299:113874. doi:10.1016/j.psychres.2021.113874

70.   Patel H, Naish K, Soreni N, Amlung M. The Effects of a Single Transcranial Direct Current Stimulation Session on Impulsivity and Risk Among a Sample of Adult Recreational Cannabis Users. *Front Hum Neurosci*. 2022;16:758285. doi:10.3389/fnhum.2022.758285

71.   Jiang X, Tian Y, Zhang Z, Zhou C, Yuan J. The Counterproductive Effect of Right Anodal/Left Cathodal Transcranial Direct Current Stimulation Over the Dorsolateral Prefrontal Cortex on Impulsivity in Methamphetamine Addicts. *Front Psychiatry*. 2022;13:915440. doi:10.3389/fpsyt.2022.915440

72.   Weidler C, Habel U, Wallheinke P, et al. Consequences of prefrontal tDCS on inhibitory control and reactive aggression. *Soc Cogn Affect Neurosci*. Feb 3 2022;17(1):120-130. doi:10.1093/scan/nsaa158

73.   Fayaz Feyzi Y, Vahed N, Sadeghamal Nikraftar N, Arezoomandan R. Synergistic effect of combined transcranial direct current stimulation and Matrix Model on the reduction of methamphetamine craving and improvement of cognitive functioning: a randomized sham-controlled study. *Am J Drug Alcohol Abuse*. May 4 2022;48(3):311-320. doi:10.1080/00952990.2021.2015771

74.   Gibson BC, Votaw VR, Stein ER, Clark VP, Claus E, Witkiewitz K. Transcranial Direct Current Stimulation Provides no Additional Benefit to Improvements in Self-Reported Craving Following Mindfulness-Based Relapse Prevention. *Mindfulness (N Y)*. Jan 2022;13(1):92-103. doi:10.1007/s12671-021-01768-5

75.   Meng Z, Li Q, Ma Y, Liu C. Transcranial direct current stimulation of the frontal-parietal-temporal brain areas reduces cigarette consumption in abstinent heroin users. *J Psychiatr Res*. Aug 2022;152:321-325. doi:10.1016/j.jpsychires.2022.06.045

76.   Ekhtiari H, Soleimani G, Kuplicki R, Yeh HW, Cha YH, Paulus M. Transcranial direct current stimulation to modulate fMRI drug cue reactivity in methamphetamine users: A randomized clinical trial. *Hum Brain Mapp*. Dec 1 2022;43(17):5340-5357. doi:10.1002/hbm.26007

77.   Khajehpour H, Parvaz MA, Kouti M, et al. Effects of Transcranial Direct Current Stimulation on Attentional Bias to Methamphetamine Cues and Its Association With EEG-Derived Functional Brain Network Topology. *Int J Neuropsychopharmacol*. Aug 16 2022;25(8):631-644. doi:10.1093/ijnp/pyac018

78.   Soleimani G, Towhidkhah F, Oghabian MA, Ekhtiari H. DLPFC stimulation alters large-scale brain networks connectivity during a drug cue reactivity task: A tDCS-fMRI study. Original Research. *Frontiers in Systems Neuroscience*. 2022-October-06 2022;16doi:10.3389/fnsys.2022.956315

79.   Schwippel T, Schroeder PA, Hasan A, Plewnia C. Implicit measures of alcohol approach and drinking identity in alcohol use disorder: A preregistered double-blind randomized trial with cathodal transcranial direct current stimulation (tDCS). *Addict Biol*. Jul 2022;27(4):e13180. doi:10.1111/adb.13180

80.   Kumar AS, Khanra S, Goyal N, Dharani R, Roy C. Adjunctive High-Definition Transcranial Direct Current Stimulation in Brain Glutamate-Glutamine and γ-Aminobutyric Acid, Withdrawal and Craving During Early Abstinence Among Patients With Opioid Use Disorder on Buprenorphine-Naloxone: A Proton Magnetic Resonance Spectroscopy-Based Pilot Study. *J ect*. Jun 1 2022;38(2):124-132. doi:10.1097/yct.0000000000000820

81.   Rezvanian S, Saraei M, Mohajeri H, Hassani-Abharian P. The Effect of Different Transcranial Direct Current Stimulation (tDCS) Protocols on Drug Craving and Cognitive Functions in Methamphetamine Addicts. *Basic Clin Neurosci*. May-Jun 2022;13(3):349-355. doi:10.32598/bcn.13.2.1929.1

82.   Camchong J, Roediger D, Fiecas M, et al. Frontal tDCS reduces alcohol relapse rates by increasing connections from left dorsolateral prefrontal cortex to addiction networks. *Brain Stimul*. Jul-Aug 2023;16(4):1032-1040. doi:10.1016/j.brs.2023.06.011

83.   Chen CY, Liu YH, Muggleton NG. Use of the P300 event-related potential component to index transcranial direct current stimulation effects in drug users. *IBRO Neurosci Rep*. Jun 2023;14:122-128. doi:10.1016/j.ibneur.2023.01.001

84.   Qin J, Chen J, Wang Y, Zou Z. Effects of psychoeducation combined with transcranial direct current stimulation on reducing cigarette craving and consumption in male smokers. *Addict Behav*. Jun 2023;141:107643. doi:10.1016/j.addbeh.2023.107643

85.   He J, Wang R, Li J, Jiang X, Zhou C, Liu J. Effect of transcranial direct current stimulation over the left dorsolateral prefrontal cortex on the aggressive behavior in methamphetamine addicts. *J Psychiatr Res*. Aug 2023;164:364-371. doi:10.1016/j.jpsychires.2023.06.038

86.   Lu J, Wu Z, Zeng F, et al. Modulation of smoker brain activity and functional connectivity by tDCS: A go/no-go task-state fMRI study. *Heliyon*. Nov 2023;9(11):e21074. doi:10.1016/j.heliyon.2023.e21074

87.   Soleimani G, Kupliki R, Paulus M, Ekhtiari H. Dose-response in modulating brain function with transcranial direct current stimulation: From local to network levels. *PLoS Comput Biol*. Oct 2023;19(10):e1011572. doi:10.1371/journal.pcbi.1011572

88.   Dayal P, Kaloiya GS, Verma R, Kumar N. Need to rethink tDCS protocols for the treatment of alcohol use disorder: Insights from a randomized sham-controlled clinical trial among detoxified inpatients. *J Addict Dis*. Oct-Dec 2024;42(4):544-550. doi:10.1080/10550887.2023.2257106

89.   Eichhammer P, Johann M, Kharraz A, et al. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. *J Clin Psychiatry*. Aug 2003;64(8):951-3. doi:10.4088/jcp.v64n0815

90.   Camprodon JA, Martínez-Raga J, Alonso-Alonso M, Shih MC, Pascual-Leone A. One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. *Drug Alcohol Depend*. Jan 5 2007;86(1):91-4. doi:10.1016/j.drugalcdep.2006.06.002

91.   Amiaz R, Levy D, Vainiger D, Grunhaus L, Zangen A. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. *Addiction*. Apr 2009;104(4):653-60. doi:10.1111/j.1360-0443.2008.02448.x

92.   Mishra BR, Nizamie SH, Das B, Praharaj SK. Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. *Addiction*. Jan 2010;105(1):49-55. doi:10.1111/j.1360-0443.2009.02777.x

93.   Höppner J, Broese T, Wendler L, Berger C, Thome J. Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence. *World J Biol Psychiatry*. Sep 2011;12 Suppl 1:57-62. doi:10.3109/15622975.2011.598383

94.   Rose JE, McClernon FJ, Froeliger B, Behm FM, Preud'homme X, Krystal AD. Repetitive transcranial magnetic stimulation of the superior frontal gyrus modulates craving for cigarettes. *Biol Psychiatry*. Oct 15 2011;70(8):794-799. doi:10.1016/j.biopsych.2011.05.031

95.   Herremans SC, Baeken C, Vanderbruggen N, et al. No influence of one right-sided prefrontal HF-rTMS session on alcohol craving in recently detoxified alcohol-dependent patients: results of a naturalistic study. *Drug Alcohol Depend*. Jan 1 2012;120(1-3):209-13. doi:10.1016/j.drugalcdep.2011.07.021

96.   Wing VC, Bacher I, Wu BS, Daskalakis ZJ, George TP. High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. *Schizophr Res*. Aug 2012;139(1-3):264-6. doi:10.1016/j.schres.2012.03.006

97.   Herremans SC, Vanderhasselt MA, De Raedt R, Baeken C. Reduced intra-individual reaction time variability during a Go-NoGo task in detoxified alcohol-dependent patients after one right-sided dorsolateral prefrontal HF-rTMS session. *Alcohol Alcohol*. Sep-Oct 2013;48(5):552-7. doi:10.1093/alcalc/agt054

98.   Li X, Malcolm RJ, Huebner K, et al. Low frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex transiently increases cue-induced craving for methamphetamine: a preliminary study. *Drug Alcohol Depend*. Dec 1 2013;133(2):641-6. doi:10.1016/j.drugalcdep.2013.08.012

99.   Li X, Hartwell KJ, Owens M, et al. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. *Biol Psychiatry*. Apr 15 2013;73(8):714-20. doi:10.1016/j.biopsych.2013.01.003

100.   Sheffer CE, Mennemeier M, Landes RD, et al. Neuromodulation of delay discounting, the reflection effect, and cigarette consumption. *J Subst Abuse Treat*. Aug 2013;45(2):206-14. doi:10.1016/j.jsat.2013.01.012

101.   Dieler AC, Dresler T, Joachim K, Deckert J, Herrmann MJ, Fallgatter AJ. Can intermittent theta burst stimulation as add-on to psychotherapy improve nicotine abstinence? Results from a pilot study. *Eur Addict Res*. 2014;20(5):248-53. doi:10.1159/000357941

102.   Dinur-Klein L, Dannon P, Hadar A, et al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. *Biol Psychiatry*. Nov 1 2014;76(9):742-9. doi:10.1016/j.biopsych.2014.05.020

103.   Prikryl R, Ustohal L, Kucerova HP, et al. Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients. *Prog Neuropsychopharmacol Biol Psychiatry*. Mar 3 2014;49:30-5. doi:10.1016/j.pnpbp.2013.10.019

104.   Pripfl J, Tomova L, Riecansky I, Lamm C. Transcranial magnetic stimulation of the left dorsolateral prefrontal cortex decreases cue-induced nicotine craving and EEG delta power. *Brain Stimul*. Mar-Apr 2014;7(2):226-33. doi:10.1016/j.brs.2013.11.003

105.   Ceccanti M, Inghilleri M, Attilia ML, et al. Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. *Can J Physiol Pharmacol*. Apr 2015;93(4):283-90. doi:10.1139/cjpp-2014-0188

106.   Girardi P, Rapinesi C, Chiarotti F, et al. Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: a comparison with standard treatment. *World J Biol Psychiatry*. Jan 2015;16(1):66-73. doi:10.3109/15622975.2014.925583

107.   Herremans SC, Van Schuerbeek P, De Raedt R, et al. The Impact of Accelerated Right Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) on Cue-Reactivity: An fMRI Study on Craving in Recently Detoxified Alcohol-Dependent Patients. *PLoS One*. 2015;10(8):e0136182. doi:10.1371/journal.pone.0136182

108.   Jansen JM, van Wingen G, van den Brink W, Goudriaan AE. Resting state connectivity in alcohol dependent patients and the effect of repetitive transcranial magnetic stimulation. *Eur Neuropsychopharmacol*. Dec 2015;25(12):2230-9. doi:10.1016/j.euroneuro.2015.09.019

109.   Mishra BR, Praharaj SK, Katshu MZ, Sarkar S, Nizamie SH. Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study. *J Neuropsychiatry Clin Neurosci*. Winter 2015;27(1):e54-9. doi:10.1176/appi.neuropsych.13010013

110.   Rapinesi C, Curto M, Kotzalidis GD, et al. Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study. *J Affect Disord*. Mar 15 2015;174:57-63. doi:10.1016/j.jad.2014.11.015

111.   Trojak B, Meille V, Achab S, et al. Transcranial Magnetic Stimulation Combined With Nicotine Replacement Therapy for Smoking Cessation: A Randomized Controlled Trial. *Brain Stimul*. Nov-Dec 2015;8(6):1168-74. doi:10.1016/j.brs.2015.06.004

112.   Bolloni C, Panella R, Pedetti M, et al. Bilateral Transcranial Magnetic Stimulation of the Prefrontal Cortex Reduces Cocaine Intake: A Pilot Study. *Front Psychiatry*. 2016;7:133. doi:10.3389/fpsyt.2016.00133

113.   Del Felice A, Bellamoli E, Formaggio E, et al. Neurophysiological, psychological and behavioural correlates of rTMS treatment in alcohol dependence. *Drug Alcohol Depend*. Jan 1 2016;158:147-53. doi:10.1016/j.drugalcdep.2015.11.018

114.   Hanlon CA, Dowdle LT, Moss H, Canterberry M, George MS. Mobilization of Medial and Lateral Frontal-Striatal Circuits in Cocaine Users and Controls: An Interleaved TMS/BOLD Functional Connectivity Study. *Neuropsychopharmacology*. Dec 2016;41(13):3032-3041. doi:10.1038/npp.2016.114

115.   Herremans SC, De Raedt R, Van Schuerbeek P, et al. Accelerated HF-rTMS Protocol has a Rate-Dependent Effect on dACC Activation in Alcohol-Dependent Patients: An Open-Label Feasibility Study. *Alcohol Clin Exp Res*. Jan 2016;40(1):196-205. doi:10.1111/acer.12937

116.   Huang W, Shen F, Zhang J, Xing B. Effect of Repetitive Transcranial Magnetic Stimulation on Cigarette Smoking in Patients with Schizophrenia. *Shanghai Arch Psychiatry*. Dec 25 2016;28(6):309-317. doi:10.11919/j.issn.1002-0829.216044

117.   Mishra BR, Maiti R, Nizamie SH. Cerebral Hemodynamics With rTMS in Alcohol Dependence: A Randomized, Sham-Controlled Study. *J Neuropsychiatry Clin Neurosci*. Fall 2016;28(4):319-324. doi:10.1176/appi.neuropsych.15110381

118.   Qiao J, Jin G, Lei L, Wang L, Du Y, Wang X. The positive effects of high-frequency right dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on memory, correlated with increases in brain metabolites detected by proton magnetic resonance spectroscopy in recently detoxified alcohol-dependent patients. *Neuropsychiatr Dis Treat*. 2016;12:2273-2278. doi:10.2147/ndt.S106266

119.   Shen Y, Cao X, Tan T, et al. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. *Biol Psychiatry*. Aug 1 2016;80(3):e13-4. doi:10.1016/j.biopsych.2016.02.006

120.   Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Gallimberti L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. *Eur Neuropsychopharmacol*. Jan 2016;26(1):37-44. doi:10.1016/j.euroneuro.2015.11.011

121.   Addolorato G, Antonelli M, Cocciolillo F, et al. Deep Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex in Alcohol Use Disorder Patients: Effects on Dopamine Transporter Availability and Alcohol Intake. *Eur Neuropsychopharmacol*. May 2017;27(5):450-461. doi:10.1016/j.euroneuro.2017.03.008

122.   Baker TE, Lesperance P, Tucholka A, et al. Reversing the Atypical Valuation of Drug and Nondrug Rewards in Smokers Using Multimodal Neuroimaging. *Biol Psychiatry*. Dec 1 2017;82(11):819-827. doi:10.1016/j.biopsych.2017.01.015

123.   Hanlon CA, Dowdle LT, Correia B, et al. Left frontal pole theta burst stimulation decreases orbitofrontal and insula activity in cocaine users and alcohol users. *Drug Alcohol Depend*. Sep 1 2017;178:310-317. doi:10.1016/j.drugalcdep.2017.03.039

124.   Li X, Du L, Sahlem GL, Badran BW, Henderson S, George MS. Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex reduces resting-state insula activity and modulates functional connectivity of the orbitofrontal cortex in cigarette smokers. *Drug Alcohol Depend*. May 1 2017;174:98-105. doi:10.1016/j.drugalcdep.2017.02.002

125.   Li X, Sahlem GL, Badran BW, et al. Transcranial magnetic stimulation of the dorsal lateral prefrontal cortex inhibits medial orbitofrontal activity in smokers. *Am J Addict*. Dec 2017;26(8):788-794. doi:10.1111/ajad.12621

126.   Liu Q, Shen Y, Cao X, et al. Either at left or right, both high and low frequency rTMS of dorsolateral prefrontal cortex decreases cue induced craving for methamphetamine. *Am J Addict*. Dec 2017;26(8):776-779. doi:10.1111/ajad.12638

127.   Sahlem GL, Baker NL, George MS, Malcolm RJ, McRae-Clark AL. Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. *Am J Drug Alcohol Abuse*. 2018;44(1):47-55. doi:10.1080/00952990.2017.1355920

128.   Su H, Zhong N, Gan H, et al. High frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex for methamphetamine use disorders: A randomised clinical trial. *Drug Alcohol Depend*. Jun 1 2017;175:84-91. doi:10.1016/j.drugalcdep.2017.01.037

129.   Kamp D, Engelke C, Wobrock T, et al. Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia. *Schizophr Res*. Feb 2018;192:481-484. doi:10.1016/j.schres.2017.05.036

130.   Kearney-Ramos TE, Dowdle LT, Lench DH, et al. Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity. *Biol Psychiatry Cogn Neurosci Neuroimaging*. Jul 2018;3(7):599-609. doi:10.1016/j.bpsc.2018.03.016

131.   Kozak K, Sharif-Razi M, Morozova M, et al. Effects of short-term, high-frequency repetitive transcranial magnetic stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in patients with schizophrenia and non-psychiatric controls. *Schizophr Res*. Jul 2018;197:441-443. doi:10.1016/j.schres.2018.02.015

132.   Liang Q, Lin J, Yang J, et al. Intervention Effect of Repetitive TMS on Behavioral Adjustment After Error Commission in Long-Term Methamphetamine Addicts: Evidence From a Two-Choice Oddball Task. *Neurosci Bull*. Jun 2018;34(3):449-456. doi:10.1007/s12264-018-0205-y

133.   Martinez D, Urban N, Grassetti A, et al. Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices Reduces Cocaine Self-Administration: A Pilot Study. *Front Psychiatry*. 2018;9:80. doi:10.3389/fpsyt.2018.00080

134.   Sheffer CE, Bickel WK, Brandon TH, et al. Preventing relapse to smoking with transcranial magnetic stimulation: Feasibility and potential efficacy. *Drug Alcohol Depend*. Jan 1 2018;182:8-18. doi:10.1016/j.drugalcdep.2017.09.037

135.   Zhang L, Cao X, Liang Q, Li X, Yang J, Yuan J. High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex restores attention bias to negative information in methamphetamine addicts. *Psychiatry Res*. Jul 2018;265:151-160. doi:10.1016/j.psychres.2018.04.039

136.   Liang Y, Wang L, Yuan TF. Targeting Withdrawal Symptoms in Men Addicted to Methamphetamine With Transcranial Magnetic Stimulation: A Randomized Clinical Trial. *JAMA Psychiatry*. Nov 1 2018;75(11):1199-1201. doi:10.1001/jamapsychiatry.2018.2383

137.   McNeill A, Monk RL, Qureshi AW, Makris S, Heim D. Continuous Theta Burst Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Impairs Inhibitory Control and Increases Alcohol Consumption. *Cogn Affect Behav Neurosci*. Dec 2018;18(6):1198-1206. doi:10.3758/s13415-018-0631-3

138.   Wu GR, Baeken C, Van Schuerbeek P, De Mey J, Bi M, Herremans SC. Accelerated repetitive transcranial magnetic stimulation does not influence grey matter volumes in regions related to alcohol relapse: An open-label exploratory study. *Drug Alcohol Depend*. Oct 1 2018;191:210-214. doi:10.1016/j.drugalcdep.2018.07.004

139.   Hanlon CA, Lench DH, Dowdle LT, Ramos TK. Neural Architecture Influences Repetitive Transcranial Magnetic Stimulation-Induced Functional Change: A Diffusion Tensor Imaging and Functional Magnetic Resonance Imaging Study of Cue-Reactivity Modulation in Alcohol Users. *Clin Pharmacol Ther*. Oct 2019;106(4):702-705. doi:10.1002/cpt.1545

140.   Jansen JM, van den Heuvel OA, van der Werf YD, et al. The Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Emotion Processing, Reappraisal, and Craving in Alcohol Use Disorder Patients and Healthy Controls: A Functional Magnetic Resonance Imaging Study. *Front Psychiatry*. 2019;10:272. doi:10.3389/fpsyt.2019.00272

141.   Kearney-Ramos TE, Dowdle LT, Mithoefer OJ, Devries W, George MS, Hanlon CA. State-Dependent Effects of Ventromedial Prefrontal Cortex Continuous Thetaburst Stimulation on Cocaine Cue Reactivity in Chronic Cocaine Users. *Front Psychiatry*. 2019;10:317. doi:10.3389/fpsyt.2019.00317

142.   Lin J, Liu X, Li H, et al. Chronic repetitive transcranial magnetic stimulation (rTMS) on sleeping quality and mood status in drug dependent male inpatients during abstinence. *Sleep Med*. Jun 2019;58:7-12. doi:10.1016/j.sleep.2019.01.052

143.   Liu T, Li Y, Shen Y, Liu X, Yuan TF. Gender does not matter: Add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents. *Prog Neuropsychopharmacol Biol Psychiatry*. Jun 8 2019;92:70-75. doi:10.1016/j.pnpbp.2018.12.018

144.   Prashad S, Dedrick ES, To WT, Vanneste S, Filbey FM. Testing the role of the posterior cingulate cortex in processing salient stimuli in cannabis users: an rTMS study. *Eur J Neurosci*. Aug 2019;50(3):2357-2369. doi:10.1111/ejn.14194

145.   Sanna A, Fattore L, Badas P, Corona G, Cocco V, Diana M. Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Cocaine Use Disorder: A Pilot Study. *Front Neurosci*. 2019;13:765. doi:10.3389/fnins.2019.00765

146.   Schluter RS, van Holst RJ, Goudriaan AE. Effects of Ten Sessions of High Frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS) Add-on Treatment on Impulsivity in Alcohol Use Disorder. *Front Neurosci*. 2019;13:1257. doi:10.3389/fnins.2019.01257

147.   Biernacki K, Lin MH, Baker TE. Recovery of reward function in problematic substance users using a combination of robotics, electrophysiology, and TMS. *Int J Psychophysiol*. Dec 2020;158:288-298. doi:10.1016/j.ijpsycho.2020.08.008

148.   Chen T, Su H, Li R, et al. The exploration of optimized protocol for repetitive transcranial magnetic stimulation in the treatment of methamphetamine use disorder: A randomized sham-controlled study. *EBioMedicine*. 2020/10/01/ 2020;60:103027. doi:https://doi.org/10.1016/j.ebiom.2020.103027

149.   Chen T, Su H, Jiang H, et al. Cognitive and emotional predictors of real versus sham repetitive transcranial magnetic stimulation treatment response in methamphetamine use disorder. *J Psychiatr Res*. Jul 2020;126:73-80. doi:10.1016/j.jpsychires.2020.05.007

150.   Gómez Pérez LJ, Cardullo S, Cellini N, et al. Sleep quality improves during treatment with repetitive transcranial magnetic stimulation (rTMS) in patients with cocaine use disorder: a retrospective observational study. *BMC Psychiatry*. Apr 6 2020;20(1):153. doi:10.1186/s12888-020-02568-2

151.   Li X, Hartwell KJ, Henderson S, Badran BW, Brady KT, George MS. Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial. *Brain Stimul*. Sep-Oct 2020;13(5):1271-1279. doi:10.1016/j.brs.2020.06.007

152.   Liu X, Zhao X, Liu T, et al. The effects of repetitive transcranial magnetic stimulation on cue-induced craving in male patients with heroin use disorder. *EBioMedicine*. Jun 2020;56:102809. doi:10.1016/j.ebiom.2020.102809

153.   Liu X, Zhao X, Shen Y, et al. The effects of DLPFC-targeted repetitive transcranial magnetic stimulation on craving in male methamphetamine patients. *Clin Transl Med*. Jun 2020;10(2):e48. doi:10.1002/ctm2.48

154.   Newman-Norlund RD, Gibson M, McConnell PA, Froeliger B. Dissociable Effects of Theta-Burst Repeated Transcranial Magnetic Stimulation to the Inferior Frontal Gyrus on Inhibitory Control in Nicotine Addiction. *Front Psychiatry*. 2020;11:260. doi:10.3389/fpsyt.2020.00260

155.   Perini I, Kämpe R, Arlestig T, et al. Repetitive transcranial magnetic stimulation targeting the insular cortex for reduction of heavy drinking in treatment-seeking alcohol-dependent subjects: a randomized controlled trial. *Neuropsychopharmacology*. Apr 2020;45(5):842-850. doi:10.1038/s41386-019-0565-7

156.   Raikwar S, Divinakumar KJ, Prakash J, Khan SA, GuruPrakash KV, Batham S. A sham-controlled trial of repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex and its effects on craving in patients with alcohol dependence. *Ind Psychiatry J*. Jul-Dec 2020;29(2):245-250. doi:10.4103/ipj.ipj_53_19

157.   Su H, Liu Y, Yin D, et al. Neuroplastic changes in resting-state functional connectivity after rTMS intervention for methamphetamine craving. *Neuropharmacology*. Sep 15 2020;175:108177. doi:10.1016/j.neuropharm.2020.108177

158.   Su H, Chen T, Zhong N, et al. γ-aminobutyric acid and glutamate/glutamine alterations of the left prefrontal cortex in individuals with methamphetamine use disorder: a combined transcranial magnetic stimulation-magnetic resonance spectroscopy study. *Ann Transl Med*. Mar 2020;8(6):347. doi:10.21037/atm.2020.02.95

159.   Su H, Chen T, Jiang H, et al. Intermittent theta burst transcranial magnetic stimulation for methamphetamine addiction: A randomized clinical trial. *Eur Neuropsychopharmacol*. Feb 2020;31:158-161. doi:10.1016/j.euroneuro.2019.12.114

160.   Yuan J, Liu W, Liang Q, Cao X, Lucas MV, Yuan TF. Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Inhibition in Abstinent Patients With Methamphetamine Addiction: A Randomized Clinical Trial. *JAMA Netw Open*. Mar 2 2020;3(3):e200910. doi:10.1001/jamanetworkopen.2020.0910

161.   Zhao D, Li Y, Liu T, Voon V, Yuan TF. Twice-Daily Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex Reduces Methamphetamine Craving: A Pilot Study. *Front Neurosci*. 2020;14:208. doi:10.3389/fnins.2020.00208

162.   Abdelrahman AA, Noaman M, Fawzy M, Moheb A, Karim AA, Khedr EM. A double-blind randomized clinical trial of high frequency rTMS over the DLPFC on nicotine dependence, anxiety and depression. *Sci Rep*. Jan 15 2021;11(1):1640. doi:10.1038/s41598-020-80927-5

163.   Bozzay ML, Brigido S, van 't Wout-Frank M, Aiken E, Swift R, Philip NS. Intermittent Theta Burst Stimulation in Veterans with Mild Alcohol Use Disorder. *J Affect Disord*. Oct 1 2021;293:314-319. doi:10.1016/j.jad.2021.06.039

164.   Cardullo S, Gómez Pérez LJ, Cuppone D, et al. A Retrospective Comparative Study in Patients With Cocaine Use Disorder Comorbid With Attention Deficit Hyperactivity Disorder Undergoing an rTMS Protocol Treatment. *Front Psychiatry*. 2021;12:659527. doi:10.3389/fpsyt.2021.659527

165.   Chen T, Su H, Wang L, et al. Modulation of Methamphetamine-Related Attention Bias by Intermittent Theta-Burst Stimulation on Left Dorsolateral Prefrontal Cortex. *Front Cell Dev Biol*. 2021;9:667476. doi:10.3389/fcell.2021.667476

166.   Garza-Villarreal EA, Alcala-Lozano R, Fernandez-Lozano S, et al. Clinical and Functional Connectivity Outcomes of 5-Hz Repetitive Transcranial Magnetic Stimulation as an Add-on Treatment in Cocaine Use Disorder: A Double-Blind Randomized Controlled Trial. *Biol Psychiatry Cogn Neurosci Neuroimaging*. Jul 2021;6(7):745-757. doi:10.1016/j.bpsc.2021.01.003

167.   Gupta AK, Kumar A, Chandrashekhar N. Adjuvant treatment with repetitive transcranial magnetic stimulation in freshly diagnosed alcohol-dependence syndrome patients from an industry: An outcome study. *Ind Psychiatry J*. Oct 2021;30(Suppl 1):S93-s96. doi:10.4103/0972-6748.328795

168.   Li X, Song GF, Yu JN, et al. Effectiveness and safety of repetitive transcranial magnetic stimulation for the treatment of morphine dependence: A retrospective study. *Medicine (Baltimore)*. Apr 9 2021;100(14):e25208. doi:10.1097/md.0000000000025208

169.   Lolli F, Salimova M, Scarpino M, et al. A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving. *PLoS One*. 2021;16(11):e0259860. doi:10.1371/journal.pone.0259860

170.   Tsai TY, Wang TY, Liu YC, et al. Add-on repetitive transcranial magnetic stimulation in patients with opioid use disorder undergoing methadone maintenance therapy. *Am J Drug Alcohol Abuse*. May 4 2021;47(3):330-343. doi:10.1080/00952990.2020.1849247

171.   Wang LJ, Mu LL, Ren ZX, et al. Predictive Role of Executive Function in the Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation Modalities for Treating Methamphetamine Use Disorder-A Randomized Clinical Trial. *Front Psychiatry*. 2021;12:774192. doi:10.3389/fpsyt.2021.774192

172.   Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. *World Psychiatry*. Oct 2021;20(3):397-404. doi:10.1002/wps.20905

173.   Ankit A, Das B, Dey P, Kshitiz KK, Khess CRJ. Efficacy of continuous theta burst stimulation - repetitive trancranial magnetic stimulation on the orbito frontal cortex as an adjunct to naltrexone in patients of opioid use disorder and its correlation with serum BDNF levels: a sham-controlled study. *J Addict Dis*. Jul-Sep 2022;40(3):373-381. doi:10.1080/10550887.2021.2007716

174.   Belgers M, Van Eijndhoven P, Markus W, Schene AH, Schellekens A. rTMS Reduces Craving and Alcohol Use in Patients with Alcohol Use Disorder: Results of a Randomized, Sham-Controlled Clinical Trial. *J Clin Med*. Feb 11 2022;11(4)doi:10.3390/jcm11040951

175.   Bidzinski KK, Lowe DJE, Sanches M, et al. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. *Schizophrenia (Heidelb)*. Feb 24 2022;8(1):2. doi:10.1038/s41537-022-00210-6

176.   Feng Z, Wu Q, Wu L, et al. Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Visual Selective Attention in Male Patients With Alcohol Use Disorder After the Acute Withdrawal. *Front Psychiatry*. 2022;13:869014. doi:10.3389/fpsyt.2022.869014

177.   Harel M, Perini I, Kämpe R, et al. Repetitive Transcranial Magnetic Stimulation in Alcohol Dependence: A Randomized, Double-Blind, Sham-Controlled Proof-of-Concept Trial Targeting the Medial Prefrontal and Anterior Cingulate Cortices. *Biol Psychiatry*. Jun 15 2022;91(12):1061-1069. doi:10.1016/j.biopsych.2021.11.020

178.   Jin L, Yuan M, Zhang W, et al. Repetitive transcranial magnetic stimulation modulates coupling among large-scale brain networks in heroin-dependent individuals: A randomized resting-state functional magnetic resonance imaging study. *Addict Biol*. Mar 2022;27(2):e13121. doi:10.1111/adb.13121

179.   Liu Q, Sun H, Hu Y, et al. Intermittent Theta Burst Stimulation vs. High-Frequency Repetitive Transcranial Magnetic Stimulation in the Treatment of Methamphetamine Patients. *Front Psychiatry*. 2022;13:842947. doi:10.3389/fpsyt.2022.842947

180.   Marques RC, Marques D, Vieira L, Cantilino A. Left frontal pole repetitive transcranial magnetic stimulation reduces cigarette cue-reactivity in correlation with verbal memory performance. *Drug Alcohol Depend*. Jun 1 2022;235:109450. doi:10.1016/j.drugalcdep.2022.109450

181.   Martinotti G, Pettorruso M, Montemitro C, et al. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: A randomized, double-blind, sham-controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry*. Jun 8 2022;116:110513. doi:10.1016/j.pnpbp.2022.110513

182.   McNeill AM, Monk RL, Qureshi AW, Makris S, Cazzato V, Heim D. Elevated ad libitum alcohol consumption following continuous theta burst stimulation to the left-dorsolateral prefrontal cortex is partially mediated by changes in craving. *Cogn Affect Behav Neurosci*. Feb 2022;22(1):160-170. doi:10.3758/s13415-021-00940-7

183.   Mikellides G, Michael P, Psalta L, Stefani A, Schuhmann T, Sack AT. Accelerated Intermittent Theta Burst Stimulation in Smoking Cessation: Placebo Effects Equal to Active Stimulation When Using Advanced Placebo Coil Technology. *Front Psychiatry*. 2022;13:892075. doi:10.3389/fpsyt.2022.892075

184.   Moeller SJ, Gil R, Weinstein JJ, et al. Deep rTMS of the insula and prefrontal cortex in smokers with schizophrenia: Proof-of-concept study. *Schizophrenia (Heidelb)*. Feb 25 2022;8(1):6. doi:10.1038/s41537-022-00224-0

185.   Shevorykin A, Carl E, Mahoney MC, et al. Transcranial Magnetic Stimulation for Long-Term Smoking Cessation: Preliminary Examination of Delay Discounting as a Therapeutic Target and the

Effects of Intensity and Duration. *Front Hum Neurosci*. 2022;16:920383. doi:10.3389/fnhum.2022.920383

186.   Su H, Yang P, Chen T, et al. Metabolomics changes after rTMS intervention reveal potential peripheral biomarkers in methamphetamine dependence. *Eur Neuropsychopharmacol*. Mar 2022;56:80-88. doi:10.1016/j.euroneuro.2021.12.006

187.   Zhang T, Song B, Li Y, et al. Neurofilament Light Chain as a Biomarker for Monitoring the Efficacy of Transcranial Magnetic Stimulation on Alcohol Use Disorder. *Front Behav Neurosci*. 2022;16:831901. doi:10.3389/fnbeh.2022.831901

188.   Li X, Toll BA, Carpenter MJ, Nietert PJ, Dancy M, George MS. Repetitive Transcranial Magnetic Stimulation for Tobacco Treatment in Cancer Patients: A Preliminary Report of a One-Week Treatment. *J Smok Cessat*. 2022;2022:2617146. doi:10.1155/2022/2617146

189.   Liu Q, Xu X, Cui H, et al. High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may reduce impulsivity in patients with methamphetamine use disorders: A pilot study. *Front Hum Neurosci*. 2022;16:858465. doi:10.3389/fnhum.2022.858465

190.   Hu X, Zhang T, Ma H, et al. Repetitive transcranial magnetic stimulation combined with cognitive behavioral therapy treatment in alcohol-dependent patients: A randomized, double-blind sham-controlled multicenter clinical trial. *Front Psychiatry*. 2022;13:935491. doi:10.3389/fpsyt.2022.935491

191.   Johnstone S, Lowe DJE, Kozak-Bidzinski K, et al. Neurocognitive moderation of repetitive transcranial magnetic stimulation (rTMS) effects on cannabis use in schizophrenia: a preliminary analysis. *Schizophrenia (Heidelb)*. Nov 17 2022;8(1):99. doi:10.1038/s41537-022-00303-2

192.   Kang T, Ding X, Zhao J, et al. Influence of improved behavioral inhibition on decreased cue-induced craving in heroin use disorder: A preliminary intermittent theta burst stimulation study. *J Psychiatr Res*. Aug 2022;152:375-383. doi:10.1016/j.jpsychires.2022.06.010

193.   Lechner WV, Philip NS, Kahler CW, Houben K, Tirrell E, Carpenter LL. Combined Working Memory Training and Transcranial Magnetic Stimulation Demonstrates Low Feasibility and Potentially Worse Outcomes on Delay to Smoking and Cognitive Tasks: A Randomized 2 × 2 Factorial Design Pilot and Feasibility Study. *Nicotine Tob Res*. Nov 12 2022;24(12):1871-1880. doi:10.1093/ntr/ntac183

194.   Sun Y, Wang H, Ku Y. Intermittent Theta-Burst Stimulation Increases the Working Memory Capacity of Methamphetamine Addicts. *Brain Sci*. Sep 8 2022;12(9)doi:10.3390/brainsci12091212

195.   Wang W, Zhu Y, Wang L, et al. High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex reduces drug craving and improves decision-making ability in methamphetamine use disorder. *Psychiatry Res*. Nov 2022;317:114904. doi:10.1016/j.psychres.2022.114904

196.   McCalley DM, Kaur N, Wolf JP, et al. Medial Prefrontal Cortex Theta Burst Stimulation Improves Treatment Outcomes in Alcohol Use Disorder: A Double-Blind, Sham-Controlled Neuroimaging Study. *Biol Psychiatry Glob Open Sci*. Apr 2023;3(2):301-310. doi:10.1016/j.bpsgos.2022.03.002

197.   Mikellides G, Michael P, Psalta L, Stefani A, Schuhmann T, Sack AT. Accelerated intermittent theta burst stimulation in smoking cessation: No differences between active and placebo stimulation when using advanced placebo coil technology. A double-blind follow-up study. *Int J Clin Health Psychol*. Apr-Jun 2023;23(2):100351. doi:10.1016/j.ijchp.2022.100351

198.   Jin L, Yuan M, Zhang W, et al. Default mode network mechanisms of repeated transcranial magnetic stimulation in heroin addiction. *Brain Imaging Behav*. Feb 2023;17(1):54-65. doi:10.1007/s11682-022-00741-7

199.   Hoven M, Schluter RS, Schellekens AF, van Holst RJ, Goudriaan AE. Effects of 10 add-on HF-rTMS treatment sessions on alcohol use and craving among detoxified inpatients with alcohol use disorder: a randomized sham-controlled clinical trial. *Addiction*. Jan 2023;118(1):71-85. doi:10.1111/add.16025

200.   Dong L, Chen WC, Su H, et al. Intermittent theta burst stimulation to the left dorsolateral prefrontal cortex improves cognitive function in polydrug use disorder patients: a randomized controlled trial. *Front Psychiatry*. 2023;14:1156149. doi:10.3389/fpsyt.2023.1156149

201.   Zhang Y, Ku Y, Sun J, Daskalakis ZJ, Yuan TF. Intermittent theta burst stimulation to the left dorsolateral prefrontal cortex improves working memory of subjects with methamphetamine use disorder. *Psychol Med*. Apr 2023;53(6):2427-2436. doi:10.1017/s003329172100430x

202.   Gersner R, Barnea-Ygael N, Tendler A. Moderators of the response to deep TMS for smoking addiction. *Front Psychiatry*. 2022;13:1079138. doi:10.3389/fpsyt.2022.1079138

203.   Shevorykin A, Carl E, Liskiewicz A, et al. Perceived research burden of a novel therapeutic intervention: A study of transcranial magnetic stimulation for smoking cessation. *Front Rehabil Sci*. 2023;4:1054456. doi:10.3389/fresc.2023.1054456

204.   Upton S, Brown AA, Ithman M, et al. Effects of Hyperdirect Pathway Theta Burst Transcranial Magnetic Stimulation on Inhibitory Control, Craving, and Smoking in Adults With Nicotine Dependence: A Double-Blind, Randomized Crossover Trial. *Biol Psychiatry Cogn Neurosci Neuroimaging*. Nov 2023;8(11):1156-1165. doi:10.1016/j.bpsc.2023.07.014

205.   Ibrahim C, Tang VM, Blumberger DM, et al. Efficacy of insula deep repetitive transcranial magnetic stimulation combined with varenicline for smoking cessation: A randomized, double-blind, sham controlled trial. *Brain Stimul*. Sep-Oct 2023;16(5):1501-1509. doi:10.1016/j.brs.2023.10.002

206.   Gong H, Huang Y, Zhu X, et al. Impact of combination of intermittent theta burst stimulation and methadone maintenance treatment in individuals with opioid use disorder: A comparative study. *Psychiatry Res*. Sep 2023;327:115411. doi:10.1016/j.psychres.2023.115411

207.   Gerace E, Baldi S, Salimova M, et al. Oral and fecal microbiota perturbance in cocaine users: Can rTMS-induced cocaine abstinence support eubiosis restoration? *iScience*. May 19 2023;26(5):106627. doi:10.1016/j.isci.2023.106627

208.   Upton S, Brown AA, Golzy M, Garland EL, Froeliger B. Right inferior frontal gyrus theta-burst stimulation reduces smoking behaviors and strengthens fronto-striatal-limbic resting-state functional connectivity: a randomized crossover trial. Original Research. *Frontiers in Psychiatry*. 2023-June-28 2023;14doi:10.3389/fpsyt.2023.1166912

209.   Ding X, Li X, Xu M, He Z, Jiang H. The effect of repetitive transcranial magnetic stimulation on electroencephalography microstates of patients with heroin-addiction. *Psychiatry Res Neuroimaging*. Mar 2023;329:111594. doi:10.1016/j.pscychresns.2023.111594